

Denise M. Elser, M.D.

Page 1

KATHRYN E. CORBET and)	SUPERIOR COURT OF NEW JERSEY
ERIC R. CORBET,)	LAW DIVISION - BERGEN COUNTY
)	DOCKET NO. BER-L-14589-14MCL
Plaintiffs,)	
)	MASTER DOCKET
vs.)	NO. BER-L-11575-14
)	
ETHICON, INC., ETHICON)	
WOMEN'S HEALTH AND)	
UROLOGY, A Division)	CIVIL ACTION
of Ethicon, Inc.,)	In Re
GYNECARE, JOHNSON &)	Pelvic Mesh/Gynecare
JOHNSON AND JOHN)	Litigation
DOES 1-20,)	
)	Case No. 291 CT
Defendants.)	

The video-recorded deposition of
DENISE M. ELSER, M.D., taken before Pauline M.
Vargo, an Illinois Certified Shorthand Reporter,
C.S.R. No. 84-1573, at the Le Meridien Chicago -
Oakbrook Center, Discovery Boardroom, 9th Floor,
2100 Spring Road, Oak Brook, Illinois, on
November 5, 2015, at 9:14 a.m.

EXHIBIT C

GOLKOW TECHNOLOGIES, INC.
877.370.3377 ph | 917.591.5672 fax
Deps@golkow.com

Denise M. Elser, M.D.

Page 2	Page 4
<p>1 APPEARANCES</p> <p>2 PRESENT ON BEHALF OF THE PLAINTIFFS:</p> <p>3 SEEGER WEISS, LLP</p> <p>4 77 Water Street</p> <p>5 New York, New York 10005</p> <p>6 888.610.6574</p> <p>7 BY: JEFFREY S. GRAND, ESQ.</p> <p>8 jgrand@seegerweiss.com</p> <p>9</p> <p>10 PRESENT ON BEHALF OF THE DEFENDANTS:</p> <p>11 BUTLER SNOW, LLP</p> <p>12 500 Office Center Drive, Suite 400</p> <p>13 Fort Washington, Pennsylvania 19034</p> <p>14 267.513.1885</p> <p>15 BY: NILS B. (BURT) SNELL, ESQ.</p> <p>16 burt.snell@butlersnow.com</p> <p>17 VIDEOGRAPHER:</p> <p>18 MILO SAVICH</p> <p>19 Golkow Technologies</p> <p>20</p> <p>21 REPORTED BY:</p> <p>22 PAULINE M. VARGO, RPR, CRR</p> <p>23 Illinois CSR No. 84-1573.</p> <p>24</p> <p>25</p>	<p>1 EXHIBITS</p> <p>2 ELSER EXHIBIT MARKED FOR ID</p> <p>3 Exhibit 1 Notice of Video Deposition of Denise M. Elser, MD 7</p> <p>4 5 Pages</p> <p>5 Exhibit 2 12/9/14 Invoice to Burt Snell 13</p> <p>6 from Denise M. Elser, MD</p> <p>7 1 Page</p> <p>8 Exhibit 3 Expert Report of Denise M. Elser, MD 32</p> <p>9 59 Pages</p> <p>10 Exhibit 4 Supplemental TVT and Corbet Case Expert Report of Denise M. Elser, MD 37</p> <p>11 Exhibit 5-A Disk, "Ethicon Gynecare Pelvic Mesh Litigation, Additional Medical Records & Transcripts Corbet 8/25/15" 54</p> <p>12</p> <p>13 Exhibit 5-B Disk, "Corbet Ethicon Gynecare Pelvic Mesh Litigation" 54</p> <p>14 Exhibit 5-C Disk, "Ethicon Gynecare Pelvic Mesh Litigation (Edwards) 6/2/15" 54</p> <p>15 Exhibit 5-D Disk, "Ethicon Gynecare Pelvic Mesh Litigation TVT-O" 54</p> <p>16</p> <p>17 Exhibit 5-E Disk, "New Prolift/POP Studies 7/31/15" 54</p> <p>18 Exhibit 5-F Disk, "Ethicon Gynecare Pelvic Mesh Litigation 7/31/15" 54</p> <p>19</p> <p>20 Exhibit 5-G Disk, "Ethicon Gynecare Pelvic Mesh Litigation (Edwards) 6/2/15" 54</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>
Page 3	Page 5
<p>1 INDEX</p> <p>2 Thursday, November 5, 2015</p> <p>3 WITNESS EXAMINATION</p> <p>4 DENISE M. ELSE, M.D.</p> <p>5 By Mr. Snell.....Page 137</p> <p>6 By Mr. Grand.....Page 167</p> <p>7 By Mr. Snell.....Page 169</p> <p>8 By Mr. Grand.....Page 171</p> <p>9 By Mr. Snell.....Page 173</p> <p>10</p> <p>11 REQUESTS FOR PRODUCTION</p> <p>12 By Mr. Grand</p> <p>13 Page 28, Line 14</p> <p>14 Page 43, Line 6</p> <p>15 Page 61, Line 24</p> <p>16 Page 108, Line 24</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p>1 EXHIBITS</p> <p>2 ELSER EXHIBIT MARKED FOR ID</p> <p>3 Exhibit 6 Thumb Drive 54</p> <p>4 Exhibit 7 "TVT Development and Early Data" 54</p> <p>5 Exhibit 8 8/27/15 Letter from Butler Snow to Denise M. Elser, MD 54</p> <p>6 1 Page</p> <p>7 Exhibit 9 Gynecare TVT Label ETH.MESH.03427878 through ETH.MESH.03427883 75</p> <p>8</p> <p>9 Exhibit 10 Gynecare TVT Label, Large Font 75</p> <p>10 Exhibit 11 Tommaselli, et al., Article 120</p> <p>11 Exhibit 12 Svenningsen, et al., Article 124</p> <p>12 Exhibit 13 Summary Report from Cochrane Website, 5 Pages (Initially marked as Exhibit 10, re-marked as Exhibit 13 at Page 159.) 110</p> <p>13</p> <p>14 Exhibit 14 AUA Guideline for the Surgical Management of Female Stress Urinary Incontinence: 2009 Update" 157</p> <p>15</p> <p>16 Exhibit 15 Karram/Maher Article, "Surgery for posterior vaginal wall prolapse" 160</p> <p>17</p> <p>18 Exhibit 16 Kuuva/Nilsson Article, "A nationwide analysis of complications associated with the tension-free vaginal tape (TVT) procedure" 162</p> <p>19</p> <p>20 Exhibit 17 Lecture/Presentation by Denise M. Elser, MD 6 Pages 162</p> <p>21</p> <p>22 Exhibit 18 Pathology Report re Kathryn Corbet 7/14/11 Surgery 165</p> <p>23</p> <p>24</p> <p>25</p>

2 (Pages 2 to 5)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 6</p> <p>1 THE VIDEOGRAPHER: We are now on the</p> <p>2 record. My name is Milo Savich, and I'm a</p> <p>3 videographer for Golkow Technologies. Today's</p> <p>4 date is November 5th, 2015, and the time on</p> <p>5 record is 9:14 a.m.</p> <p>6 This video deposition is being held</p> <p>7 in Oak Brook, Illinois, in the matter of</p> <p>8 Kathryn E. Corbet, et al., versus Ethicon,</p> <p>9 Inc., et al., for the Superior Court of New</p> <p>10 Jersey, Law Division, Bergen County.</p> <p>11 The deponent is Dr. Denise M. Elser.</p> <p>12 Will counsel please identify</p> <p>13 themselves for the record.</p> <p>14 MR. GRAND: Jeff Grand from Seeger</p> <p>15 Weiss for Kathryn Corbet.</p> <p>16 MR. SNELL: Burt Snell from Butler</p> <p>17 Snow for Defendants Ethicon and Johnson &</p> <p>18 Johnson.</p> <p>19 THE VIDEOGRAPHER: The court reporter</p> <p>20 today is Pauline Vargo, who will now swear in</p> <p>21 the witness and we may then proceed.</p> <p>22 THE REPORTER: Raise your right hand,</p> <p>23 please.</p> <p>24 (The witness was duly sworn.)</p> <p>25</p>	<p style="text-align: right;">Page 8</p> <p>1 BY MR. GRAND:</p> <p>2 Q. First off, I will mark as Exhibit 1 a</p> <p>3 copy of the deposition notice for today.</p> <p>4 Have you seen this before?</p> <p>5 A. I have.</p> <p>6 Q. I would like to go to Exhibit A, which I</p> <p>7 believe is the third page. I sort of want to run</p> <p>8 through this and see what you may have brought with</p> <p>9 you today or do not have.</p> <p>10 With respect to number 1, documents</p> <p>11 related to your fees, billing and time spent in</p> <p>12 connection with your opinions in any pelvic mesh</p> <p>13 litigation, have you brought that here today?</p> <p>14 A. I have brought a copy of an invoice</p> <p>15 related to writing of the original report on this</p> <p>16 case, so I would have that with me.</p> <p>17 Q. Okay. Let's stop for a second, and have</p> <p>18 you -- when was the last time you were deposed on</p> <p>19 a -- for the TVT product in a case relating --</p> <p>20 involving the TVT product?</p> <p>21 A. The last deposition --</p> <p>22 Q. Yes.</p> <p>23 A. -- was the one we did. I don't remember</p> <p>24 the date.</p> <p>25 Q. You don't remember the date?</p>
<p style="text-align: right;">Page 7</p> <p>1 DENISE M. ELSER, M.D.,</p> <p>2 called as a witness herein, having been first duly</p> <p>3 sworn, was examined and testified as follows:</p> <p>4 EXAMINATION</p> <p>5 BY MR. GRAND:</p> <p>6 Q. Good morning, Dr. Elser. My name is</p> <p>7 Jeffrey Grand. I'm here to ask you some questions</p> <p>8 today on behalf of Plaintiffs Kathleen Corbet --</p> <p>9 Kathryn Corbet. Sorry.</p> <p>10 I know you have been deposed before --</p> <p>11 A. Yes.</p> <p>12 Q. -- so I'm not going to waste your time</p> <p>13 going through all the rules again. Let me just say</p> <p>14 if you feel like you need a break at any time, just</p> <p>15 let me know. I will be happy to accommodate you.</p> <p>16 I only ask that if we are in the middle of a</p> <p>17 question and answer that we finish it before we</p> <p>18 break.</p> <p>19 If I ask something that doesn't make</p> <p>20 sense to you or in a confusing way, which is highly</p> <p>21 probable, I ask just let me know and I will try to</p> <p>22 reframe my question.</p> <p>23 A. Okay.</p> <p>24 (Elser Exhibit 1 was marked for</p> <p>25 identification as of 11/5/15.)</p>	<p style="text-align: right;">Page 9</p> <p>1 A. I don't.</p> <p>2 Q. How many times have you been deposed?</p> <p>3 How many times have you served as an expert for</p> <p>4 TVT?</p> <p>5 A. For TVT, twice before.</p> <p>6 Q. Twice before. And have you served as an</p> <p>7 expert since the time you were retained to serve as</p> <p>8 a consultant in this case?</p> <p>9 A. No.</p> <p>10 Q. Have you served as an expert in mesh</p> <p>11 litigation involving any other Ethicon mesh</p> <p>12 products?</p> <p>13 A. For a Prolift case.</p> <p>14 Q. Prolift case. And which case was that?</p> <p>15 A. I don't remember the patient's name.</p> <p>16 Q. And did you sit for a deposition in that</p> <p>17 case?</p> <p>18 A. I don't think so.</p> <p>19 Q. Have you served as an expert in cases</p> <p>20 involving any other -- any of the other TVT</p> <p>21 products, such as TVT Secur or the TVT-O?</p> <p>22 A. There was a TVT-O case.</p> <p>23 Q. TVT-O case. And do you remember the</p> <p>24 name of that case?</p> <p>25 A. No.</p>

3 (Pages 6 to 9)

Denise M. Elser, M.D.

Page 10	Page 12
<p>1 Q. Just correct me if I'm wrong. Did you</p> <p>2 say that you have been an expert for two other TVT</p> <p>3 cases?</p> <p>4 A. Correct. I was including the TVT-O in</p> <p>5 that.</p> <p>6 Q. Okay. So --</p> <p>7 A. I took that -- sorry. I took your</p> <p>8 question as TVT family.</p> <p>9 Q. I'm sorry if I wasn't clear.</p> <p>10 For the purposes of today, it's actually</p> <p>11 a good point, I'm going to refer to specific -- the</p> <p>12 specific product. So, if I say TVT, I am not --</p> <p>13 unless I say otherwise, I'm not referring to the</p> <p>14 TVT family of products. I would be referring to</p> <p>15 the TVR retropubic.</p> <p>16 A. So, if you say "TVT," then you mean the</p> <p>17 original TVT.</p> <p>18 Q. The retropubic.</p> <p>19 A. And if you say "Exact" you are going to</p> <p>20 say Exact. Okay.</p> <p>21 Q. Okay. And Dr. Elser, when did -- when</p> <p>22 were you first retained to be a TVT consultant, an</p> <p>23 expert in any mesh litigation?</p> <p>24 A. I don't remember the date. A few years</p> <p>25 ago.</p>	<p>1 devices to treat SUI or pelvic organ prolapse?</p> <p>2 A. So, I'm sorry, can you -- am I working</p> <p>3 on developing new products? No.</p> <p>4 Q. So, it would be fair to say that your</p> <p>5 consultation today, as of this time, is limited to</p> <p>6 litigation consulting for Ethicon and Johnson &</p> <p>7 Johnson?</p> <p>8 A. Yes.</p> <p>9 Q. Are you currently a speaker for Johnson</p> <p>10 & Johnson or Ethicon?</p> <p>11 A. No.</p> <p>12 Q. Do you do any trainings for Johnson &</p> <p>13 Johnson or Ethicon?</p> <p>14 A. No.</p> <p>15 Q. And do you recall when you were first</p> <p>16 retained to work on the Corbet case?</p> <p>17 A. I know I worked on the original report</p> <p>18 in July. I don't remember if that was the first</p> <p>19 time I started working on it, but that was when I</p> <p>20 wrote the report.</p> <p>21 Q. Well, your first report was submitted in</p> <p>22 July of 2014, correct?</p> <p>23 A. Correct.</p> <p>24 Q. Do you recall how long it took you to</p> <p>25 prepare that report?</p>
Page 11	Page 13
<p>1 Q. Can we narrow that down? Was it 2012?</p> <p>2 A. That sounds right.</p> <p>3 MR. SNELL: Just note for the record</p> <p>4 this was covered in the original deposition.</p> <p>5 Just, I mean, I don't know if you read it, but</p> <p>6 I think there is a date in that deposition</p> <p>7 where she did.</p> <p>8 MR. GRAND: Yeah, I'm not doubting</p> <p>9 that. I'm just trying to find out what she</p> <p>10 has done since then.</p> <p>11 MR. SNELL: No, I don't care. I'm</p> <p>12 just saying for the record reference, I mean,</p> <p>13 there is a prior deposition where that date</p> <p>14 may be available.</p> <p>15 BY MR. GRAND:</p> <p>16 Q. Have you served as an expert consultant</p> <p>17 for any other mesh products besides Ethicon</p> <p>18 products?</p> <p>19 A. No.</p> <p>20 Q. Do you currently serve as a consultant</p> <p>21 to any other mesh manufacturer other than Johnson &</p> <p>22 Johnson?</p> <p>23 A. No.</p> <p>24 Q. Are you currently involved in any -- in</p> <p>25 the development of any Johnson & Johnson medical</p>	<p>1 A. I would look at my invoice to see</p> <p>2 because I already wrote down my hours for that.</p> <p>3 It's in the invoice.</p> <p>4 Q. Why don't we get that out if it will</p> <p>5 refresh your recollection.</p> <p>6 A. Okay.</p> <p>7 MR. SNELL: Do you just want to tell</p> <p>8 me where it is?</p> <p>9 THE WITNESS: It was on the top of</p> <p>10 that box, just free-floating paper.</p> <p>11 (Document tendered to the witness.)</p> <p>12 BY THE WITNESS:</p> <p>13 A. So, I worked a total on this, including</p> <p>14 record review, literature search and writing the</p> <p>15 report, phone consultations was 40 -- 62 hours.</p> <p>16 THE REPORTER: 40?</p> <p>17 THE WITNESS: 62.</p> <p>18 MR. GRAND: And that's -- is that a</p> <p>19 copy of that for me?</p> <p>20 MR. SNELL: You can mark it.</p> <p>21 MR. GRAND: Why don't we just mark</p> <p>22 this as Exhibit 2, and for the record, I'm</p> <p>23 marking an invoice to Burt Snell of Butler</p> <p>24 Snow from Dr. Elser dated December 9th, 2014.</p> <p>25 (Elser Exhibit 2 was marked for</p>

4 (Pages 10 to 13)

Denise M. Elser, M.D.

Page 14	Page 16
<p>1 identification as of 11/5/15.)</p> <p>2 BY MR. GRAND:</p> <p>3 Q. And have you prepared an invoice for the</p> <p>4 preparation of your supplemental report?</p> <p>5 A. I have not.</p> <p>6 Q. Can you tell me how many hours you spent</p> <p>7 preparing your supplemental report?</p> <p>8 A. I'm estimating 25 to 30.</p> <p>9 Q. Well, your initial report -- your</p> <p>10 initial report took -- never mind. Strike that.</p> <p>11 Then when did you begin work on the</p> <p>12 supplemental report?</p> <p>13 A. Last week on Monday.</p> <p>14 Q. So you did not begin any work on the</p> <p>15 supplemental report until Monday of last week?</p> <p>16 A. Well, I'm always reading the literature,</p> <p>17 always having articles that I may want to pull into</p> <p>18 reports, but as I looked at the renewed records</p> <p>19 that came in on this case, that's when I started</p> <p>20 specifically working on writing the report.</p> <p>21 Q. And were you asked -- were you asked by</p> <p>22 counsel to submit a supplemental report?</p> <p>23 A. I believe so.</p> <p>24 Q. And was that on or about Monday of last</p> <p>25 week?</p>	<p>1 I'm just asking.</p> <p>2 MR. SNELL: But she did produce -- in</p> <p>3 the prior deposition she produced invoices.</p> <p>4 Didn't you?</p> <p>5 THE WITNESS: I don't remember.</p> <p>6 MR. SNELL: It's my recollection that</p> <p>7 she did.</p> <p>8 BY MR. GRAND:</p> <p>9 Q. Do you know how many hours this year</p> <p>10 apart from your work on the Corbet case you have</p> <p>11 spent on mesh litigation?</p> <p>12 A. No.</p> <p>13 Q. It would be less than 50?</p> <p>14 A. Less than 50 hours total? No. I think</p> <p>15 it's more than 50.</p> <p>16 Q. Well, you estimated probably about 30</p> <p>17 for your supplemental report?</p> <p>18 A. Correct.</p> <p>19 Q. You aren't working on the Corbet</p> <p>20 supplemental report at any point this year prior to</p> <p>21 last week, were you?</p> <p>22 A. No.</p> <p>23 Q. So, prior to last week, any hours you've</p> <p>24 spent as a mesh consultant has been for another</p> <p>25 case?</p>
Page 15	Page 17
<p>1 A. Yes.</p> <p>2 Q. So after this deposition was noticed,</p> <p>3 you were asked to supplement your report?</p> <p>4 A. Yes.</p> <p>5 Q. Presently my understanding is you have a</p> <p>6 busy practice, correct?</p> <p>7 A. Yes.</p> <p>8 Q. About how many hours a week do you</p> <p>9 devote to your practice?</p> <p>10 A. About 60.</p> <p>11 Q. And about how many hours a week do you</p> <p>12 typically devote to consulting work of any kind?</p> <p>13 A. Some weeks none, some weeks 30.</p> <p>14 Q. Have you prepared any estimates -- do</p> <p>15 you have invoices for any other cases you are</p> <p>16 working on as a mesh consultant?</p> <p>17 A. No, not with me.</p> <p>18 MR. GRAND: Are you guys objecting to</p> <p>19 producing that, Burt?</p> <p>20 MR. SNELL: Yeah. Your experts never</p> <p>21 produced all their invoices. I know, for</p> <p>22 example, Dr. Elliot has been paid probably</p> <p>23 over \$800,000 and I haven't received all his</p> <p>24 invoices.</p> <p>25 MR. GRAND: No need to make speeches.</p>	<p>1 A. Correct.</p> <p>2 MR. SNELL: Hold on. I'm going to put</p> <p>3 an objection on the record. She is a general</p> <p>4 expert and has issued general updated expert</p> <p>5 reports in other cases.</p> <p>6 MR. GRAND: Okay. Then let's break it</p> <p>7 out that way.</p> <p>8 BY MR. GRAND:</p> <p>9 Q. For your general report on the TVT, how</p> <p>10 many hours have you spent this year on that?</p> <p>11 A. I couldn't answer that right now. I</p> <p>12 would sit down and look at my records.</p> <p>13 Q. Have you issued a general -- a general</p> <p>14 report for any other Ethicon mesh products, such as</p> <p>15 the Prolift?</p> <p>16 A. No.</p> <p>17 Q. So, other than the TVT-O you have not</p> <p>18 written any other general reports?</p> <p>19 A. Correct.</p> <p>20 Q. And the general report that's been</p> <p>21 submitted in this case, the Corbet case, only</p> <p>22 applies to the TVT retropubic, correct?</p> <p>23 A. Yes.</p> <p>24 Q. If you look back at Exhibit A, which you</p> <p>25 still have in front of you, a copy of your</p>

5 (Pages 14 to 17)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 18</p> <p>1 up-to-date CV, is your -- have there been any</p> <p>2 changes to your CV since, I guess, last week?</p> <p>3 A. No.</p> <p>4 Q. And the one that was attached to your</p> <p>5 supplemental report was up to date?</p> <p>6 A. Yes.</p> <p>7 Q. Did you update that yourself?</p> <p>8 A. Yes.</p> <p>9 Q. In your own practice, I believe you</p> <p>10 testified that you -- how many SUI procedures</p> <p>11 involving mesh do you perform a year, would you</p> <p>12 estimate?</p> <p>13 A. In past years, it has been about 150.</p> <p>14 This last year it was about 90.</p> <p>15 Q. And what -- what different mesh products</p> <p>16 do you recommend for your clients with SUI if you</p> <p>17 are recommending a mesh sling?</p> <p>18 MR. SNELL: Form, clients.</p> <p>19 MR. GRAND: Sorry. Patients.</p> <p>20 BY THE WITNESS:</p> <p>21 A. Thank you. The slings that I use</p> <p>22 currently are the TVT Exact, the Abbrevo, and I</p> <p>23 also use MiniArc.</p> <p>24 BY MR. GRAND:</p> <p>25 Q. You do not currently use the TVT-R or</p>	<p style="text-align: right;">Page 20</p> <p>1 Q. I know. I'm just trying to...</p> <p>2 And none of those hospitals currently</p> <p>3 carry the TVT retropubic or the TVT-O?</p> <p>4 A. I have not seen the product there in a</p> <p>5 while.</p> <p>6 Q. Have you ever discussed with anyone at</p> <p>7 the hospital why they don't carry those products</p> <p>8 any more?</p> <p>9 A. No.</p> <p>10 Q. Have you ever requested that they carry</p> <p>11 those products?</p> <p>12 A. No. I was happy with the transition to</p> <p>13 the Exact and the Abbrevo.</p> <p>14 Q. Now, you said with the exception of last</p> <p>15 year, which I believe you said you have done about</p> <p>16 90 procedures so far, you said on average you did</p> <p>17 about 150 per year?</p> <p>18 A. Correct.</p> <p>19 Q. Do you use any mesh products other than</p> <p>20 Ethicon products?</p> <p>21 A. Are you saying for stress incontinence</p> <p>22 or other indications?</p> <p>23 Q. Yes, for stress incontinence.</p> <p>24 A. So, the MiniArc is a AMS product.</p> <p>25 Q. All right. Anything else?</p>
<p style="text-align: right;">Page 19</p> <p>1 the TVT-O?</p> <p>2 A. Correct.</p> <p>3 Q. And when did you stop using those</p> <p>4 products? Strike that.</p> <p>5 Did you ever use those products?</p> <p>6 A. Yes, I did.</p> <p>7 Q. Okay. When did you stop using those</p> <p>8 products?</p> <p>9 A. I don't know the date. It has been at</p> <p>10 least two years.</p> <p>11 Q. And why did you stop using those</p> <p>12 products?</p> <p>13 A. Mostly availability.</p> <p>14 Q. And when you say availability, you mean</p> <p>15 the products weren't available at the hospital in</p> <p>16 which you worked?</p> <p>17 A. Correct.</p> <p>18 Q. And I'm sure I have it in your CV, but</p> <p>19 what hospital do you work out of?</p> <p>20 A. I operate out of four hospitals.</p> <p>21 Q. Okay.</p> <p>22 A. Christ Hospital is Oak Lawn, Good</p> <p>23 Samaritan Hospital in Downers Grove, Edward</p> <p>24 Hospital in Naperville and Elmhurst Hospital in</p> <p>25 Elmhurst. That's all on my CV.</p>	<p style="text-align: right;">Page 21</p> <p>1 A. Occasionally a Boston Scientific sling,</p> <p>2 the Advantage.</p> <p>3 Q. And are there certain -- what drives</p> <p>4 your decision to use one product as opposed to</p> <p>5 another in a given patient?</p> <p>6 A. Can you be more specific? Are you</p> <p>7 talking about whether I would use the Advantage or</p> <p>8 the Exact --</p> <p>9 Q. Yes.</p> <p>10 A. -- or whether I would use the Exact</p> <p>11 versus an obturator?</p> <p>12 Q. I believe you said you don't use the</p> <p>13 TVT-O any more, correct?</p> <p>14 A. Well, Abbrevo is an obturator sling, so</p> <p>15 I don't -- I don't understand what you are trying</p> <p>16 to ask me.</p> <p>17 Q. I'm not trying to focus in on the</p> <p>18 approach necessarily. I'm just asking, is there --</p> <p>19 is there a particular reason why you might use one</p> <p>20 product versus another with a patient that you were</p> <p>21 recommending a sling for?</p> <p>22 A. So, again, I'm finding that a little</p> <p>23 vague. Do you want to know why I would use the</p> <p>24 Advantage versus the Exact?</p> <p>25 Q. Sure. Let's start there.</p>

6 (Pages 18 to 21)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 22</p> <p>1 A. Okay. It could be that there was one 2 Exact on the shelf and somebody dropped it when 3 they opened it and others, an Advantage is on the 4 shelf and I would use that, but it's not my 5 preferred. 6 Q. Okay. So, is there -- do you view these 7 as being relatively comparable? 8 A. Relatively, but different. 9 Q. Have your billing rates changed? And 10 for litigation consulting, have your billing rates 11 changed since the last time you were deposed? 12 A. I don't think so. 13 Q. And I believe you said you have yet to 14 issue an invoice for the supplemental report, 15 correct? 16 A. Correct. 17 Q. Now, with respect to your own, the mesh 18 procedures you perform, do you keep any internal 19 databases that track those clients? I mean, track 20 those patients. 21 A. We have a EMR that has a lot of data in 22 it, so from time to time I will evaluate our 23 followup, how many cases we have done, which 24 product. 25 Q. I guess let me just try to approach more</p>	<p style="text-align: right;">Page 24</p> <p>1 A. Over a year. 2 Q. I just want to be clear. Did you look 3 at a year-long period or did you look beyond a 4 year-long period? 5 A. So, I don't remember what the time 6 period was. I know that my intention was to look 7 at a year after their incident, case. 8 Q. Okay. So, just to be clear, I want to 9 make sure I understand what you are saying in your 10 report and here today. If, for example, last year 11 you did a hundred mesh procedures, a hundred mesh 12 procedures, you would have looked at a hundred 13 patients; you didn't go back beyond that -- 14 MR. SNELL: Form. 15 Q. -- into prior years? 16 MR. SNELL: Form objection. Go ahead. 17 A. I would have looked at, say, the 18 patients that had surgery two years ago, over, 19 like, say 2013, so that even the ones at the end of 20 the year would have had a year followup. Does that 21 make sense? 22 Q. Okay. So, are you saying that you -- 23 your 4.5 percent is over a two-year period from 24 implant? 25 A. I wanted to make sure that the least</p>
<p style="text-align: right;">Page 23</p> <p>1 directly what I'm trying to get at. I believe in 2 your report you said that you had a revision rate, 3 an erosion rate of about 4.5 percent -- 4 A. Yes. 5 MR. SNELL: Objection. 6 Q. -- for your clients -- for your 7 patients? 8 MR. SNELL: Objection, compound, 9 misstates. 10 A. I said a reoperation rate of 4-1/2 11 percent. 12 Q. Okay. So a reoperation rate of any -- 13 for any reason? 14 A. Correct. 15 Q. How did you arrive at that 4.5 percent? 16 A. I don't remember which dates I looked 17 at, but I pulled the data on a substantial number 18 of slings in our practice and then tracked how many 19 of those over a certain period of time went back 20 for reoperation. 21 Q. Okay. What period of time did that 22 cover? 23 A. I don't remember. I believe it was at 24 least a year. 25 Q. Over a year? Just a year?</p>	<p style="text-align: right;">Page 25</p> <p>1 followup was a year. 2 Q. Okay. But it could have been longer, 3 you are saying? 4 A. Correct. 5 Q. But you can't tell me that today. I 6 mean, how many patients did you look at in total? 7 A. I don't remember. 8 Q. Would you have any dates? Would you 9 have any notes or calculations in your office? 10 A. Yes. 11 MR. GRAND: We are going to request 12 production of those. 13 THE WITNESS: Can I ask you a favor? 14 Because you say -- you are saying "mesh" 15 frequently and that makes me think of prolapse 16 surgery. So, if you mean sling, could you say 17 sling? Would that be okay? 18 MR. GRAND: Sure. Believe me, I'm not 19 trying to intentionally be confusing, by any 20 means. 21 THE WITNESS: You are probably used to 22 saying it that way, but it really throws me 23 off. 24 MR. GRAND: I will do my best. 25 MR. SNELL: And I will listen and</p>

7 (Pages 22 to 25)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 26</p> <p>1 object from now on when he is overboard. I'm</p> <p>2 sorry. I should have caught that.</p> <p>3 BY MR. GRAND:</p> <p>4 Q. All right. Just to be clear, so the 4.5</p> <p>5 percent reoperation rate that you referred to in</p> <p>6 your report, that refers to sling products or does</p> <p>7 that also include other mesh products?</p> <p>8 A. That was slings.</p> <p>9 Q. That would be slings only.</p> <p>10 And your analysis included patients -- I</p> <p>11 mean, generally you wanted to make sure you had a</p> <p>12 year-long followup period?</p> <p>13 A. Correct.</p> <p>14 Q. But your analysis did not go back three</p> <p>15 years or five years, did it?</p> <p>16 A. I will answer that when I look at the</p> <p>17 report. I don't remember how far it went back.</p> <p>18 MR. SNELL: You can look at the report</p> <p>19 too any time. I mean, you can always look at</p> <p>20 your materials. You brought all them here to.</p> <p>21 BY MR. GRAND:</p> <p>22 Q. Did you bring those materials that</p> <p>23 includes that calculation with you?</p> <p>24 A. No.</p> <p>25 MR. SNELL: I thought you said report.</p>	<p style="text-align: right;">Page 28</p> <p>1 patient previously and they are seeing somebody</p> <p>2 else, you would have no way of knowing whether they</p> <p>3 have had any subsequent complications?</p> <p>4 MR. SNELL: Form.</p> <p>5 A. Correct. There is some patients I won't</p> <p>6 know what happened.</p> <p>7 Q. And did your analysis address anything</p> <p>8 other than reoperations?</p> <p>9 A. No.</p> <p>10 Q. And if you were called to trial, do you</p> <p>11 intend to testify about your 4.5 reoperation rate</p> <p>12 in your practice?</p> <p>13 A. If you or Burt ask me.</p> <p>14 MR. GRAND: We are going to request</p> <p>15 production of backup, whatever supports that.</p> <p>16 MR. SNELL: We will take it under</p> <p>17 advisement. I will note for the record some</p> <p>18 of your experts have made similar statements</p> <p>19 yet have not produced the backup data.</p> <p>20 MR. GRAND: I don't know if you have</p> <p>21 asked for them or not. I'm asking for it.</p> <p>22 MR. SNELL: I know. I'm just putting</p> <p>23 my point on the record.</p> <p>24 BY MR. GRAND:</p> <p>25 Q. Other than what is in your CV, have you</p>
<p style="text-align: right;">Page 27</p> <p>1 I'm sorry.</p> <p>2 THE WITNESS: I said the 4.5 percent</p> <p>3 in the report, but I don't know that I</p> <p>4 included all the details of what I looked at.</p> <p>5 MR. SNELL: My point is, you can look</p> <p>6 at your -- he doesn't care if you -- I'm sure</p> <p>7 you don't mind if she looks at her report.</p> <p>8 MR. GRAND: No.</p> <p>9 BY MR. GRAND:</p> <p>10 Q. In fact, I would rather you not guess,</p> <p>11 and if you need to look at your report, you can. I</p> <p>12 don't believe your report has any specifics other</p> <p>13 than the 4.5 percent reoperation rate. That's why</p> <p>14 I'm actually asking you these questions, because</p> <p>15 I'm trying to determine how you arrived at that 4.5</p> <p>16 percent number and what number of patients are</p> <p>17 included in that.</p> <p>18 A. Understood. I don't think I put the</p> <p>19 details in the report either.</p> <p>20 Q. Do you have any -- do you track data in</p> <p>21 your office to determine how many of -- how many</p> <p>22 patients in which you've implanted a mesh sling you</p> <p>23 still currently treat?</p> <p>24 A. No.</p> <p>25 Q. So, if you implanted a mesh sling in a</p>	<p style="text-align: right;">Page 29</p> <p>1 done any -- have you published any articles</p> <p>2 relating to mesh, mesh slings?</p> <p>3 A. Any -- any articles are in the CV.</p> <p>4 Q. Okay. There has been nothing since that</p> <p>5 time?</p> <p>6 A. No.</p> <p>7 Q. And you don't currently -- are you</p> <p>8 currently teaching any classes?</p> <p>9 A. Classes?</p> <p>10 Q. Yes.</p> <p>11 A. No.</p> <p>12 Q. Are you currently doing any research</p> <p>13 relating for stress urinary incontinence?</p> <p>14 A. Yes.</p> <p>15 Q. What would that research be?</p> <p>16 A. We are studying a product called Vesair,</p> <p>17 V-e-s-a-i-r.</p> <p>18 MR. SNELL: Before you go any further,</p> <p>19 let me just caution you. If you are under any</p> <p>20 confidentiality agreements, and I don't know</p> <p>21 if you are or not, for other manufacturers,</p> <p>22 you need to take that into account before you</p> <p>23 give Mr. Grand an answer.</p> <p>24 THE WITNESS: Absolutely. I will not</p> <p>25 disclose anything I'm not supposed to.</p>

8 (Pages 26 to 29)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 30</p> <p>1 BY THE WITNESS:</p> <p>2 A. So, I can't tell you any results of the</p> <p>3 study, any data, but it is an intravesical balloon</p> <p>4 that's put in in the office.</p> <p>5 BY MR. GRAND:</p> <p>6 Q. And that's not an Ethicon product, is</p> <p>7 it?</p> <p>8 A. No.</p> <p>9 Q. And you are -- are you an investigator</p> <p>10 for that study?</p> <p>11 A. Yes.</p> <p>12 Q. Did you design the study?</p> <p>13 A. No.</p> <p>14 Q. And for how long have you been</p> <p>15 conducting the study?</p> <p>16 A. Roughly a year.</p> <p>17 Q. Are you involved in any other research</p> <p>18 relating to SUI or pelvic organ prolapse?</p> <p>19 A. The other study is a postmarketing study</p> <p>20 for the Impressa.</p> <p>21 Q. How do you spell "Impressa"?</p> <p>22 MR. SNELL: Yeah, what is it?</p> <p>23 BY MR. GRAND:</p> <p>24 Q. That's not an Ethicon product, is it?</p> <p>25 A. No.</p>	<p style="text-align: right;">Page 32</p> <p>1 don't know which pile it's in.</p> <p>2 BY MR. GRAND:</p> <p>3 Q. So we are looking at the same thing, is</p> <p>4 this your first report or the supplemental report?</p> <p>5 A. This is the first report, but I don't</p> <p>6 see the CV in here, so I --</p> <p>7 Q. You can be -- you can -- well, I have</p> <p>8 the copy that was in my report. I can give that to</p> <p>9 you.</p> <p>10 A. That would be great.</p> <p>11 MR. GRAND: We will mark your July</p> <p>12 2014 report as Elser 3.</p> <p>13 (Elser Exhibit 3 was marked for</p> <p>14 identification as of 11/5/15.)</p> <p>15 MR. GRAND: Did you want this?</p> <p>16 MR. SNELL: I will take it. I don't</p> <p>17 think I have her CV. If I did, it's somewhere</p> <p>18 in all of this stuff.</p> <p>19 MR. GRAND: So, I've got it. It's</p> <p>20 Attachment A.</p> <p>21 THE WITNESS: A lot of trees in this</p> <p>22 room.</p> <p>23 MR. GRAND: Yes.</p> <p>24 BY THE WITNESS:</p> <p>25 A. Okay. Now I forgot what you asked. You</p>
<p style="text-align: right;">Page 31</p> <p>1 Q. No. And is that I-m-p-r-e-s-s-a?</p> <p>2 A. Yes, it is.</p> <p>3 Q. Okay. You never know with these pharma</p> <p>4 products.</p> <p>5 A. It's a Kimberly Clark product.</p> <p>6 Q. And is that -- is that a device or a</p> <p>7 pharmaceutical product?</p> <p>8 A. Well, it's an over-the-counter device,</p> <p>9 so it's basically an intravaginal tampon</p> <p>10 specifically designed to put pressure on the</p> <p>11 urethra so when women wear it they can exercise and</p> <p>12 not leak.</p> <p>13 Q. And you are an investigator in that</p> <p>14 study?</p> <p>15 A. Yes.</p> <p>16 Q. Did you design that study?</p> <p>17 A. No.</p> <p>18 Q. In general do you have -- do you have</p> <p>19 any experience designing clinical trials?</p> <p>20 A. Yes.</p> <p>21 Q. What clinical trials have you designed?</p> <p>22 A. We can look at my CV.</p> <p>23 Q. If you want to, look at your CV.</p> <p>24 A. Sure. Hold on.</p> <p>25 THE WITNESS: Thank you, Burt. I</p>	<p style="text-align: right;">Page 33</p> <p>1 want to know what studies I had designed. Was that</p> <p>2 specifically with regard to stress incontinence?</p> <p>3 BY MR. GRAND:</p> <p>4 Q. Well, actually, I would like to know if</p> <p>5 you -- if you have ever designed a clinical study</p> <p>6 as opposed to being an investigator for a clinical</p> <p>7 study.</p> <p>8 MR. SNELL: Form. Go ahead.</p> <p>9 A. So, I'm on Page 4.</p> <p>10 Q. Okay.</p> <p>11 A. The last one on that page, abdominal</p> <p>12 sacrocolpopexy and urinary incontinence, was my</p> <p>13 design.</p> <p>14 Q. Was that a randomized control trial?</p> <p>15 A. No. That was a retrospective K series.</p> <p>16 Q. That was a retrospective K series?</p> <p>17 A. Yes. On the next page, Page 5, the last</p> <p>18 two.</p> <p>19 Q. And what types of studies were those?</p> <p>20 A. The comparison of the different</p> <p>21 catheters was a randomized controlled trial.</p> <p>22 And the last study was also an RCT,</p> <p>23 which I helped design as part of the continence</p> <p>24 program for women, and that's it on this page. The</p> <p>25 others were not published.</p>

9 (Pages 30 to 33)

Denise M. Elser, M.D.

Page 34	Page 36
<p>1 Q. Do you currently sit as a reviewer for</p> <p>2 any medical journals?</p> <p>3 A. Yes.</p> <p>4 Q. Which ones?</p> <p>5 A. The International Urogynecologic</p> <p>6 Journal, The Obstetrics and Gynecology Journal, The</p> <p>7 American Journal of Obstetrics and Gynecology and</p> <p>8 Female Pelvic Medicine Reconstructive Surgery.</p> <p>9 Q. And actually, while you have your resume</p> <p>10 open, if you look at -- sorry -- Page 4. I just</p> <p>11 wanted to clarify. The consultation for the Food</p> <p>12 and Drug Administration panel --</p> <p>13 A. Yes.</p> <p>14 Q. -- did that begin in 2013 or was it</p> <p>15 2014?</p> <p>16 A. They do background checks, so they first</p> <p>17 asked me to be part of it in 2013.</p> <p>18 Q. Okay. So but the first time you sat on</p> <p>19 a panel was 2014, correct?</p> <p>20 A. Yes -- no. Sorry. The first time I sat</p> <p>21 on it was 2015.</p> <p>22 Q. 2015, okay. And you are a nonvoting</p> <p>23 member, correct?</p> <p>24 A. Correct.</p> <p>25 Q. Would you hold yourself out as an expert</p>	<p>1 clinical trial design.</p> <p>2 A. I have had statistic courses, and then</p> <p>3 throughout our training and working career we have</p> <p>4 journal club where we talk about how to analyze</p> <p>5 articles.</p> <p>6 Q. When was the last time you had a</p> <p>7 statistics course?</p> <p>8 A. Oh. 15 years ago.</p> <p>9 Q. And can you tell me a little bit more</p> <p>10 about this journal club you just referenced.</p> <p>11 A. In our practice we will have meetings</p> <p>12 where we pull articles to read and discuss them</p> <p>13 with other physicians and have someone analyze the</p> <p>14 article.</p> <p>15 Q. And what's the name of that journal</p> <p>16 club?</p> <p>17 A. It doesn't have a name. It's just our</p> <p>18 practice and we have --</p> <p>19 Q. So you do that within your private</p> <p>20 practice?</p> <p>21 A. Yes.</p> <p>22 Q. Okay. So, you get together with the</p> <p>23 physicians in your practice and you discuss</p> <p>24 articles?</p> <p>25 A. Correct.</p>
Page 35	Page 37
<p>1 in clinical trial design? Do you consider yourself</p> <p>2 an expert in clinical trial design?</p> <p>3 A. I'm very familiar with clinical trial</p> <p>4 design, but it's not what I do on a regular basis.</p> <p>5 Q. So is that a no?</p> <p>6 MR. SNELL: I object to the form,</p> <p>7 asked and answered.</p> <p>8 Q. Do you hold yourself out as an expert in</p> <p>9 clinical trial design?</p> <p>10 A. I understand clinical trial design. I'm</p> <p>11 not an expert in it.</p> <p>12 Q. What about material science? Do you</p> <p>13 consider yourself an expert in material science?</p> <p>14 A. No.</p> <p>15 Q. Do you consider yourself an expert in</p> <p>16 the design of medical devices?</p> <p>17 A. No.</p> <p>18 Q. Do you consider yourself an expert in</p> <p>19 epidemiology?</p> <p>20 A. No.</p> <p>21 Q. Have you received special training with</p> <p>22 respect to analyzing clinical -- analyzing and</p> <p>23 evaluating clinical studies?</p> <p>24 A. What do you mean by "special training"?</p> <p>25 Q. Courses in epidemiology or statistics or</p>	<p>1 Q. How often does that happen?</p> <p>2 A. Every few months.</p> <p>3 Q. Every few months. I would like to mark</p> <p>4 as --</p> <p>5 A. Does that mean I can close this one now,</p> <p>6 that page?</p> <p>7 Q. Yes.</p> <p>8 A. That page? Okay.</p> <p>9 Q. Yeah. If it is easier for you to refer</p> <p>10 to your report moving forward, please feel free to</p> <p>11 do so. I just want to have a copy of your report</p> <p>12 in the record.</p> <p>13 MR. GRAND: I'm going to mark as</p> <p>14 Elser 4 your supplemental report.</p> <p>15 (Elser Exhibit 4 was marked for</p> <p>16 identification as of 11/5/15.)</p> <p>17 BY MR. GRAND:</p> <p>18 Q. Do you need a copy of that?</p> <p>19 A. I have a copy here.</p> <p>20 Q. Now, in your first report from July of</p> <p>21 2014 you had reserved the right to supplement your</p> <p>22 report based on new information --</p> <p>23 A. Yes.</p> <p>24 Q. -- in response to Plaintiffs' experts,</p> <p>25 as I recall. Is that correct?</p>

10 (Pages 34 to 37)

Denise M. Elser, M.D.

Page 38	Page 40
<p>1 A. Correct.</p> <p>2 Q. And one of the things that was revised</p> <p>3 in your supplemental report was the list of</p> <p>4 materials you relied on, correct?</p> <p>5 A. Correct.</p> <p>6 Q. Okay. Did you prepare that reliance</p> <p>7 list?</p> <p>8 A. It was a combination.</p> <p>9 Q. A combination of what?</p> <p>10 A. Of some were provided to me by the</p> <p>11 attorneys and there were many articles that I</p> <p>12 pulled and provided to them.</p> <p>13 Q. Okay. Just to be clear, I'm actually --</p> <p>14 I will ask about that. I'm going to ask</p> <p>15 specifically about the preparation of the list</p> <p>16 itself. Did you prepare the reliance list, or was</p> <p>17 that prepared by attorneys?</p> <p>18 MR. SNELL: You mean the paper?</p> <p>19 MR. GRAND: Yeah, the actual list that</p> <p>20 was submitted.</p> <p>21 MR. SNELL: We prepared that. I will</p> <p>22 put that on the record.</p> <p>23 BY MR. GRAND:</p> <p>24 Q. Okay. Were you aware that there were</p> <p>25 approximately 575 new medical articles added to</p>	<p>1 A. Yes.</p> <p>2 Q. Okay. So, if you look about the fifth</p> <p>3 from the bottom on your revised list, which is the</p> <p>4 one on your left, you see that "Abdel-Fattah,</p> <p>5 Transobturator tension-free vaginal tapes: Are</p> <p>6 they the way forward"? Do you see that article?</p> <p>7 A. Yes.</p> <p>8 Q. Dated 2007?</p> <p>9 A. Yes.</p> <p>10 Q. Do you see that article in your original</p> <p>11 reliance list?</p> <p>12 A. No, I don't see that one.</p> <p>13 Q. That was an article that was certainly</p> <p>14 available at the time that you wrote your original</p> <p>15 report, correct?</p> <p>16 A. Yes. It had already been printed, but</p> <p>17 sometimes when you do a literature search not</p> <p>18 everything may show up. You may find new articles</p> <p>19 even if they were printed previously.</p> <p>20 Q. Would it surprise you if the majority --</p> <p>21 that the majority of the ones you added were</p> <p>22 available many, many years before you wrote your</p> <p>23 report?</p> <p>24 A. I don't know. I have not analyzed that</p> <p>25 yet.</p>
Page 39	Page 41
<p>1 that list?</p> <p>2 MR. SNELL: I'm going to object it</p> <p>3 lacks foundation.</p> <p>4 Q. All right. We will go through them one</p> <p>5 by one. I want you to put both your reports beside</p> <p>6 you there so that you can compare the reliance list</p> <p>7 in the original report to the one in your</p> <p>8 supplemental report.</p> <p>9 A. Okay. I start -- this doesn't look like</p> <p>10 the page that you have.</p> <p>11 Q. No. I'm looking at the second report,</p> <p>12 the supplemental report.</p> <p>13 A. Okay. I'm with you.</p> <p>14 Q. So, before we actually look at those,</p> <p>15 when you were preparing your report, did you --</p> <p>16 when you first drafted this report for the Corbet</p> <p>17 case, the original report, how did you seek to</p> <p>18 identify articles that would be relevant to your</p> <p>19 opinions?</p> <p>20 A. Some I knew existed from prior reading,</p> <p>21 so I pulled and printed them to have available.</p> <p>22 Some I did literature search to look for articles I</p> <p>23 thought would be relevant, and some were provided</p> <p>24 to me.</p> <p>25 Q. Some were provided to you by attorneys?</p>	<p>1 Q. Do you have a copy of this article in</p> <p>2 your file? You brought your file here today.</p> <p>3 A. I don't know if that one is in it or</p> <p>4 not.</p> <p>5 Q. Are all the articles you relied on in</p> <p>6 your file?</p> <p>7 A. Not everything from this reliance list</p> <p>8 is in my file, but there are many articles in the</p> <p>9 file.</p> <p>10 Q. If you didn't rely on it, why would it</p> <p>11 be in your file?</p> <p>12 A. Some of these are here because they were</p> <p>13 provided and some were ones that I've read in the</p> <p>14 past. I may not specifically have cited it in the</p> <p>15 report.</p> <p>16 Q. So there may be articles in your</p> <p>17 reliance list that have nothing to do with your</p> <p>18 opinions?</p> <p>19 MR. SNELL: Form.</p> <p>20 A. There could be.</p> <p>21 Q. Did you review this list before it</p> <p>22 was -- the revised list before it was submitted?</p> <p>23 A. I looked at it.</p> <p>24 Q. You know there are a number of articles</p> <p>25 relating to the Prolift product in there?</p>

11 (Pages 38 to 41)

Denise M. Elser, M.D.

Page 42	Page 44
<p>1 A. Yes.</p> <p>2 Q. Is that relative to your opinions in</p> <p>3 this case?</p> <p>4 A. Not in this case.</p> <p>5 Q. Then why did you have it in your report?</p> <p>6 MR. SNELL: I told you, we prepared</p> <p>7 that.</p> <p>8 MR. GRAND: Okay. Well, it's her</p> <p>9 report, though. Either she knows or she</p> <p>10 doesn't know.</p> <p>11 MR. SNELL: That's fine.</p> <p>12 BY THE WITNESS:</p> <p>13 A. No. This list was prepared, was printed</p> <p>14 by the attorneys' office. I did not -- some</p> <p>15 articles were added.</p> <p>16 BY MR. GRAND:</p> <p>17 Q. So, is it fair to say this really isn't</p> <p>18 a reliance list for your report?</p> <p>19 A. Are you saying this is not the list</p> <p>20 specific to my report?</p> <p>21 Q. Yes.</p> <p>22 A. Some of the articles are not specific to</p> <p>23 this report.</p> <p>24 Q. So, this list actually just is all the</p> <p>25 articles you may have reviewed or had sent to you</p>	<p>1 MR. SNELL: She told you to pull that</p> <p>2 stuff is --</p> <p>3 MR. GRAND: She has to go through it.</p> <p>4 MR. SNELL: Well, we will try to go</p> <p>5 through it then at a break or at lunch. How</p> <p>6 about that?</p> <p>7 MR. GRAND: Okay.</p> <p>8 MR. SNELL: She has already said the</p> <p>9 Prolift stuff isn't -- isn't going to be</p> <p>10 discussed or pertinent.</p> <p>11 BY MR. GRAND:</p> <p>12 Q. Have you read all the articles that are</p> <p>13 on this list?</p> <p>14 A. Not every article.</p> <p>15 Q. What?</p> <p>16 A. Not every article.</p> <p>17 Q. If you go several pages in, beyond the</p> <p>18 medical articles, do you see there is a list of</p> <p>19 documents?</p> <p>20 MR. SNELL: What page are you -- which</p> <p>21 one are you referring to?</p> <p>22 MR. GRAND: It's not numbered.</p> <p>23 MR. SNELL: The one that's -- are you</p> <p>24 talking about production materials or other</p> <p>25 material? I mean, they are labeled at the</p>
Page 43	Page 45
<p>1 by attorneys?</p> <p>2 A. Correct.</p> <p>3 Q. So if I wanted to know which articles in</p> <p>4 here you viewed as new information or material that</p> <p>5 you've reviewed in response to the Plaintiffs'</p> <p>6 expert reports, how would I be able to identify</p> <p>7 that?</p> <p>8 A. Well, I would be happy to mark up a copy</p> <p>9 for you and get it to you.</p> <p>10 Q. Okay. I am going to request that, and</p> <p>11 I'm not trying to be difficult. I'm trying to</p> <p>12 understand what you will be talking about when you</p> <p>13 come to trial as opposed to what is completely</p> <p>14 irrelevant to your report.</p> <p>15 A. Okay.</p> <p>16 Q. I'm expecting you can. I don't want to</p> <p>17 spend the day going through this list one by one.</p> <p>18 A. Are you sure?</p> <p>19 MR. SNELL: Well, we can do that. She</p> <p>20 is here to help you or to do whatever you</p> <p>21 want, and you have her report where she cites</p> <p>22 to articles and discusses them. So, you know,</p> <p>23 if you want to ask her, ask her.</p> <p>24 MR. GRAND: She just told me she</p> <p>25 doesn't know.</p>	<p>1 top.</p> <p>2 MR. GRAND: Yes, it would be</p> <p>3 production materials.</p> <p>4 BY MR. GRAND:</p> <p>5 Q. Do you see it? Are you there?</p> <p>6 A. Starts with letter to the FDA -- from</p> <p>7 the FDA?</p> <p>8 Q. Yes. That would be the first item on</p> <p>9 that list. Have you reviewed all the materials on</p> <p>10 this list?</p> <p>11 A. No. I have reviewed several but not</p> <p>12 every one.</p> <p>13 Q. Is it fair to say if you didn't review</p> <p>14 it, you certainly didn't rely on it, correct?</p> <p>15 A. Correct.</p> <p>16 Q. And then after that is a list of medical</p> <p>17 records and as well as other types of materials and</p> <p>18 the expert reports. Do you see that?</p> <p>19 A. Not yet.</p> <p>20 Q. If you keep going, I think it is</p> <p>21 probably the next page.</p> <p>22 A. Yeah, I think I'm getting there, yeah.</p> <p>23 Okay.</p> <p>24 Q. Now, is this -- is this an update to the</p> <p>25 list of medical records you reviewed, or are these</p>

12 (Pages 42 to 45)

Denise M. Elser, M.D.

Page 46	Page 48
<p>1 new records you reviewed since the last report?</p> <p>2 A. No. Some of these I would have reviewed</p> <p>3 for the original report.</p> <p>4 Q. Okay. And have you seen or reviewed the</p> <p>5 IME report that was done by Dr. Fleischmann?</p> <p>6 A. No.</p> <p>7 Q. Would that be relevant to your opinions?</p> <p>8 A. I would be interested in her findings.</p> <p>9 Q. Well, she conducted --</p> <p>10 A. My opinions are based on the exams to</p> <p>11 date and medical records provided to me.</p> <p>12 Q. Okay. Were you aware that last month</p> <p>13 Dr. Fleischmann conducted a medical examination of</p> <p>14 Kathryn Corbet?</p> <p>15 A. I only just heard about it.</p> <p>16 Q. Okay. When did you hear about it?</p> <p>17 A. This morning.</p> <p>18 Q. Okay. Did you request a copy of the</p> <p>19 examination?</p> <p>20 A. No, not yet.</p> <p>21 Q. It would certainly be relevant to your</p> <p>22 opinion, correct?</p> <p>23 A. It might be.</p> <p>24 Q. Well, for instance, if she were</p> <p>25 suffering -- if she had complaint of dyspareunia,</p>	<p>1 little long.</p> <p>2 MR. GRAND: I'm not trying to hold you</p> <p>3 to doing that in ten minutes.</p> <p>4 THE WITNESS: We want to do it</p> <p>5 justice.</p> <p>6 MR. SNELL: Obviously all the material</p> <p>7 is cited in her reports directly.</p> <p>8 MR. GRAND: Yes. I'm not questioning</p> <p>9 that, and just to be clear, I appreciate that</p> <p>10 there are articles cited in the text of the</p> <p>11 report itself, and it's very clear to me that</p> <p>12 you are relying on those articles.</p> <p>13 MR. SNELL: Okay.</p> <p>14 MR. GRAND: What's not clear to me is</p> <p>15 there is a lot of -- a lot of additional</p> <p>16 materials in the supplemental reliance list,</p> <p>17 and I need to know what I need to be prepared</p> <p>18 for at trial.</p> <p>19 MR. SNELL: Let's go off the record</p> <p>20 for a second. Is that okay?</p> <p>21 MR. GRAND: Sure.</p> <p>22 THE VIDEOGRAPHER: The time is</p> <p>23 10:13 a.m., and we are going off the video</p> <p>24 record.</p> <p>25 (Discussion was had off the</p>
Page 47	Page 49
<p>1 that would be relevant to your opinion, correct?</p> <p>2 MR. SNELL: Form.</p> <p>3 A. I would certainly want to --</p> <p>4 MR. SNELL: Foundation. Go ahead.</p> <p>5 A. I would want to know what her current</p> <p>6 complaints are and, more importantly, what the exam</p> <p>7 finding are.</p> <p>8 Q. Right. To be fair, to render an opinion</p> <p>9 in this case, you would want to have the most</p> <p>10 up-to-date information available, correct?</p> <p>11 MR. SNELL: Objection, form.</p> <p>12 A. I would like to look at the up-to-date</p> <p>13 exam.</p> <p>14 Q. Me too.</p> <p>15 A. We are closing this set right now? I</p> <p>16 don't want to mess up the papers.</p> <p>17 Q. We are closing the reliance list.</p> <p>18 A. Okay.</p> <p>19 Q. I don't want to ask you any more</p> <p>20 questions about the reliance list. My</p> <p>21 understanding is you are going to look at it during</p> <p>22 the break and try to tell me what you think is</p> <p>23 relevant to your opinions.</p> <p>24 MR. SNELL: We will probably do that</p> <p>25 over a break at lunch because it might take a</p>	<p>1 record.)</p> <p>2 THE VIDEOGRAPHER: The time is</p> <p>3 10:17 a.m., and we are back on the video</p> <p>4 record.</p> <p>5 BY MR. GRAND:</p> <p>6 Q. Dr. Elser, I understand that you have</p> <p>7 brought your file with you today, correct?</p> <p>8 A. Yes.</p> <p>9 Q. And as part of that you have brought us</p> <p>10 a thumb drive and seven DVDs or CD-ROMs with --</p> <p>11 seven CD-ROMs, correct?</p> <p>12 A. Yes.</p> <p>13 Q. Does this constitute all of the medical</p> <p>14 literature and records or documents you will have</p> <p>15 reviewed for this case?</p> <p>16 MR. SNELL: I'm going to object to</p> <p>17 form. There is other stuff she brought, just</p> <p>18 so the record is clear, because the video is</p> <p>19 not showing all of the materials she brought.</p> <p>20 MR. GRAND: Okay.</p> <p>21 MR. SNELL: I just want it to be</p> <p>22 accurate. That's all.</p> <p>23 MR. GRAND: No. I want to understand</p> <p>24 what we need to be walking away from here with</p> <p>25 today, so...</p>

13 (Pages 46 to 49)

Denise M. Elser, M.D.

Page 50	Page 52
<p>1 MR. SNELL: You are free to mark 2 everything, and I have no problem with it, and 3 I think that's why the doctor brought it, so 4 you would have fair notice on all of the stuff 5 she has reviewed and considered. I know it is 6 pretty voluminous, but I don't know any way 7 around that, to be honest with you. 8 MR. GRAND: Okay. 9 MR. SNELL: Sometimes your experts 10 just show up a thumb drive, sometimes they 11 have hard copies. I mean, I make judgments on 12 what I mark and don't mark, but I don't want 13 there to be, you know, some misrepresentation 14 that that's all she has looked at, because she 15 did bring some hard copy stuff here today that 16 may or may not be in that. That's all I am 17 trying to say. 18 BY MR. GRAND: 19 Q. Doctor, I'm trying to identify what 20 materials you reviewed and relied on in preparing 21 your report, both of your reports. 22 Beyond this thumb drive and these CDs, 23 what else is there? 24 A. I believe -- I believe the thumb drive 25 is pretty comprehensive, but as Burt said, there</p>	<p>1 that's dated July 2nd, 2015. 2 Now, would this pertain to the TVT-O 3 case we were discussing earlier? 4 A. Yes. 5 Q. Would there be materials on this that 6 are relevant to your opinions in this case? 7 A. There could be. 8 Q. Another one marked "Ethicon Gynecare 9 Pelvic Mesh Litigation TVT-O." 10 Another one dated July 31st, 2015, "New 11 Prolift/POP studies." 12 Another one dated 7/31/15 that says 13 "Sling Long-Term Articles." 14 Another one dated June 2nd, 2015, 15 pertaining to the Edwards case. 16 And these are -- all of these CD-ROMs 17 are labeled Butler Snow. Is it fair to say these 18 were provided to you by Butler Snow? 19 A. Yes. 20 Q. Okay. And then we have additional 21 medical records and transcripts from the Corbet 22 case and this is dated August 25th, 2015? 23 A. Yes. 24 Q. Would it be fair to say you were working 25 on the supplemental report as early as August 25th,</p>
Page 51	Page 53
<p>1 may be some medical records and articles in these 2 binders that are not included on that thumb drive. 3 MR. GRAND: Okay. I'm going to mark, 4 I guess -- I don't know how else to do it. I 5 don't know if I'm going to put a sticker on 6 this or not. 7 MR. SNELL: That's what I usually do. 8 Just mark them in order so that they are 9 clear. 10 MR. GRAND: I'm going to mark the 11 thumb drive and the -- 12 MR. SNELL: Why don't you mark the 13 thumb drive separate. 14 MR. GRAND: All right. I'm going to 15 mark the CDs as Elser 5, and there is seven of 16 them, and I'm going to read out the titles of 17 them. 18 One is "Ethicon Gynecare Pelvic Mesh 19 Litigation, Additional Medical Records & 20 Transcripts Corbet," and that appears to be 21 dated 8/25/15. 22 Another one is marked "Corbet Ethicon 23 Gynecare Pelvic Mesh Litigation." 24 Another one is marked "Ethicon 25 Gynecare Pelvic Mesh Litigation Edwards," and</p>	<p>1 2015? 2 MR. SNELL: Form. 3 A. No. I put the date on of when the 4 disk -- when I opened the envelope just to help me 5 keep track. I may not have even have looked at it 6 until I knew that we were going to do an additional 7 report. 8 MR. GRAND: Okay. So those we are 9 going to let the court reporter -- can you 10 take and make a copy of it so we can get the 11 originals back to Dr. Elser? 12 THE REPORTER: I think so. 13 MR. GRAND: I'm going to mark as 14 Elser 6 -- 15 MR. SNELL: And can I just make a 16 request whenever they are copied, can the 17 cover that Mr. Grand read be reflected, can 18 they be separated maybe 7, you know, A, B, C, 19 D so that we know the different DVDs instead 20 of one large PDF file that is a cumulation of 21 all the electronic files on there. I don't 22 know if I'm being clear, but... 23 MR. GRAND: Yeah, no. My feeling, I 24 would request if we could actually just get 25 burned copies of the CDs and then maybe just a</p>

14 (Pages 50 to 53)

Denise M. Elser, M.D.

Page 54	Page 56
<p>1 PDF of the cover and the cover sheet.</p> <p>2 MR. SNELL: Yeah, that's what I</p> <p>3 meant.</p> <p>4 MR. GRAND: I'm not suggesting we have</p> <p>5 to print all these out.</p> <p>6 I'm marking the thumb drive as</p> <p>7 Elser 6, and let me just go off the record for</p> <p>8 a second.</p> <p>9 THE VIDEOGRAPHER: The time is</p> <p>10 10:21 a.m., and we are going off the video</p> <p>11 record.</p> <p>12 (Recess taken, 10:21 - 10:36 a.m.)</p> <p>13 (Said disks were marked Elser</p> <p>14 Exhibits 5-A through Exhibit 5-G,</p> <p>15 said thumb drive was marked as</p> <p>16 Exhibit 6, and certain documents</p> <p>17 were marked Exhibits 7 and 8, for</p> <p>18 identification, as of 11/5/15.)</p> <p>19 THE VIDEOGRAPHER: The time is</p> <p>20 10:36 a.m., and we are back on the video</p> <p>21 record.</p> <p>22 MR. GRAND: Okay. So the record is</p> <p>23 clear, the court reporter is going to take</p> <p>24 Exhibit 5, which was the seven CD-ROMs. She</p> <p>25 is going to copy them for us, and they will be</p>	<p>1 you looked at these articles?</p> <p>2 A. No.</p> <p>3 Q. What did you do on your own to</p> <p>4 investigate or find out information about the</p> <p>5 development of the TVT product and any early data</p> <p>6 for that product?</p> <p>7 A. You mean ever in my whole career?</p> <p>8 Q. In connection with the Corbet case.</p> <p>9 A. Well, some of --</p> <p>10 MR. SNELL: Form. Go ahead.</p> <p>11 A. Well, certainly I have been practicing</p> <p>12 since TVT first came to the U.S., so I have been</p> <p>13 reading articles about TVT and its development for</p> <p>14 many, many years, so some of those articles I had</p> <p>15 already read and were already in my files and I</p> <p>16 would have pulled for this case to re-review, and</p> <p>17 some were provided to me, which I don't remember</p> <p>18 when between August and now, but I read those</p> <p>19 again.</p> <p>20 Q. Okay. So, these are not -- these</p> <p>21 articles you were already aware of. Did you</p> <p>22 request that they be compiled for you this way, or</p> <p>23 did the attorneys do that for you?</p> <p>24 A. I did not request that.</p> <p>25 Q. Okay. Let me just keep these together.</p>
Page 55	Page 57
<p>1 labeled 5-A and 5-B, accordingly, as well as</p> <p>2 Elser 6, which was the thumb drive.</p> <p>3 BY MR. GRAND:</p> <p>4 Q. During the break I went through your</p> <p>5 file, and I am satisfied that the things contained</p> <p>6 in the file are listed on the -- they are things we</p> <p>7 are already aware of, such as deposition</p> <p>8 transcripts and various articles, which I do not</p> <p>9 need to mark or include at this point.</p> <p>10 There is one thing that I did want to</p> <p>11 ask you about, which I have marked as Elser 7,</p> <p>12 which appears to be a small bound document called</p> <p>13 TVT Development and Early Data.</p> <p>14 A. Yes.</p> <p>15 Q. Okay. Did you make this yourself?</p> <p>16 A. No.</p> <p>17 Q. Was this provided to you by Butler Snow?</p> <p>18 A. Yes.</p> <p>19 Q. And in fact, there is a letter in here</p> <p>20 which I have marked as Elser 8, which is a letter</p> <p>21 from a paralegal at Butler Snow transmitting this</p> <p>22 to you for your review. It's dated August 27th,</p> <p>23 2015. Do you see that?</p> <p>24 A. Yes.</p> <p>25 Q. So is August 27, 2015, the first time</p>	<p>1 What have you done to satisfy yourself</p> <p>2 that you have a thorough collection of TVT</p> <p>3 articles?</p> <p>4 A. I'm not sure I understand.</p> <p>5 Q. Well, this is a select group of</p> <p>6 articles, correct?</p> <p>7 A. Correct.</p> <p>8 Q. You don't believe that this is every</p> <p>9 article relating to the TVT development or early</p> <p>10 data on the TVT, correct?</p> <p>11 A. Oh, no.</p> <p>12 Q. So, my question is, did you -- what did</p> <p>13 you do to make sure you found other articles that</p> <p>14 were not provided to you by attorneys?</p> <p>15 A. Well, I do literature searches all the</p> <p>16 time or I read journals as they come out every</p> <p>17 month related to my field.</p> <p>18 Q. We will just set these aside.</p> <p>19 I want to circle back for a minute and</p> <p>20 ask you some more questions about your practice.</p> <p>21 What course of treatment do you currently recommend</p> <p>22 for patients suffering from SUI?</p> <p>23 MR. SNELL: Form. Go ahead.</p> <p>24 A. Patients coming in with stress</p> <p>25 incontinence, I always counsel them that their</p>

15 (Pages 54 to 57)

Denise M. Elser, M.D.

Page 58	Page 60
<p>1 options are conservative to start with. They don't 2 need to treat it. They can -- if they are 3 overweight they can lose weight, which should help. 4 They can control their constipation, which affects 5 bladder function, and we can start with pelvic 6 exercise, and specifically my preference is 7 physical therapy, although not all patients have 8 access to that.</p> <p>9 Other options are to use a device like a 10 pessary or the new Impressa that's over the 11 counter. We have available to us then surgery for 12 treating the stress incontinence.</p> <p>13 Q. Okay. With respect to surgery, what 14 types of surgical options do you currently 15 recommend or discuss with your patients?</p> <p>16 A. My number one recommendation is a sling, 17 a midurethral sling, and there are some instances 18 where I will perform a Burch, and then also I did 19 not include periurethral injections of bulking 20 agents which are indicated for a subset of 21 patients.</p> <p>22 Q. So, just to be clear, your -- is your 23 sort of -- and understanding this may vary from 24 patient to patient and how they present to you, 25 your first-line recommendation would be more</p>	<p>1 prolapse, do you still do procedures involving mesh 2 to treat pelvic organ prolapse?</p> <p>3 A. Yes.</p> <p>4 Q. Is that -- do you typically do that 5 through the abdominal approach or transvaginal?</p> <p>6 A. If I use mesh, the majority are 7 abdominal, but I still employ vaginal mesh.</p> <p>8 Q. And which products do you currently use 9 to treat pelvic organ prolapse, mesh products?</p> <p>10 A. Most commonly I will use the Elevate, 11 which is an AMS product.</p> <p>12 Q. Do you use any Gynecare meshes to treat 13 pelvic organ prolapse currently?</p> <p>14 A. No.</p> <p>15 Q. Okay. I'm going to ask you some 16 questions about your first report, the July report.</p> <p>17 A. Okay. I think that's this one.</p> <p>18 Q. Towards the bottom of Page 1 you said, 19 you state, second-to-the-last line from the bottom, 20 "I am involved in teaching at the resident and 21 fellow level." Is that rounds, basically?</p> <p>22 A. We have had fellows in the office, 23 although currently I don't have one, and residents 24 work with us in the office and in the operating 25 room.</p>
Page 59	Page 61
<p>1 conservative treatments?</p> <p>2 A. Yes.</p> <p>3 Q. And then if you feel a surgical option 4 is needed, you would then go to a mesh sling?</p> <p>5 A. Yes.</p> <p>6 Q. And would you do that -- when you said 7 that the injections are limited to a certain subset 8 of patients, what patients are those better limited 9 to?</p> <p>10 A. Well, the bulking agents are indicated 11 for patients with intrinsic sphincteric deficiency, 12 which we abbreviate as ISD, and most specifically 13 those that don't have a hypermobile urethra, so a 14 fixed urethra; and it tends to not be a good option 15 for young women and it's more reserved for frail 16 elderly.</p> <p>17 Q. Other than a Burch procedure, are there 18 any types of, for lack of a better word, 19 traditional surgical options that you still employ?</p> <p>20 A. So, if you are asking about traditional 21 pubovesical slings, I don't perform those any more.</p> <p>22 Q. Okay.</p> <p>23 A. And I have done lots of them, but I 24 don't offer them.</p> <p>25 Q. And with respect to pelvic organ</p>	<p>1 Q. Okay. And you have already discussed 2 the slings that were -- the mesh slings that are 3 available at your hospital, correct?</p> <p>4 A. Yes.</p> <p>5 Q. And when you do procedures at any -- at 6 the hospitals in which you work in, are you -- do 7 you have your own informed consents or do you rely 8 on the hospital's forms?</p> <p>9 A. When I'm working at the hospital or when 10 I'm consenting a patient for surgery?</p> <p>11 Q. Consenting a patient for surgery.</p> <p>12 A. Okay. So, I do have my own consents in 13 the office that I will go over with the patient 14 when we are talking about surgery, implanting it.</p> <p>15 Q. Do you have a different -- a different 16 consent form that you use for mesh slings?</p> <p>17 MR. SNELL: Form.</p> <p>18 A. I have a consent form for stress 19 incontinence surgery and I have a consent form for 20 prolapse surgery.</p> <p>21 Q. Would you have a copy of those in your 22 file?</p> <p>23 A. I don't think so.</p> <p>24 MR. GRAND: We would like to request a 25 copy of those consent forms, just whatever the</p>

16 (Pages 58 to 61)

Denise M. Elser, M.D.

Page 62	Page 64
<p>1 template is.</p> <p>2 BY MR. GRAND:</p> <p>3 Q. And does your consent form vary from the</p> <p>4 hospital's? Is it different from the hospital's</p> <p>5 consent form?</p> <p>6 A. Yes.</p> <p>7 Q. The hospital's consent form tends to be</p> <p>8 a sort of catchall for anything that could go wrong</p> <p>9 in a procedure?</p> <p>10 MR. SNELL: Form.</p> <p>11 A. The hospital's consent form is pretty</p> <p>12 vague and generic.</p> <p>13 Q. Do you think that's generally true of</p> <p>14 hospitals?</p> <p>15 A. Yes.</p> <p>16 Q. Now, looking at Page 2 of that report,</p> <p>17 you say, "In a typical week, I perform numerous</p> <p>18 incontinence and prolapse surgeries involving mesh</p> <p>19 and native tissue repairs, in addition to other</p> <p>20 surgeries"?</p> <p>21 A. Yes.</p> <p>22 Q. "I have also performed revision</p> <p>23 surgeries following incontinence and prolapse</p> <p>24 surgeries."</p> <p>25 Do you perform revision surgeries -- is</p>	<p>1 Q. And in fact, it may relate to other</p> <p>2 products besides the TVT Exact or Abbrevio, correct?</p> <p>3 A. Yes.</p> <p>4 Q. It could include Boston Scientific or</p> <p>5 AMS products as well, correct?</p> <p>6 A. Correct.</p> <p>7 Q. Skipping ahead to Page 30 of your</p> <p>8 report, which I believe is where you begin to</p> <p>9 address Kathleen Corbet specifically, on Page 31</p> <p>10 you note, "At her deposition, Mrs. Corbet testified</p> <p>11 she experienced symptoms of both urge and stress</p> <p>12 urinary incontinence leading up to her July 14th,</p> <p>13 2011 surgery."</p> <p>14 Do you see that?</p> <p>15 A. Yes.</p> <p>16 Q. What symptoms of urge incontinence are</p> <p>17 you asserting that she testified to?</p> <p>18 A. I can look at her deposition with you,</p> <p>19 but I can't be more specific than that right now.</p> <p>20 This is what I assessed at the time I was looking</p> <p>21 at her deposition.</p> <p>22 Q. You say she also reported those symptoms</p> <p>23 on Dr. Harrell's intake questionnaire in April of</p> <p>24 2011, correct?</p> <p>25 A. Correct.</p>
Page 63	Page 65
<p>1 that generally on your own patients, or do you find</p> <p>2 that you are referred patients from other doctors</p> <p>3 for revision surgeries?</p> <p>4 A. Both.</p> <p>5 Q. Now, you said, "Our practice's sling</p> <p>6 revision rate for either exposure or incomplete</p> <p>7 bladder emptying is 4.5 percent." We discussed</p> <p>8 that earlier, correct?</p> <p>9 A. Correct.</p> <p>10 Q. Of that 4.5 percent, do you know, none</p> <p>11 of those, based on what you told me, none of those</p> <p>12 would relate to the TVT, correct?</p> <p>13 MR. SNELL: Form.</p> <p>14 Q. The TVT retropubic.</p> <p>15 A. I don't think that's true.</p> <p>16 Q. Well, you said you haven't used the TVT</p> <p>17 retropubic.</p> <p>18 A. Oh, I'm sorry. You mean not Exact.</p> <p>19 Most likely not, because I think at the time I</p> <p>20 looked at this data it was after we were already</p> <p>21 using Exact.</p> <p>22 Q. Okay. So this 4.5 percent would not</p> <p>23 relate to the TVT retropubic product, correct?</p> <p>24 MR. SNELL: Form.</p> <p>25 A. I don't think so.</p>	<p>1 Q. What symptoms of urge incontinence did</p> <p>2 she have in Dr. Harrell's intake questionnaire?</p> <p>3 A. Well, again, do you want me to -- do you</p> <p>4 want to look at those?</p> <p>5 Q. Sure.</p> <p>6 A. Okay.</p> <p>7 I'm just not finding it right now, but</p> <p>8 I'll keep looking.</p> <p>9 Oh. The questionnaire is -- there is a</p> <p>10 questionnaire here with 18 questions, and it's</p> <p>11 number 12, "When you feel the desire to urinate, do</p> <p>12 you lose urine before you can get to the bathroom</p> <p>13 or toilet seat?"</p> <p>14 Q. Okay. So based on the response to that</p> <p>15 one question, you are of the opinion that she had</p> <p>16 urge incontinence prior to implant of her sling?</p> <p>17 A. Yes.</p> <p>18 MR. SNELL: Form. Go ahead.</p> <p>19 Q. And she did not have frequent urination</p> <p>20 during the night, correct?</p> <p>21 A. No. She said no at that time.</p> <p>22 Q. And she did not have frequent urination</p> <p>23 during the daytime hours either, did she?</p> <p>24 MR. SNELL: Form.</p> <p>25 A. She said -- "Do you empty your bladder</p>

17 (Pages 62 to 65)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 66</p> <p>1 frequently?" She said "Sometimes." 2 Q. I'm looking at question 14. 3 A. I know. 14 she said no, but 15 is a 4 sometimes. 5 Q. And obviously Dr. Harrell examined her 6 during that -- at that time, correct? 7 A. Correct. 8 Q. And Dr. Harrell did not diagnose her 9 with urge incontinence, correct? 10 A. I will look at his first note. 11 The impressions that he wrote down was 12 cystocele and rectocele. 13 Q. Keep going. And stress urinary 14 incontinence, correct? 15 A. Well, I'm sorry. Are we on a different 16 page? 17 Q. Well, you were reading the diagnosis. 18 A. Yeah. This says chief complaints, 19 complained of dropped bladder, new patient, and 20 this is a typed -- 21 Q. Okay. 22 A. -- note, and you might be looking at H&P 23 before surgery. 24 Q. Do you see chief complaint, dropped 25 bladder and stress urinary incontinence?</p>	<p style="text-align: right;">Page 68</p> <p>1 What are you basing that on? 2 A. Well, I wrote there that I took it from 3 her deposition, so I would need to look at her 4 deposition. Do you want me to pull that out? 5 Q. No. I just want to know what your basis 6 was. 7 A. Okay. 8 Q. And you've indicated Mrs. Corbet signed 9 a hospital consent that warned of permanent injury 10 and death, correct? 11 A. Yes. 12 Q. Okay. And that's the same sort of vague 13 consent form that the hospital uses? 14 MR. SNELL: Objection, form. 15 Q. You described it before as vague, 16 correct? 17 MR. SNELL: No. Objection, 18 foundation, form. 19 A. I described mine as vague, but as far as 20 I know, that was just a hospital consent that would 21 apply to any surgery. 22 Q. Right. I guess that's my point. It was 23 a hospital consent form that applied to any 24 surgical procedure in the hospital, correct? 25 A. Yes.</p>
<p style="text-align: right;">Page 67</p> <p>1 A. I think mine looks like an office note. 2 It just says chef complaints, dropped bladder, new 3 patient. 4 Q. Okay. 5 A. Oh, yes. Complaints of occasional SUI. 6 I think we are on different pages. 7 Q. That's fine. Have you seen any records 8 from Dr. Harrell prior to her surgery indicating he 9 had diagnosed her with -- have you reviewed any 10 records from Dr. Harrell prior to her surgery, 11 implant surgery, where he diagnosed her with urge 12 incontinence? 13 A. He didn't list that as a diagnosis. 14 Q. And again, Dr. Harrell examined her at 15 that time, correct? 16 A. It appears so. 17 Q. And you have never examined Mrs. Corbet, 18 correct? 19 A. No. 20 Q. On Page 32 of your report, the last 21 sentence on Page 31 leading into 32, you state, 22 "Mrs. Corbet also testified that Dr. Harrell warned 23 her of a risk of dyspareunia, although there is a 24 dispute as to whether he described it as 25 temporary."</p>	<p style="text-align: right;">Page 69</p> <p>1 Q. There is always a potential for 2 permanent injury and death when you undergo a 3 surgical procedure, correct? 4 A. Yes. 5 Q. If you go down a little bit further, the 6 fourth sentence from the bottom on Page 32, you see 7 you indicated by December 2011 more than five 8 months after surgery the patient felt better? 9 A. Yes. 10 Q. Is it your opinion that her symptoms she 11 had following surgery had resolved by December 12 2011? 13 A. That's how it appeared. 14 And if I could clarify, this was she was 15 feeling pressure from this blood clot, and I 16 believe that's what we were referring to here. 17 Q. Okay. So you are not suggesting that 18 she wasn't experiencing other symptoms at that 19 time? 20 A. Right. 21 Q. So you are just referring to the 22 hematoma? 23 A. Right. She was being followed for a 24 hematoma. 25 Q. But you saw prior to that there were</p>

18 (Pages 66 to 69)

Denise M. Elser, M.D.

Page 70	Page 72
<p>1 complaint of dyspareunia, correct?</p> <p>2 MR. SNELL: Form.</p> <p>3 A. Yes.</p> <p>4 Q. And those complaints continued into the</p> <p>5 following year, correct?</p> <p>6 A. Yes, yes.</p> <p>7 Q. In fact, you wrote May 2012, ten months</p> <p>8 postoperatively, Mrs. Corbet continued to have</p> <p>9 complaints, correct?</p> <p>10 A. Yes.</p> <p>11 Q. And did you review the pathology from</p> <p>12 the mesh revision?</p> <p>13 A. I had seen the pathology report.</p> <p>14 Q. And just to be clear, she was diagnosed</p> <p>15 with the mesh exposure and it was removed in</p> <p>16 January of 2013, correct?</p> <p>17 A. Yes.</p> <p>18 Q. And you know the pathology noted a</p> <p>19 chronic inflammation and foreign body giant cell</p> <p>20 reaction, correct?</p> <p>21 MR. SNELL: Form.</p> <p>22 A. Yes.</p> <p>23 Q. Is it your understanding that the</p> <p>24 foreign body reaction that takes place once a mesh</p> <p>25 is implanted is transient or a -- or chronic</p>	<p>1 Q. Okay. I just want to make sure I wasn't</p> <p>2 -- I was trying to determine whether that was a</p> <p>3 criticism of the treating doctor to treat her this</p> <p>4 way?</p> <p>5 A. No.</p> <p>6 Q. Is that how you would have treated her?</p> <p>7 A. It's an option.</p> <p>8 Q. Is that how you would have treated her?</p> <p>9 A. I personally don't perform InterStim.</p> <p>10 Some patients I refer to a partner for InterStim,</p> <p>11 but my first line may have been different.</p> <p>12 Q. What would your first line have been?</p> <p>13 A. I would work more on the physical</p> <p>14 therapy and neuromodulation. That's less invasive.</p> <p>15 Q. And you said you sometimes performed</p> <p>16 revisions of slings?</p> <p>17 A. Yes. Thank you. I caught that, yeah.</p> <p>18 Q. How many revisions do you perform a</p> <p>19 year, would you say, sling revisions?</p> <p>20 A. I haven't counted that recently, so it</p> <p>21 would be a guess, but, you know, maybe a couple a</p> <p>22 month, and it's getting less and less, we are</p> <p>23 seeing.</p> <p>24 Q. I want to ask you some questions about</p> <p>25 Mrs. Corbet's hematoma. Is it your opinion that</p>
Page 71	Page 73
<p>1 ongoing reaction?</p> <p>2 A. I believe it can be chronic.</p> <p>3 Q. You believe it can be chronic. And what</p> <p>4 factors do you think affects whether it's chronic</p> <p>5 or transient?</p> <p>6 A. I really don't know.</p> <p>7 Q. If you go ahead to Page 34 in your</p> <p>8 report, at the very top you wrote, "Despite the</p> <p>9 findings of stress incontinence and elevated</p> <p>10 bladder capacity with no DO, even at 780</p> <p>11 millimeters bladder filling, the patient was</p> <p>12 randomized to an invasive procedure for OAB and</p> <p>13 underwent a two-stage InterStim implantation."</p> <p>14 Are you suggesting that this was an</p> <p>15 incorrect course of treatment?</p> <p>16 A. Excuse me. No. I just -- having been</p> <p>17 involved in other studies regarding urge</p> <p>18 incontinence, usually patients with OAB have a</p> <p>19 small bladder capacity. So, I was just surprised</p> <p>20 that the study criteria allowed a patient with a</p> <p>21 maximum capacity of 800, which is very high, to be</p> <p>22 in the study.</p> <p>23 Q. Okay. So you --</p> <p>24 A. I'm not saying that someone with sensory</p> <p>25 urgency doesn't benefit from InterStim.</p>	<p>1 the hematoma was caused by her prolapse repair as</p> <p>2 opposed to the mesh, as opposed to the mesh sling?</p> <p>3 A. We don't know if it was caused by the</p> <p>4 prolapse repair or the sling procedure.</p> <p>5 Q. So you don't have an opinion either way?</p> <p>6 MR. SNELL: Form.</p> <p>7 A. It could be from either one. No one can</p> <p>8 know for sure.</p> <p>9 Q. And then you state on the next page,</p> <p>10 "The TVT IFU adequately warns of the risk of</p> <p>11 hematoma" --</p> <p>12 A. I'm sorry. What's the next page?</p> <p>13 Q. I'm sorry. Page 35, the last sentence</p> <p>14 right before the urge incontinence section.</p> <p>15 A. Yes.</p> <p>16 Q. You said, "The TVT IFU adequately warns</p> <p>17 of the risk of hematoma by warning of punctures or</p> <p>18 lacerations to vessels."</p> <p>19 A. Yes.</p> <p>20 Q. And you are referring to the IFU that</p> <p>21 was in place at the time of her surgery or the</p> <p>22 current IFU for the TVT?</p> <p>23 A. It would have been the one in place at</p> <p>24 the time of her surgery.</p> <p>25 Q. And you believe the warning of the risk</p>

19 (Pages 70 to 73)

Denise M. Elser, M.D.

Page 74	Page 76
<p>1 of puncturing or laceration is going to be the same</p> <p>2 thing as warning of the risk of hematoma?</p> <p>3 A. I believe any surgeon doing an</p> <p>4 incontinence or prolapse surgery knows that when</p> <p>5 operating on anybody you can create bleeding or</p> <p>6 hematoma, and certainly you know if there is a</p> <p>7 vessel injury there can be blood loss at the time</p> <p>8 of surgery or a hematoma that collects.</p> <p>9 MR. GRAND: Move to strike as</p> <p>10 nonresponsive.</p> <p>11 BY MR. GRAND:</p> <p>12 Q. Do you believe that warning of the risk</p> <p>13 of hematoma is the same as warning of the risk of</p> <p>14 punctures or lacerations to vessels?</p> <p>15 MR. SNELL: Form.</p> <p>16 A. I believe it's adequate warning.</p> <p>17 Q. Have you reviewed the new TVT label?</p> <p>18 A. The new label, the new IFU?</p> <p>19 Q. Yes, yes.</p> <p>20 A. I reviewed one in the OR yesterday that</p> <p>21 was a 2014, but I understand there is an even newer</p> <p>22 one.</p> <p>23 Q. You haven't seen the new one yet?</p> <p>24 A. No.</p> <p>25 MR. GRAND: I'm going to mark -- what</p>	<p>1 THE WITNESS: I said I can read Greek,</p> <p>2 but you want the English, right?</p> <p>3 BY MR. GRAND:</p> <p>4 Q. Yes. I'm going to ask you to turn to</p> <p>5 Page 5 of each one.</p> <p>6 A. Okay.</p> <p>7 Okay.</p> <p>8 Q. So, I want to call your attention to the</p> <p>9 adverse reaction section.</p> <p>10 A. Okay.</p> <p>11 Q. So you will see that --</p> <p>12 A. The big one is the new one, right?</p> <p>13 Q. Yes, the big one is the new one.</p> <p>14 A. All right.</p> <p>15 Q. And if you look, they still -- if you</p> <p>16 look at the first bullet point under the adverse</p> <p>17 reactions, it says, "Punctures or lacerations of</p> <p>18 vessels, nerves, structures or organs, including</p> <p>19 the bladder, urethra or bowel, may occur and may</p> <p>20 require surgical repair."</p> <p>21 That is largely the same as in the</p> <p>22 original?</p> <p>23 A. Right.</p> <p>24 Q. I think the only difference is they</p> <p>25 added in the word "structures" as well as</p>
Page 75	Page 77
<p>1 are we up to? 9.</p> <p>2 THE WITNESS: I might need a</p> <p>3 magnifying glass.</p> <p>4 MR. GRAND: I apologize. This is the</p> <p>5 way I got it.</p> <p>6 I'm going to mark as Elser 9 the TVT</p> <p>7 label that was in place at the time of</p> <p>8 Mrs. Corbet's implant.</p> <p>9 THE WITNESS: I have to lean back a</p> <p>10 little bit, okay? Am I still in camera range?</p> <p>11 THE VIDEOGRAPHER: Oh, yes.</p> <p>12 MR. GRAND: And I'm going to mark as</p> <p>13 No. 10 the label that was revised in January</p> <p>14 of this year.</p> <p>15 (Elser Exhibits 9 and 10 were marked</p> <p>16 for identification as of 11/5/15.)</p> <p>17 THE WITNESS: Thank you.</p> <p>18 MR. GRAND: Burt, need copies?</p> <p>19 MR. SNELL: Yes, please.</p> <p>20 THE WITNESS: That one is a lot</p> <p>21 bigger.</p> <p>22 MR. GRAND: Yes. That one is easier to</p> <p>23 read.</p> <p>24 THE WITNESS: I can read Greek --</p> <p>25 MR. GRAND: What?</p>	<p>1 "urethra." But you see further down they also</p> <p>2 included "bleeding, including hemorrhage and</p> <p>3 hematoma," if you go several bullet points down in</p> <p>4 the new label.</p> <p>5 A. Yes.</p> <p>6 Q. In fact, there is multiple reactions</p> <p>7 that have been added to this new label that are not</p> <p>8 listed in the first label, such as do you see</p> <p>9 "acute and chronic pain"?</p> <p>10 A. Yes.</p> <p>11 Q. Do you see "voiding dysfunction"?</p> <p>12 A. Yes.</p> <p>13 Q. Do you see "pain with intercourse,"</p> <p>14 which in some patients may not resolve"?</p> <p>15 A. Yes.</p> <p>16 Q. Do you see "neuromuscular problems</p> <p>17 including acute and/or chronic pain in the groin,</p> <p>18 thigh, leg, pelvic and/or abdominal area may</p> <p>19 occur"?</p> <p>20 A. Yes.</p> <p>21 Q. Do you see "recurrence of incontinence"?</p> <p>22 A. Yes.</p> <p>23 Q. And you already said bleeding, including</p> <p>24 hemorrhage or hematoma.</p> <p>25 "One or more revision surgeries may be</p>

20 (Pages 74 to 77)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 78</p> <p>1 necessary to treat these adverse reactions"?</p> <p>2 A. Yes.</p> <p>3 Q. "Additionally, the Prolene mesh is a</p> <p>4 permanent implant that integrates into the tissue.</p> <p>5 In cases in which the Prolene mesh needs to be</p> <p>6 removed in part or whole, significant dissection</p> <p>7 may be required"?</p> <p>8 A. Yes.</p> <p>9 Q. And by that, that's not necessarily a</p> <p>10 snip in the doctor's office, correct, when they are</p> <p>11 talking about a significant dissection?</p> <p>12 MR. SNELL: Form.</p> <p>13 A. If it has to be removed in its whole,</p> <p>14 right, that would not be done in the office.</p> <p>15 Q. That's not a -- that's a much more</p> <p>16 invasive procedure, correct?</p> <p>17 A. Right.</p> <p>18 MR. SNELL: Form.</p> <p>19 Q. And it's generally going to have to be</p> <p>20 done under general anesthesia?</p> <p>21 A. Under anesthesia.</p> <p>22 Q. Do you see under other adverse reactions</p> <p>23 they have added a whole other section there? Do</p> <p>24 you see that?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 80</p> <p>1 MR. SNELL: Form.</p> <p>2 A. You are asking if it is temporary or if</p> <p>3 it says it is temporary?</p> <p>4 Q. I'm asking if the risks associated with</p> <p>5 the surgery tend to be temporary conditions rather</p> <p>6 than permanent conditions.</p> <p>7 MR. SNELL: Form. I don't know what</p> <p>8 you mean by "the surgery." That's my form.</p> <p>9 MR. GRAND: You don't know what</p> <p>10 surgery we are talking about?</p> <p>11 MR. SNELL: Are you talking about a</p> <p>12 straight TVT or are you talking about --</p> <p>13 MR. GRAND: I'm talking about -- well,</p> <p>14 she's -- strike that. Let's just go back.</p> <p>15 MR. SNELL: That's my form. If you</p> <p>16 want to correct it, correct it. I don't care.</p> <p>17 MR. GRAND: I will strike the</p> <p>18 question.</p> <p>19 BY MR. GRAND:</p> <p>20 Q. Is it your opinion that with the</p> <p>21 exception of exposure all the risks listed in this</p> <p>22 new label under adverse reactions, the ones we have</p> <p>23 just been discussing, are -- are the same risk that</p> <p>24 would be in any pelvic floor surgery?</p> <p>25 A. Okay. So, foreign body response, you</p>
<p style="text-align: right;">Page 79</p> <p>1 Q. It has urge incontinence. That wasn't</p> <p>2 in the original label either, correct?</p> <p>3 A. Correct.</p> <p>4 Q. Urinary frequency, urinary retention,</p> <p>5 adhesion formation, atypical vaginal discharge, and</p> <p>6 exposed mesh may cause pain or discomfort to the</p> <p>7 patient's partner during intercourse. That wasn't</p> <p>8 in the original label, correct?</p> <p>9 A. No.</p> <p>10 Q. Do you think that the new label gives</p> <p>11 better warnings than the original label?</p> <p>12 MR. SNELL: Form.</p> <p>13 A. It gives more warnings, but taking that,</p> <p>14 really, you know, what's unique about using mesh</p> <p>15 versus doing surgery without mesh is the exposure,</p> <p>16 erosion. So, being a surgeon, most of these are</p> <p>17 generic to surgery. So, it gives more warnings,</p> <p>18 more specific warnings, but it's not -- these are</p> <p>19 not especially enlightening.</p> <p>20 Q. A lot of risks associated with the</p> <p>21 surgery are temporary reactions, correct?</p> <p>22 A. Like bleeding, you would hope that would</p> <p>23 be temporary, yeah.</p> <p>24 Q. Well, even -- even pain with</p> <p>25 intercourse?</p>	<p style="text-align: right;">Page 81</p> <p>1 could have permanent sutures with foreign body</p> <p>2 response, and that could happen with any prolapse</p> <p>3 surgery. I think the only other thing here unique</p> <p>4 to sling versus surgery without using mesh is that</p> <p>5 the mesh might need to be removed in its whole.</p> <p>6 But otherwise, any surgery for</p> <p>7 incontinence can have voiding dysfunction, acute or</p> <p>8 chronic pain, dyspareunia or apareunia, hemorrhage,</p> <p>9 bleeding, recurrence of incontinence. So, these</p> <p>10 are pretty nonspecific.</p> <p>11 Q. Exposed mesh that may cause pain or</p> <p>12 discomfort to the patient's partner during</p> <p>13 intercourse, that's certainly not with every</p> <p>14 surgery, right?</p> <p>15 A. No, but permanent sutures had the same</p> <p>16 risk, so sometimes surgeries were done with</p> <p>17 permanent sutures in the vagina, and that also had</p> <p>18 the risk.</p> <p>19 Q. Is it your testimony that the sutures</p> <p>20 that may have been done in a more traditional</p> <p>21 repair carry the same risk of a foreign body</p> <p>22 response as a large piece of mesh?</p> <p>23 MR. SNELL: Form.</p> <p>24 A. I wouldn't call a sling a large piece of</p> <p>25 mesh, but I don't know if it has the same foreign</p>

21 (Pages 78 to 81)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 82</p> <p>1 body response. I've not looked at the pathology. 2 But certainly clinically we have patients that come 3 back with granulation tissue, chronic inflammation, 4 and need a couple procedures to get rid of those 5 polyps or granulation tissue, bleeding with 6 intercourse because of those permanent sutures 7 that's in the vaginal wall. 8 Q. Relative to sutures, there is a lot more 9 mesh in a sling than in a suture, correct? 10 MR. SNELL: Form. 11 A. There is more mesh in a sling. 12 Q. So if a patient is suffering from a 13 foreign body response, they are going to have a 14 greater foreign body response to the sling than to 15 a suture, correct? 16 MR. SNELL: Form, foundation. 17 A. There is more mesh material to react. 18 I've never thought of it, like said clinically a 19 patient is suffering from a foreign body response. 20 It's just an unusual phrase. 21 Q. Have you ever seen materials provided to 22 doctors for TVT products that suggest that the 23 irritation is just transient as opposed to ongoing? 24 A. The irritation? 25 Q. The foreign body response.</p>	<p style="text-align: right;">Page 84</p> <p>1 MR. SNELL: Form. 2 A. I don't have that information. 3 Q. You haven't studied that issue? 4 A. Right. 5 Q. Have you seen studies showing an 6 increase in urge incontinence following mesh -- the 7 implantation of a mesh sling as high as 25 percent 8 of patients? 9 A. Yes. 10 Q. Put the label aside for now. 11 So, you don't have any opinion as to 12 whether the new label is a more -- is a more 13 adequate label than the label that was in place at 14 the time Dr. Harrell implanted the -- I mean, 15 sorry -- Dr. Harrell implanted the sling in 16 Mrs. Corbet? 17 A. No. The IFU is the IFU, and as a 18 surgeon, we don't rely on this to know what could 19 go wrong with pelvic surgery. We want to know 20 specifics to the product. So, again, there is very 21 little here specific about the product that 22 somebody implanting slings would not already know 23 where it's covered. We know mesh exposure can 24 happen. We know patients can have pain. We know 25 that a sling may need to be removed partially or in</p>
<p style="text-align: right;">Page 83</p> <p>1 A. I don't recall. 2 Q. But it's your view that the foreign body 3 response can be ongoing and chronic, correct? 4 A. Yes. 5 Q. And it would certainly provide more 6 information to doctors to indicate that it could be 7 ongoing and chronic rather than just transient, 8 correct? 9 MR. SNELL: Form, foundation. 10 A. I don't understand. Can you say that 11 again? 12 Q. It would be better to provide doctors 13 with information that tells them it can be ongoing 14 and chronic rather than it would just be transient 15 or temporary, correct? 16 MR. SNELL: Same objection, form, 17 foundation. 18 A. No, because what I was thinking, it 19 could be chronic. I don't know. We don't take all 20 our slings and bring them out of patients and 21 analyze and say is there any foreign body response 22 microscopically. I don't know if it goes on for a 23 long time or transient. 24 Q. So you don't hold yourself out as an 25 expert in that area, correct?</p>	<p style="text-align: right;">Page 85</p> <p>1 whole. 2 Q. You are aware Dr. Harrell testified that 3 he didn't know of many of these issues, correct? 4 MR. SNELL: Form, foundation. 5 A. I need to look at his testimony again. 6 Q. Did you read his testimony? 7 A. I did, yes, absolutely. I don't 8 remember that specific answer. 9 Q. Were you aware that he testified that 10 had he known about the foreign -- the chronic 11 foreign body reaction he would not have implanted 12 the sling? 13 A. No, I don't remember that. 14 Q. You are not -- your opinions about what 15 surgeons know don't extend to Dr. Harrell, do they? 16 MR. SNELL: Form. 17 A. Meaning I don't know what he knows? 18 Q. Meaning you don't know what risks 19 Dr. Harrell believes were attendant to the mesh at 20 the time he implanted it in Mrs. Corbet? 21 A. I don't know exactly what he thought the 22 risks were, but again, someone doing incontinence 23 surgery and prolapse surgery knows the risks -- 24 should know the risks of pelvic surgery. 25 Q. Is that just an opinion you are holding</p>

22 (Pages 82 to 85)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 86</p> <p>1 for all, all surgeons?</p> <p>2 A. Yes.</p> <p>3 Q. So, in your opinion, what risks should</p> <p>4 have been known to Dr. Harrell at the time he</p> <p>5 implanted the TVT retropubic in Mrs. Corbet?</p> <p>6 A. That's pretty vague. Did you want me to</p> <p>7 talk about all risks of surgery, about anything</p> <p>8 that could and might happen with the sling?</p> <p>9 MR. GRAND: Strike that question.</p> <p>10 BY MR. GRAND:</p> <p>11 Q. Getting back to your report -- I'm</p> <p>12 sorry, actually. You wrote in your report on</p> <p>13 Page 36 that the IFU adequately warned of the risk</p> <p>14 of urge incontinence by warning surgeons that with</p> <p>15 other procedures detrusor instability can occur.</p> <p>16 A. Okay.</p> <p>17 Q. And then it says to minimize this risk,</p> <p>18 make sure that the tape tension -- the tape is</p> <p>19 placed tension-free in the midurethral position.</p> <p>20 Do you see that in the label?</p> <p>21 A. No. What page are you on?</p> <p>22 Q. I'm sorry. Above the adverse event</p> <p>23 section.</p> <p>24 A. Okay. You've got highlights. I don't</p> <p>25 have that advantage. Okay.</p>	<p style="text-align: right;">Page 88</p> <p>1 in, much of this would be knowledge to them without</p> <p>2 it being specifically in the IFU.</p> <p>3 Q. Well, if for some reason a doctor didn't</p> <p>4 receive lots of training...</p> <p>5 MR. SNELL: Is there a question?</p> <p>6 MR. GRAND: I was about to finish. I</p> <p>7 thought you were about to make an objection.</p> <p>8 MR. SNELL: Well, I am going to.</p> <p>9 BY MR. GRAND:</p> <p>10 Q. Okay. Do you know how much training</p> <p>11 Dr. Harrell received?</p> <p>12 A. No.</p> <p>13 Q. Okay. Were you aware that Ethicon</p> <p>14 suspended its training on the TVT after a certain</p> <p>15 period of time following launch?</p> <p>16 MR. SNELL: Objection, foundation.</p> <p>17 A. Suspended? I did know they were not</p> <p>18 offering training programs for a while.</p> <p>19 Q. There certainly is no harm in having</p> <p>20 more information in the IFU, correct?</p> <p>21 A. No. I don't see any harm in it.</p> <p>22 Q. So you don't disagree with -- do you</p> <p>23 disagree with any of the changes they made to the</p> <p>24 label?</p> <p>25 A. No.</p>
<p style="text-align: right;">Page 87</p> <p>1 Q. It's like three bullet points up.</p> <p>2 A. Yes.</p> <p>3 THE VIDEOGRAPHER: Excuse me,</p> <p>4 counselor. We have to end this tape now.</p> <p>5 MR. GRAND: We need to switch the tape</p> <p>6 out.</p> <p>7 THE VIDEOGRAPHER: The time is</p> <p>8 11:25 a.m. This is the end of Tape 1, and we</p> <p>9 are going off the video record.</p> <p>10 (Recess taken, 11:25 - 11:31 a.m.)</p> <p>11 THE VIDEOGRAPHER: The time is</p> <p>12 11:31 a.m. This is the beginning of Tape 2,</p> <p>13 and we are back on the video record.</p> <p>14 BY MR. GRAND:</p> <p>15 Q. Just to be clear, with respect to the</p> <p>16 new label versus the label that was in place at the</p> <p>17 time of Mrs. Corbet's implantation, you think the</p> <p>18 original label is just as adequate as the current</p> <p>19 label --</p> <p>20 A. I do.</p> <p>21 Q. -- in terms of giving doctors</p> <p>22 information?</p> <p>23 A. Well, because this should not be the</p> <p>24 only source of information, so I think if a doctor</p> <p>25 is doing a sling and putting a permanent implant</p>	<p style="text-align: right;">Page 89</p> <p>1 Q. I mean, ultimately you would like</p> <p>2 doctors to have as much information as they can</p> <p>3 about a product, correct?</p> <p>4 MR. SNELL: Form.</p> <p>5 A. I want them, right, to understand about</p> <p>6 the surgery they are doing before they do the</p> <p>7 surgery. I just don't know that IFU is the place</p> <p>8 where physicians should get their education.</p> <p>9 Q. IFU is not the sole source of</p> <p>10 information about the product, correct?</p> <p>11 A. Correct.</p> <p>12 Q. Getting back to your original report, if</p> <p>13 we could draw your attention to Page 36, with</p> <p>14 respect to constipation, is it your opinion that</p> <p>15 Mrs. Corbet suffered from chronic constipation</p> <p>16 prior to her implant?</p> <p>17 A. Yes.</p> <p>18 Q. And what about post implant?</p> <p>19 A. I have to look at her records after the</p> <p>20 implant on the constipation. Do you want me to?</p> <p>21 Q. Yeah, sure.</p> <p>22 A. Okay. When she sees Dr. Smith</p> <p>23 January 31st she reports constipation.</p> <p>24 Q. And you know how her constipation was</p> <p>25 being managed at that time?</p>

23 (Pages 86 to 89)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 90</p> <p>1 A. She was taking Colace.</p> <p>2 Q. And have you seen visit notes where she</p> <p>3 says she is doing fine with the stool softener?</p> <p>4 A. I don't recall. I would have to look.</p> <p>5 Q. Is it your opinion that the constipation</p> <p>6 is a causal factor to her urge incontinence?</p> <p>7 A. It can be, yes. It can contribute</p> <p>8 significantly.</p> <p>9 Q. Is it your opinion that it contributed</p> <p>10 significantly in this case?</p> <p>11 A. It is very likely to be part of the</p> <p>12 problem.</p> <p>13 Q. Is it your opinion that the constipation</p> <p>14 has contributed to her dyspareunia?</p> <p>15 A. It can as well.</p> <p>16 Q. Is it your opinion that it has</p> <p>17 contributed to the dyspareunia in this case?</p> <p>18 A. It's very likely to be a part of the</p> <p>19 cause of the dyspareunia.</p> <p>20 Q. And what are you basing that on?</p> <p>21 A. Based on the patients I take care of</p> <p>22 with constipation and status post the posterior</p> <p>23 repair as well as literature, which including the</p> <p>24 one I put in the report, which was just a patient</p> <p>25 education brochure talking about constipation.</p>	<p style="text-align: right;">Page 92</p> <p>1 A. Yes.</p> <p>2 Q. Okay.</p> <p>3 A. This is really a ground-breaking study</p> <p>4 because up until that time everyone thought if you</p> <p>5 have constipation, the posterior repair, the</p> <p>6 posterior colporrhaphy fixes your constipation when</p> <p>7 you fix a rectocele, and this is really the first</p> <p>8 study that shows that's wrong. You have to treat</p> <p>9 constipation separately because it is a cause of</p> <p>10 pain and it's related to pain and sexual</p> <p>11 dysfunction.</p> <p>12 Q. Okay. But the surgery you cite</p> <p>13 doesn't -- doesn't state that the constipation is</p> <p>14 causing sexual dysfunction; it's that the prior</p> <p>15 surgery causes sexual dysfunction?</p> <p>16 MR. SNELL: Form.</p> <p>17 A. Right. I'm saying the constipation can</p> <p>18 lead to pelvic pain which can cause sexual</p> <p>19 dysfunction.</p> <p>20 Q. Okay. I'm asking you what are you</p> <p>21 basing that on.</p> <p>22 A. I'm basing it on my experience, as well</p> <p>23 as if you carry on down, there is more examples of</p> <p>24 some of that literature that supports that, which</p> <p>25 is Dr. Butrick talking about the pelvic floor</p>
<p style="text-align: right;">Page 91</p> <p>1 Q. Okay. Just to be clear, the dyspareunia</p> <p>2 in the brochure is a complication related to</p> <p>3 posterior vaginal wall repair, correct?</p> <p>4 A. Okay. Yes.</p> <p>5 Q. It's not relating it to constipation,</p> <p>6 correct?</p> <p>7 A. Right. They just warn about</p> <p>8 constipation there.</p> <p>9 Q. Okay.</p> <p>10 A. But yes, if you go on to the next page</p> <p>11 where I talk about pelvic floor hypertonicity,</p> <p>12 which can be related to -- causally to</p> <p>13 constipation, it frequently causes dyspareunia.</p> <p>14 Q. If we go on to Page 38.</p> <p>15 I just want to -- so, just to go back to</p> <p>16 your constipation section in the report, you cite</p> <p>17 -- on Page 37 you cite the Kahn study from 1997?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. That study linked that the</p> <p>20 surgery, which was a colporrhaphy -- did I get that</p> <p>21 correct?</p> <p>22 A. Yeah. That was good.</p> <p>23 Q. I have a hard time with that one.</p> <p>24 -- that the colporrhaphy may worsen or</p> <p>25 cause constipation, correct?</p>	<p style="text-align: right;">Page 93</p> <p>1 hypertonicity, which it's all a vicious cycle. It</p> <p>2 can be caused by constipation, it can be caused by</p> <p>3 a posterior colporrhaphy, but they are all</p> <p>4 connected.</p> <p>5 Q. Are you aware of any studies that link,</p> <p>6 that demonstrate a causal association between</p> <p>7 constipation and dyspareunia?</p> <p>8 A. I don't have those cited here, but I</p> <p>9 could probably find something.</p> <p>10 Q. And you didn't rely on such studies for</p> <p>11 your report, correct?</p> <p>12 A. I'm relying on my experience.</p> <p>13 Q. Your experience, and that's your</p> <p>14 experience with your patients, correct?</p> <p>15 A. Right, and reading about the issue, so</p> <p>16 I'm sure I've also read about it.</p> <p>17 Q. If we can proceed ahead to the section</p> <p>18 on dyspareunia beginning on Page 38. You cite the</p> <p>19 Pauls report from 2007?</p> <p>20 A. Yes.</p> <p>21 Q. That report examined women six months</p> <p>22 postoperatively?</p> <p>23 A. Yes.</p> <p>24 Q. You don't think that's an indicator of</p> <p>25 any potential long-term dyspareunia, correct?</p>

24 (Pages 90 to 93)

Denise M. Elser, M.D.

Page 94	Page 96
<p>1 A. It can be.</p> <p>2 Q. But the study only looked at people six</p> <p>3 months postoperatively, correct?</p> <p>4 A. Correct.</p> <p>5 Q. You wouldn't consider that a long-term</p> <p>6 study, correct?</p> <p>7 A. Oh, no. I'm saying it could be</p> <p>8 long-term because of my experience with patients</p> <p>9 that when they have the surgery, they can have</p> <p>10 chronic pain afterwards, whether or not they have</p> <p>11 an incontinence procedure.</p> <p>12 Q. For purposes of looking at potential</p> <p>13 adverse effects of mesh implantation, what would</p> <p>14 you consider to be a long-term study?</p> <p>15 A. Long-term study. So, you know, when I</p> <p>16 was a fellow, long-term was more than six weeks, so</p> <p>17 we were really excited to get three-month data or</p> <p>18 six-month data, and the practice of our medicine in</p> <p>19 urogynecology has really changed over the last</p> <p>20 couple of decades. So, now we want to really get</p> <p>21 one-year data, but five-year data makes us feel</p> <p>22 much more comfortable that we know the long-term</p> <p>23 effects.</p> <p>24 Q. Is it your opinion that Mrs. Corbet</p> <p>25 suffered from dyspareunia prior to her implant?</p>	<p>1 Q. There were still questions on here</p> <p>2 regarding pain.</p> <p>3 A. I know we just looked at it. Here we</p> <p>4 go. No, they don't have any question about it</p> <p>5 here. Okay. So, the answer is no.</p> <p>6 Q. On Page 41, your comments on the case,</p> <p>7 towards the bottom you say, "In my opinion TVT was</p> <p>8 a good option for Mrs. Corbet."</p> <p>9 A. Yes.</p> <p>10 Q. What other options would have been</p> <p>11 available to Mrs. Corbet? Strike that.</p> <p>12 Is it your opinion that the TVT should</p> <p>13 have been the sort of first-line option for</p> <p>14 Mrs. Corbet based on her presentation?</p> <p>15 A. Well, that's the decision made between a</p> <p>16 patient and her physician.</p> <p>17 Q. I understand that. I'm asking your</p> <p>18 opinion.</p> <p>19 A. She had stress incontinence and she is</p> <p>20 seeking surgical treatment of prolapse and is</p> <p>21 counseled and accepts to have an incontinence</p> <p>22 procedure done at the same time; I have no problem</p> <p>23 with that.</p> <p>24 Q. So you are not suggesting Dr. Harrell --</p> <p>25 you are not of the opinion that Dr. Harrell did</p>
Page 95	Page 97
<p>1 A. I did not state that, but let me take a</p> <p>2 look.</p> <p>3 Q. I didn't think you did either. I'm just</p> <p>4 trying to make sure I understand.</p> <p>5 A. Okay. Do you want me to keep looking</p> <p>6 or...</p> <p>7 Q. If you can tell me that that's not what</p> <p>8 you -- that's not your opinion, that's fine.</p> <p>9 A. Okay.</p> <p>10 Q. Then you don't need to look at anything.</p> <p>11 Are you still looking?</p> <p>12 A. Yeah, but I'm listening.</p> <p>13 Q. Okay. I don't want --</p> <p>14 A. I'm a multi-tasker.</p> <p>15 Q. If you don't have a need to look for it,</p> <p>16 that's fine. I just --</p> <p>17 A. I'm curious. I want to look for it.</p> <p>18 Q. Are you going to supplement your report</p> <p>19 right now?</p> <p>20 A. Well...</p> <p>21 I just want to look at that one</p> <p>22 questionnaire we addressed a couple minutes ago.</p> <p>23 Q. Oh, okay.</p> <p>24 A. That was where we talked about the urge</p> <p>25 incontinence.</p>	<p>1 anything wrong by implanting a Prolift at that</p> <p>2 time?</p> <p>3 MR. SNELL: Form. There was no</p> <p>4 Prolift implanted.</p> <p>5 MR. GRAND: I'm sorry. Strike that.</p> <p>6 BY MR. GRAND:</p> <p>7 Q. You are not suggesting that Dr. Harrell</p> <p>8 did anything wrong by implanting a TVT retropubic</p> <p>9 at that time as opposed to an alternative</p> <p>10 treatment?</p> <p>11 A. Right.</p> <p>12 Q. Mrs. Corbet's hematoma and the mesh --</p> <p>13 her mesh exposure are both on the left side,</p> <p>14 correct?</p> <p>15 A. Right, yes, correct.</p> <p>16 Q. And your understanding is that the left</p> <p>17 arm and a portion of the sling were removed but</p> <p>18 that the right arm remained in place, correct?</p> <p>19 MR. SNELL: Foundation, form. There</p> <p>20 is no arm in the sling. I think you are</p> <p>21 confusing Prolift again.</p> <p>22 MR. GRAND: I'm going by the revision</p> <p>23 record. Let's see.</p> <p>24 MR. SNELL: Okay.</p> <p>25 MR. GRAND: "Arm" may not be the right</p>

25 (Pages 94 to 97)

Denise M. Elser, M.D.

Page 98	Page 100
<p>1 word.</p> <p>2 MR. SNELL: Form and foundation.</p> <p>3 BY MR. GRAND:</p> <p>4 Q. Is it your understanding that the</p> <p>5 left -- the left portion of the sling was removed</p> <p>6 but the right portion was left intact?</p> <p>7 A. I would just like to look at the</p> <p>8 operative report.</p> <p>9 Dr. Smith called it the left arm of the</p> <p>10 sling and removed a portion on the left side of the</p> <p>11 urethra.</p> <p>12 Q. And by "arm," we are not talking about</p> <p>13 the longer arms that would be -- would accompany</p> <p>14 the Prolift, for example. We are talking about the</p> <p>15 section of the sling that would go to the left and</p> <p>16 to the right of the bladder, correct?</p> <p>17 A. Yes.</p> <p>18 Q. And at the time of the revision, she had</p> <p>19 presented with dyspareunia, correct?</p> <p>20 A. Yes.</p> <p>21 Q. And she had, at least according to</p> <p>22 Dr. Smith, mild evidence of vaginal atrophy,</p> <p>23 correct?</p> <p>24 A. Yes.</p> <p>25 Q. Is it your opinion that atrophy</p>	<p>1 A. Well, we have a few articles that I know</p> <p>2 are in our list talking about the risk of pain</p> <p>3 after a posterior repair compared to the ongoing</p> <p>4 pain risk in the long-term sling data, which runs</p> <p>5 at about 1 percent; and it is also my experience</p> <p>6 that when we have patients who have chronic pain</p> <p>7 after surgery when they've had both prolapse repair</p> <p>8 and a sling, it's most often the repair in the</p> <p>9 pelvic muscles.</p> <p>10 Q. You haven't -- when you say you are</p> <p>11 comparing the incidence of pain in sling studies,</p> <p>12 and you are saying it's lower than incidence of</p> <p>13 pain in posterior repair?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. But you are not talking about a</p> <p>16 study that does a direct comparison of those two,</p> <p>17 correct?</p> <p>18 A. Well, we have the Pauls study that we</p> <p>19 looked at a minute ago which said patients had a</p> <p>20 posterior repair if they have had pain. It did not</p> <p>21 matter if they had a sling. The presence of a</p> <p>22 sling or no incontinence surgery did not make a</p> <p>23 difference in the pain outcome.</p> <p>24 Q. But in terms of an analysis of studies,</p> <p>25 it wouldn't be proper to just take one study done</p>
Page 99	Page 101
<p>1 contributed to her dyspareunia?</p> <p>2 A. Yes. Excuse me. Yes.</p> <p>3 Q. What are you basing that on?</p> <p>4 A. I base that on experience that vaginal</p> <p>5 atrophy contributes to dyspareunia.</p> <p>6 Q. Even mild vaginal atrophy?</p> <p>7 A. Yes.</p> <p>8 Q. And on Page 42 -- I believe I may have</p> <p>9 already asked you this, I just want to be clear --</p> <p>10 you indicate that Mrs. Corbet's OAB symptoms</p> <p>11 preexisted her July 14th, 2011 surgery, correct?</p> <p>12 A. Correct.</p> <p>13 Q. And that's just based on --</p> <p>14 A. That questionnaire.</p> <p>15 Q. -- that one question in the</p> <p>16 questionnaire?</p> <p>17 In the next paragraph you write,</p> <p>18 "Further, posterior repair is much more likely to</p> <p>19 result in ongoing pain than a sling even in the</p> <p>20 presence of sling exposure."</p> <p>21 What is that based on?</p> <p>22 A. That's based on experience and also on</p> <p>23 literature.</p> <p>24 Q. Okay. What literature supports that</p> <p>25 statement?</p>	<p>1 in one group of patients maybe in a different</p> <p>2 period of time undergoing certain procedures and</p> <p>3 let's say the incidence was, you know, 5 percent in</p> <p>4 that study and then go look at a completely</p> <p>5 different sling study with maybe a different</p> <p>6 patient population, different products, and if the</p> <p>7 incident was one study -- was 1 percent in that</p> <p>8 study, it wouldn't be fair to say that it's -- the</p> <p>9 difference is 5 percent to 1 percent, correct?</p> <p>10 MR. SNELL: Form, foundation.</p> <p>11 A. I would say there -- that may not be the</p> <p>12 same patient population, granted, but also using --</p> <p>13 those numbers are so much higher, and it is also my</p> <p>14 experience that patients who have prolapse surgery</p> <p>15 are much more likely to have pain than we see in a</p> <p>16 patient with a simple sling exposure.</p> <p>17 Q. Okay. So when you say the posterior</p> <p>18 repair is much more likely to result in ongoing</p> <p>19 pain than a sling, you are really sort of basing</p> <p>20 that on your own feeling based on studies you've</p> <p>21 reviewed over the years from your own practice</p> <p>22 experience?</p> <p>23 MR. SNELL: Form, misstates. Go</p> <p>24 ahead.</p> <p>25 A. My own conclusion -- I wouldn't say it's</p>

26 (Pages 98 to 101)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 102</p> <p>1 an emotional feeling -- my conclusion that knowing</p> <p>2 in my experience of operating on patients for two</p> <p>3 decades and reading the literature that the rates</p> <p>4 are much -- that the incidence of pain is almost</p> <p>5 always going to be directly related to the prolapse</p> <p>6 repair and not to the sling.</p> <p>7 Q. And have you done any analysis, any</p> <p>8 attempts to pull the studies you've reviewed or do</p> <p>9 a meta-analysis of the different studies?</p> <p>10 A. No.</p> <p>11 Q. Are you familiar with the concept of</p> <p>12 heterogeneity?</p> <p>13 A. Yes.</p> <p>14 Q. And do you know whether the studies that</p> <p>15 you looked at relating to dyspareunia following</p> <p>16 posterior repair, were they long-term studies or</p> <p>17 short-term studies?</p> <p>18 A. I would need to look at those.</p> <p>19 Q. How many studies are we talking about?</p> <p>20 A. More than a couple.</p> <p>21 Q. And what about the -- first off, as a</p> <p>22 general matter, there is actually very few studies</p> <p>23 that address the incidence of dyspareunia following</p> <p>24 pelvic floor surgery or mesh sling surgery,</p> <p>25 correct?</p>	<p style="text-align: right;">Page 104</p> <p>1 this will take me a few minutes.</p> <p>2 BY MR. GRAND:</p> <p>3 Q. That's all right. I'm not so sure how</p> <p>4 well I highlighted.</p> <p>5 A. I have groin pain in the meta-analysis</p> <p>6 by Schimpf, which runs .34 to 6 percent in the</p> <p>7 various types of incontinence surgeries.</p> <p>8 And in the subsequent study, which is</p> <p>9 the Schimpf study from 2014, which is the</p> <p>10 systematic review and meta-analysis, they talk</p> <p>11 about dyspareunia in retropubic obturator</p> <p>12 mini-slings or pubovaginal slings, and that is 0 to</p> <p>13 .99 percent; and the numbers of women in these</p> <p>14 studies are over 3,000 in total.</p> <p>15 Q. That's not the TVT retropubic, is it?</p> <p>16 MR. SNELL: Objection, form,</p> <p>17 foundation.</p> <p>18 A. Two of the studies were retropubic</p> <p>19 slings, which had about 500 women.</p> <p>20 Q. Okay. Do you know whether those studies</p> <p>21 actually tracked dyspareunia?</p> <p>22 A. Where they tracked, I don't have those</p> <p>23 numbers.</p> <p>24 Q. You don't know whether the underlying</p> <p>25 numbers actually tracked dyspareunia, do you?</p>
<p style="text-align: right;">Page 103</p> <p>1 MR. SNELL: Objection, form,</p> <p>2 foundation.</p> <p>3 A. I think there are -- we are gathering</p> <p>4 quite a bit of evidence in both of those. A long</p> <p>5 time ago if it wasn't reported, then we never knew</p> <p>6 the pre-op incidence, but there are not only</p> <p>7 reports that talk about pre and post-op but also</p> <p>8 validated questionnaires that are used very</p> <p>9 commonly in surgical data. So, I wouldn't say it's</p> <p>10 rare to find it.</p> <p>11 Q. Well, certainly with the older studies</p> <p>12 it wasn't even asked about, correct?</p> <p>13 A. Right.</p> <p>14 Q. So what are the new studies that you</p> <p>15 rely on that actually track dyspareunia in patients</p> <p>16 receiving -- patients implanted with mesh slings?</p> <p>17 A. Do you want to go through them one by</p> <p>18 one?</p> <p>19 Q. Yeah.</p> <p>20 A. Okay.</p> <p>21 Q. I would like to know what those are.</p> <p>22 THE WITNESS: I'm so sorry. I'm</p> <p>23 running out of space here.</p> <p>24 BY THE WITNESS:</p> <p>25 A. I did not highlight as well as you, so</p>	<p style="text-align: right;">Page 105</p> <p>1 MR. SNELL: Form.</p> <p>2 A. Meaning they tracked it. Well, it</p> <p>3 wouldn't be reported in here if it wasn't in the</p> <p>4 study.</p> <p>5 Okay. I guess I'm not understanding</p> <p>6 your question. Do I know if they asked pre and</p> <p>7 post-op? I'm not looking at those studies right</p> <p>8 now.</p> <p>9 Q. Right. You don't know how it was</p> <p>10 tracked, correct? You don't know whether it was by</p> <p>11 questionnaire --</p> <p>12 A. Right.</p> <p>13 Q. -- self-reported, whether it was a</p> <p>14 validated questionnaire? Do you know whether those</p> <p>15 studies were long-term or short-term?</p> <p>16 A. For those particular results, so they</p> <p>17 required a minimum of 12 months followup.</p> <p>18 Q. So one year?</p> <p>19 A. Right.</p> <p>20 Q. Which wouldn't be long-term, correct?</p> <p>21 MR. SNELL: Form.</p> <p>22 A. It is the minimum allowable for</p> <p>23 long-term. Five years is preferable, but the</p> <p>24 minimum we want to see is one year.</p> <p>25 Q. For something involving a medical device</p>

27 (Pages 102 to 105)

Denise M. Elser, M.D.

Page 106	Page 108
<p>1 do you consider one year a long-term followup?</p> <p>2 MR. SNELL: Asked and answered, form.</p> <p>3 A. It is better than six weeks for sure.</p> <p>4 Q. But would you consider it long-term</p> <p>5 followup?</p> <p>6 A. It's in the range. So, we want five,</p> <p>7 five is ideal, but one year gives us very good</p> <p>8 information. Actually, when we look at the studies</p> <p>9 that are up to five and ten years that report no</p> <p>10 increasing rates of adverse effects related to the</p> <p>11 mesh over a five-year period.</p> <p>12 Q. We are going to talk about those studies</p> <p>13 soon. But based on your review, there are not a</p> <p>14 lot of studies that are addressing dyspareunia in</p> <p>15 women receiving a TVT sling, correct?</p> <p>16 MR. SNELL: Objection, misstates.</p> <p>17 A. There are studies. What I pulled out</p> <p>18 for you is studies involving 500 women with the</p> <p>19 retropubic specifically.</p> <p>20 Q. And those studies aren't comparative</p> <p>21 studies to women who've just had other pelvic floor</p> <p>22 procedures, correct?</p> <p>23 A. No.</p> <p>24 Q. Would you consider Mrs. Corbet to be at</p> <p>25 risk for future erosion?</p>	<p>1 Q. Okay. So, when you said she is not</p> <p>2 using estrogen, you are referring to --</p> <p>3 A. Yeah, the cream.</p> <p>4 MR. GRAND: The cream, okay. I want</p> <p>5 to turn to your supplemental report.</p> <p>6 Let's see. What time is it? It is</p> <p>7 12:05 p.m. This is probably a good time to</p> <p>8 break for lunch.</p> <p>9 THE VIDEOGRAPHER: The time is</p> <p>10 12:06 p.m., and we are going off the video</p> <p>11 record.</p> <p>12 (Lunch recess taken,</p> <p>13 12:06 - 1:06 p.m.)</p> <p>14 A F T E R N O O N S E S S I O N</p> <p>15 THE VIDEOGRAPHER: The time is</p> <p>16 1:06 p.m., and we are back on the video</p> <p>17 record.</p> <p>18 BY MR. GRAND:</p> <p>19 Q. Dr. Elser, were you able to during the</p> <p>20 break look at the reliance list and determine?</p> <p>21 A. We started, but it was a little bit too</p> <p>22 much to get through in one lunch session.</p> <p>23 Q. Okay. I guess I would ask that once you</p> <p>24 have completed it you could forward a revised</p> <p>25 reliance list through counsel.</p>
Page 107	Page 109
<p>1 A. Erosion or exposure?</p> <p>2 Q. Exposure. Well, both. How are you --</p> <p>3 first off, what's the difference to you?</p> <p>4 A. Erosion, it means that the mesh has</p> <p>5 eroded into an organ nearby, such as bladder or</p> <p>6 bowel. Exposure is when the mesh is open into the</p> <p>7 vaginal canal so the epithelium has an opening.</p> <p>8 Q. Do you think she is at future risk for</p> <p>9 either occurring?</p> <p>10 A. I think it's extremely unlikely that she</p> <p>11 will develop an erosion, and the mesh has been cut,</p> <p>12 so it's no longer under tension at all. There is</p> <p>13 no band across, under the bladder that can cut into</p> <p>14 the bladder.</p> <p>15 Is she at risk for future exposure? It</p> <p>16 can happen with aging and more thinning of the</p> <p>17 vaginal epithelium, and she is not using any</p> <p>18 estrogen and she already has atrophy, but we know</p> <p>19 from the long-term studies that the incidence of</p> <p>20 exposure ongoing ten years after a sling does not</p> <p>21 seem to be very high at all; in fact, minimum.</p> <p>22 Q. Is it your position that she is not</p> <p>23 currently using estrogen cream?</p> <p>24 A. I don't know if she is using it right</p> <p>25 now or not.</p>	<p>1 A. Yes.</p> <p>2 Q. Thank you. I want to ask you some</p> <p>3 questions about some of the studies you cite in</p> <p>4 your supplemental report.</p> <p>5 First I want to ask you, under the</p> <p>6 section Cochrane Review, you have written, "The</p> <p>7 Cochrane reviews are of the highest level of</p> <p>8 evidence as demonstrated by the Oxford levels of</p> <p>9 evidence pyramid."</p> <p>10 A. Yes.</p> <p>11 Q. You are familiar with other evidence</p> <p>12 pyramids that would rate randomized clinical trials</p> <p>13 as the highest form of evidence?</p> <p>14 MR. SNELL: Form.</p> <p>15 A. No. This is the one that I usually</p> <p>16 relied on.</p> <p>17 Q. This is the one you rely on. Have you</p> <p>18 seen others?</p> <p>19 A. I've not looked at others.</p> <p>20 Q. Do you view the Crochrane review as a</p> <p>21 systematic review or a meta-analysis?</p> <p>22 A. Yes.</p> <p>23 Q. Which?</p> <p>24 A. Oh. Sometimes they are a combination,</p> <p>25 but usually a meta-analysis.</p>

28 (Pages 106 to 109)

Denise M. Elser, M.D.

Page 110	Page 112
<p>1 Q. Okay. Now, the specific review you are</p> <p>2 talking about is the one that came out this year,</p> <p>3 the Ford review?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. I wanted to ask you some</p> <p>6 questions about that. I don't know if you have the</p> <p>7 complete report with you.</p> <p>8 A. I think I do.</p> <p>9 Q. You do. All 250 pages of it?</p> <p>10 A. That's why this book is so fat. Do you</p> <p>11 want to look at the short report?</p> <p>12 Q. For my purposes -- you may need to refer</p> <p>13 to the longer report. For my purposes, I'm going</p> <p>14 to mark into evidence the shorter one.</p> <p>15 A. Okay.</p> <p>16 Q. But I was trying to spare everyone the</p> <p>17 burden of walking away with a 250-page report.</p> <p>18 (Elser Exhibit 10 was marked for</p> <p>19 identification and re-marked as</p> <p>20 Exhibit 13 at Page 161.)</p> <p>21 BY MR. GRAND:</p> <p>22 Q. I'm going to mark the summary report</p> <p>23 from the Cochrane website as Elser 10. Can you</p> <p>24 take a look at that and make sure we are both</p> <p>25 talking about the same report.</p>	<p>1 tabulated results for the TVT retropubic.</p> <p>2 A. Let me look then. Hold on.</p> <p>3 Do you have a copy of the short form,</p> <p>4 not the summary?</p> <p>5 Q. Yes. That's right in front of you.</p> <p>6 A. This is the summary, not the short form.</p> <p>7 There is also a shorter paper.</p> <p>8 Q. That's what I have.</p> <p>9 A. Okay. I don't know if I brought that.</p> <p>10 Yeah, I have to look at the tables on</p> <p>11 the short form to answer that directly.</p> <p>12 Q. You don't have that?</p> <p>13 A. I'm still looking.</p> <p>14 MR. SNELL: This is -- we are off the</p> <p>15 record.</p> <p>16 THE VIDEOGRAPHER: The time is</p> <p>17 1:14 p.m., and we are off video record.</p> <p>18 (Discussion was had off the</p> <p>19 record.)</p> <p>20 THE VIDEOGRAPHER: The time is</p> <p>21 1:15 p.m., and we are back on the video</p> <p>22 record.</p> <p>23 BY MR. GRAND:</p> <p>24 Q. So I'm looking at Page 45.</p> <p>25 A. Yes.</p>
Page 111	Page 113
<p>1 A. Okay.</p> <p>2 Q. And this is a summary of the long form</p> <p>3 report which you are referring to in your report,</p> <p>4 correct?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. On Page 2 of your supplemental</p> <p>7 report -- are you there?</p> <p>8 A. I am.</p> <p>9 Q. And in that second paragraph you state,</p> <p>10 "Most recently, an updated Cochrane review for 2015</p> <p>11 assessed the literature, including RCTs and</p> <p>12 registries and observed that for TVT the number of</p> <p>13 procedures reported ranged from 809 to 4281, and</p> <p>14 there were found to be low rates of major</p> <p>15 complications."</p> <p>16 Did I read that correctly?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. When you say "TVT" in this</p> <p>19 sentence, are you referring to the TVT retropubic</p> <p>20 or are you referring to all mesh slings?</p> <p>21 A. That would be retropubic.</p> <p>22 Q. How did you arrive at these numbers for</p> <p>23 the TVT retropubic? I could not find in that -- in</p> <p>24 the long form report, which I looked at online, I</p> <p>25 could not find a break down that specifically</p>	<p>1 Q. It's on the section Retropubic Tapes.</p> <p>2 A. Yes.</p> <p>3 Q. So, that was information pulled from</p> <p>4 registries, correct?</p> <p>5 A. Yes.</p> <p>6 Q. It was not information pulled from</p> <p>7 randomized controlled clinical trials, correct?</p> <p>8 A. These are reports from registries.</p> <p>9 Q. And there is nothing here that indicates</p> <p>10 that this was just the TVT retropubic or whether it</p> <p>11 included other sling -- retropubic sling products?</p> <p>12 MR. SNELL: Form, misstates.</p> <p>13 A. Okay. It doesn't state here</p> <p>14 specifically what the registries are from, but most</p> <p>15 of the registries involve the TVT retropubic.</p> <p>16 Q. Okay. But there may be other products</p> <p>17 involved in here besides the TVT retropubic,</p> <p>18 correct?</p> <p>19 A. There may be.</p> <p>20 Q. Do you know one way or the other?</p> <p>21 A. No. I would have to re-look at those</p> <p>22 registries.</p> <p>23 Q. Okay. And does it indicate here how</p> <p>24 many of these involved short-term trials versus</p> <p>25 long-term trials?</p>

29 (Pages 110 to 113)

Denise M. Elser, M.D.

Page 114	Page 116
<p>1 A. Not on this page. I would have to 2 re-look at those registries.</p> <p>3 Q. And you know that the Cochrane review is 4 somewhat leery of registry data as opposed to 5 randomized clinical control -- randomized control 6 study data, correct?</p> <p>7 MR. SNELL: Form.</p> <p>8 A. I don't know if they are leery.</p> <p>9 Q. Were you aware that only four of the 10 trials had outcomes of greater than five years?</p> <p>11 A. I don't recall that.</p> <p>12 Q. Let's turn to the summary for a moment. 13 If you could turn to the second page of the 14 summary, it says, "These trials show that over 80 15 percent of women with stress urinary incontinence 16 are cured or have significant improvement in their 17 symptoms with either operation for up to five years 18 after surgery."</p> <p>19 Did I read that correctly?</p> <p>20 A. Yes.</p> <p>21 Q. And that's referring to comparing the 22 transobuturator approach to the retropubic approach?</p> <p>23 A. I don't know if it is comparing them.</p> <p>24 Q. Well, if you look at what this review 25 tried to find out on the first page -- strike that.</p>	<p>1 foundation on that. You mean referenced in 2 this?</p> <p>3 Q. In the Cochrane review, would it 4 surprise you if there were only four trials out of 5 all of the ones reviewed that had data for more 6 than five years?</p> <p>7 A. No.</p> <p>8 Q. If you go down to the section that says 9 "Limitations of the Review."</p> <p>10 A. Yes.</p> <p>11 Q. It said, "Most of our results are based 12 on moderate quality evidence," correct?</p> <p>13 A. Yes.</p> <p>14 Q. "Most trials did not describe their 15 methods clearly, thus leading to some degree of 16 uncertainty in the findings."</p> <p>17 Did I read that correctly?</p> <p>18 A. Yes.</p> <p>19 Q. "At present there are only a limited 20 number of randomized controlled trials (these 21 produced the most reliable results) that have 22 published data beyond five years after surgery. 23 This means that evidence about how effective and 24 safe these procedures are in the longer term lags 25 behind the evidence for them in the short and</p>
Page 115	Page 117
<p>1 This study is not comparing midurethral 2 sling procedures to more traditional forms of 3 treating stress urinary incontinence, correct?</p> <p>4 MR. SNELL: Form, misstates the 5 document.</p> <p>6 A. So, this review is about midurethral 7 slings. It's not talking about any traditional 8 repair such as colposuspension or pubovaginal 9 sling.</p> <p>10 Q. Correct. It's comparing transobuturator 11 approach versus retropubic approach, correct?</p> <p>12 A. Right.</p> <p>13 Q. And under either approach, 80 percent of 14 women are cured and presumably 20 percent are not, 15 correct?</p> <p>16 A. 80 percent are cured, right, right.</p> <p>17 Q. And you see a little further down it 18 says, "Only a few trials provided information about 19 the effectiveness of these tapes more than five 20 years after surgery."</p> <p>21 Did I read that correctly?</p> <p>22 A. Yes.</p> <p>23 Q. Would you be surprised if there were 24 actually only four trials?</p> <p>25 MR. SNELL: I'm going to object to</p>	<p>1 medium term, up to five years."</p> <p>2 Did I read that correctly?</p> <p>3 A. Yes.</p> <p>4 Q. So, would you agree with them that 5 long-term evidence is going to be greater than five 6 years and anything less than that would be short- 7 to medium-term?</p> <p>8 A. They call short- and medium-term up to 9 five years. I would call five years long-term 10 data, and this is still -- the evidence on these 11 slings is still more robust than any evidence we 12 have for the traditional surgery.</p> <p>13 Q. Would you agree that this is an efficacy 14 review and not a safety review?</p> <p>15 MR. SNELL: Object to form, misstates.</p> <p>16 A. They do report on safety, but they talk 17 -- it said that they are -- that what this review 18 tried to find out is that efficacy, how effective 19 they are and the rate of potential complication.</p> <p>20 Q. Right, but it's fair to say in the 21 underlying -- underlying studies they reviewed they 22 didn't all report on the same safety -- safety 23 endpoints?</p> <p>24 MR. SNELL: Form.</p> <p>25 A. They probably didn't all report on the</p>

30 (Pages 114 to 117)

Denise M. Elser, M.D.

Page 118	Page 120
<p>1 same efficacy endpoints either.</p> <p>2 Q. Fair enough. And so when I look at your</p> <p>3 report and I see basically reprinted that table you</p> <p>4 were looking at on Page 45, you can't say that that</p> <p>5 table actually applies to the TVT retropubic</p> <p>6 product as opposed to other products that may be</p> <p>7 included in this?</p> <p>8 MR. SNELL: Form, misstates.</p> <p>9 A. I'm sorry. We would look at those</p> <p>10 registries that it came from, and most of the data</p> <p>11 is going to be from TVT because that was what was</p> <p>12 involved in most of the registries, but it's not</p> <p>13 all TVT retropubic.</p> <p>14 Q. Right, but you can't say that these</p> <p>15 particular percentages that you give apply to the</p> <p>16 TVT product, correct?</p> <p>17 A. Well, other studies that look at the</p> <p>18 5- and 10-year data on the TVT have similar rates.</p> <p>19 Q. In the Cochrane study which you are</p> <p>20 citing, you cannot say that these rates apply to</p> <p>21 the TVT retropubic product, correct?</p> <p>22 MR. SNELL: Hold on. Objection, asked</p> <p>23 and answered, misstates.</p> <p>24 A. They're reported for retropubic slings.</p> <p>25 MR. GRAND: Excuse me?</p>	<p>1 (Elser Exhibit 11 was marked for</p> <p>2 identification as of 11/5/15.)</p> <p>3 MR. GRAND: Do you want a copy, Burt?</p> <p>4 MR. SNELL: Actually, I have one in</p> <p>5 here. I'm good. Thank you.</p> <p>6 THE WITNESS: Yours is bigger font.</p> <p>7 I'm going to look at this one.</p> <p>8 MR. GRAND: Sure.</p> <p>9 BY MR. GRAND:</p> <p>10 Q. Now, like the Cochrane review we just</p> <p>11 looked at, this compares the obturator approach to</p> <p>12 the retropubic approach, correct?</p> <p>13 A. Yes.</p> <p>14 Q. And if you look at, I guess it's Table 1</p> <p>15 of the study on Page 1256, only five of the studies</p> <p>16 actually involve the TVT retropubic, correct?</p> <p>17 A. That's what it looks like.</p> <p>18 Q. And in some cases it's comparing it to</p> <p>19 the TVT-O; in other cases it's comparing it to</p> <p>20 other manufacturer's products; correct?</p> <p>21 A. Yes.</p> <p>22 Q. And in fact, it looks like there is less</p> <p>23 than 400 TVT-R patients implicated at all, correct?</p> <p>24 A. I haven't added it up, but that looks</p> <p>25 like a good ballpark.</p>
Page 119	Page 121
<p>1 THE REPORTER: Say it again, please.</p> <p>2 A. They are reported for retropubic slings,</p> <p>3 which may not all be TVT.</p> <p>4 Q. On the next page of your supplemental</p> <p>5 report, Page 3, you discuss the Tommaselli</p> <p>6 meta-analysis?</p> <p>7 A. Okay. Sorry. I am flipping back and</p> <p>8 forth here.</p> <p>9 Q. I can give you a copy of it.</p> <p>10 A. I have the Tommaselli right here.</p> <p>11 Q. I'm going to mark a version so it's in</p> <p>12 the record, but you can feel free to use your own</p> <p>13 copy.</p> <p>14 A. Okay. Is yours highlighted?</p> <p>15 Q. No. My copy is, not yours.</p> <p>16 A. Okay.</p> <p>17 Q. Burt would object if I gave you a</p> <p>18 highlighted copy.</p> <p>19 A. I'm sorry. What page of the report were</p> <p>20 you on?</p> <p>21 Q. I was just referring to Page 3 of your</p> <p>22 report where you begin to talk about Tommaselli.</p> <p>23 A. Okay.</p> <p>24 MR. GRAND: I'll mark this as</p> <p>25 Elser 11.</p>	<p>1 Q. And only 35 of those patients had</p> <p>2 followup of five years or greater, correct?</p> <p>3 A. Well, you have 35 in study number 15.</p> <p>4 Study number 18 is 60 months, so that's also five</p> <p>5 years.</p> <p>6 Q. And 82 of them were at three years,</p> <p>7 correct?</p> <p>8 A. (No verbal response.)</p> <p>9 Q. And it looks like some of these trials</p> <p>10 involved validated questionnaires and some did not,</p> <p>11 correct?</p> <p>12 A. Correct.</p> <p>13 Q. And in fact, it looks like this involved</p> <p>14 ten different slings, correct, not just the TVT-R?</p> <p>15 A. I counted nine, but okay.</p> <p>16 Q. You may be correct. I was eyeballing</p> <p>17 it. In fact, if you look at the next page,</p> <p>18 Table 3...</p> <p>19 A. All right. I'm on Table 2, so it's the</p> <p>20 next page, the next-next page, Table 3.</p> <p>21 Q. Yes. It lists the number of patients</p> <p>22 treated and evaluated in the medium-term and</p> <p>23 long-term per type of device?</p> <p>24 A. Yes.</p> <p>25 Q. Then you see for TVT retropubic for</p>

31 (Pages 118 to 121)

Denise M. Elser, M.D.

Page 122	Page 124
<p>1 randomized controlled studies there was 319</p> <p>2 patients?</p> <p>3 A. Yes.</p> <p>4 Q. And then there is, I guess, 3,482</p> <p>5 patients from other types of studies?</p> <p>6 A. Yes.</p> <p>7 Q. In your experience, is it good practice</p> <p>8 to combine studies from randomized controlled --</p> <p>9 combine data from randomized controlled clinical</p> <p>10 trials with other types of studies?</p> <p>11 A. I think other types of studies are still</p> <p>12 very valuable, and so to gather as much as evidence</p> <p>13 as we can, which I put all the information</p> <p>14 together, I think it's wise to look at everything.</p> <p>15 Q. My question is not that it's wise to</p> <p>16 look at everything. My question is whether --</p> <p>17 whether combining the results from all different</p> <p>18 types of studies will give you accurate</p> <p>19 information.</p> <p>20 A. It gives us more information.</p> <p>21 Q. But not necessarily accurate?</p> <p>22 MR. SNELL: Form.</p> <p>23 A. The RCTs have limitations as well. I</p> <p>24 want to look at all the information, long-term</p> <p>25 studies from surgeons doing lots of TVTs and what's</p>	<p>1 2013 TVT registry. I will mark that as Exhibit 12.</p> <p>2 (Elser Exhibit 12 was marked for</p> <p>3 identification as of 11/5/15.)</p> <p>4 MR. GRAND: Do you want a copy of</p> <p>5 that, Burt?</p> <p>6 MR. SNELL: Let me see if I have.</p> <p>7 Yeah, I will take a courtesy copy if you have</p> <p>8 it. Thank you.</p> <p>9 BY MR. GRAND:</p> <p>10 Q. Now, this study attempted to follow up</p> <p>11 on women who had undergone a TVT retropubic</p> <p>12 procedure, correct?</p> <p>13 A. Yes.</p> <p>14 Q. And this was basically a registry study?</p> <p>15 A. Well, they've pulled women from the</p> <p>16 registry and invited them back specifically to</p> <p>17 answer questions about this study, so it is not</p> <p>18 strictly a registry study.</p> <p>19 Q. Right. They -- I believe they</p> <p>20 identified initially 603 women over a four-year</p> <p>21 period?</p> <p>22 A. Yes.</p> <p>23 Q. Of those, 542 were still alive?</p> <p>24 A. Yes.</p> <p>25 Q. And of those, they included 483 women?</p>
Page 123	Page 125
<p>1 available in the RCTs as well.</p> <p>2 Q. Well, presumably you did. You've cited</p> <p>3 this study, correct?</p> <p>4 A. Right.</p> <p>5 Q. So, you think this was a sound</p> <p>6 approach --</p> <p>7 A. It's an approach to get --</p> <p>8 Q. -- or meta-analysis?</p> <p>9 A. -- as much data as we can to learn about</p> <p>10 the outcome.</p> <p>11 Q. So, with respect to the conclusions you</p> <p>12 cite in your report about the number of vaginal</p> <p>13 erosions at 2.1 percent for retropubic, that's for</p> <p>14 all retropubic regardless of product, correct?</p> <p>15 A. Correct.</p> <p>16 Q. So, if the TVT were higher and another</p> <p>17 product were lower, it would have averaged out to</p> <p>18 2.1, correct?</p> <p>19 A. That is potentially, but since most of</p> <p>20 the studies we know out there which are TVT, not</p> <p>21 retropubic, because it has been out there the</p> <p>22 longest, it probably skews the evidence toward</p> <p>23 whatever was really TVT results.</p> <p>24 Q. Set that aside.</p> <p>25 I want to ask you about the Svenningsen</p>	<p>1 A. Yes.</p> <p>2 Q. Do you know why they excluded some</p> <p>3 women?</p> <p>4 A. I know that some were not willing to</p> <p>5 participate, but I would have to look back, look</p> <p>6 through to see why.</p> <p>7 Q. And of the 483 women, 327 actually</p> <p>8 attended a clinical consultation and the other 156</p> <p>9 participated by phone, correct?</p> <p>10 A. Yes.</p> <p>11 Q. Now, did you review the questionnaires</p> <p>12 from this study?</p> <p>13 A. No.</p> <p>14 Q. Do you know whether they actually asked</p> <p>15 these women about dyspareunia?</p> <p>16 A. I don't know.</p> <p>17 Q. And in this study, de novo urgency</p> <p>18 increased from 4 percent in the first 6 to 12</p> <p>19 months following surgery up to almost 15 percent at</p> <p>20 the 10-year followup point, correct?</p> <p>21 A. As I believe is included in my report,</p> <p>22 over ten years' time women this age especially have</p> <p>23 a natural incidence of increasing urge</p> <p>24 incontinence, so I would not conclude that that's</p> <p>25 because they had a TVT.</p>

32 (Pages 122 to 125)

Denise M. Elser, M.D.

Page 126	Page 128
<p>1 Q. And in terms of -- well, sorry. I just 2 lost my place. One second. 3 And the way that they evaluated 4 complications was to ask the women what 5 complications they remembered over a 10-year 6 period; is that correct? 7 A. By questionnaire, it was by 8 questionnaire. 9 Q. Now, the authors of this did not 10 conclude that the increased incontinence was due to 11 a natural increased incontinence that would happen 12 over time, correct? 13 MR. SNELL: Form. 14 Q. They didn't reach the same conclusion 15 you did? 16 MR. SNELL: Same objection. 17 A. I'm on Page 1275. "Our study 18 illustrates the difficulties encountered when 19 evaluating long-term results in an aging 20 population. Recurrence of stress incontinence as 21 well as recurrence or occurrence of prolapse 22 urgency and urge incontinence over time could be 23 consequences of the surgical procedure ten years 24 previously as well as the effects of normal 25 deterioration of the pelvic floor caused by</p>	<p>1 A. Well, I'm not a person who works in a 2 lab studying materials all day, but I am familiar 3 with the Amid classifications and which type of 4 mesh seem to heal well in the pelvis as compared to 5 other types of mesh. 6 Q. Okay. You looked at other 7 classifications beside the Amid classification? 8 A. No. 9 Q. Have you ever looked at studies that 10 show what the pore size of the mesh is under 11 stress? 12 MR. SNELL: Form. 13 A. I have seen that. 14 Q. Are you going to be offering opinions at 15 trial about the pore sizes of the mesh? 16 A. If I'm asked about them. 17 MR. SNELL: And I will say she has 18 identified as macroporous, so those opinions 19 will be elicited at trial. 20 MR. GRAND: All right. We will take 21 that up in motion practice. 22 BY MR. GRAND: 23 Q. You don't consult as a materials expert, 24 correct? 25 MR. SNELL: Form.</p>
Page 127	Page 129
<p>1 advancing age." 2 Q. And on Page 1277 they note that the 3 14.9 percent of women reporting de novo urgency is 4 consistent with incontinence rates in other TVT 5 publications, correct? 6 A. Right. 7 Q. So, you would agree with that? 8 Regardless of what you would attribute it to, you 9 would agree that that number is consistent with 10 other TVT studies? 11 A. Yes. 12 Q. Now, on Page 8 of your supplemental 13 report -- 14 MR. SNELL: I'm sorry. I didn't hear 15 what page. 16 MR. GRAND: Page 8. 17 THE WITNESS: Okay. I'm there. 18 BY MR. GRAND: 19 Q. You give some opinions on the lower half 20 of the page regarding biocompatibility of the mesh 21 and whether the mesh is macroporous and 22 monofilament. Do you see that? 23 A. Yes. 24 Q. You are not a materials expert, correct? 25 MR. SNELL: Form.</p>	<p>1 A. No. 2 Q. And you have never designed a mesh, 3 correct? 4 A. No. 5 Q. And you haven't studied explants of 6 mesh, correct? 7 MR. SNELL: Form. 8 A. No. 9 Q. And have you done any research into the 10 effects of -- scratch that. 11 Strike that. 12 Okay. On the next page you state, "I 13 have used the TVT for about 17 years and noticed no 14 clinical difference between mechanical and 15 laser-cut mesh." 16 Have you reviewed internal documents by 17 Ethicon in which they know the difference between 18 mechanical and laser-cut mesh? 19 MR. SNELL: Actually, objection, 20 foundation on that one. 21 BY MR. GRAND: 22 Q. Have you reviewed any of the Ethicon's 23 internal documents relating to the differences 24 between mechanical and laser-cut mesh? 25 A. It's been a while. I have read some,</p>

Denise M. Elser, M.D.

Page 130	Page 132
<p>1 but I'm really referring to our clinical 2 experience, and we don't see a difference. 3 Q. How do you know the difference between 4 mechanical and laser-cut mesh out of the package? 5 A. The edges appear smooth, appear more 6 solid and smoother on the laser cut. 7 Q. Okay. So, you can tell if I were to 8 hand you two pieces of mesh which was mechanical 9 and which was laser cut? 10 A. I think so. 11 Q. And you have tracked that in your 12 practice? 13 A. We know when the changes were made in 14 the different devices that we're using, and we 15 don't see a change in our cure rates or our 16 exposure rates. 17 Q. Have you tracked which of your patients 18 received laser-cut mesh versus mechanical-cut mesh? 19 A. No. 20 Q. In fact, you haven't tracked recently 21 any of your patients who have received a TVT 22 retropubic laser cut versus mechanical cut, 23 correct? 24 MR. SNELL: Form. 25 A. I haven't tracked recently. I have not</p>	<p>1 A. I don't -- I think I've heard that 2 before, but it was not something I knew. 3 Q. Okay. So, this isn't something you have 4 actually tracked in your practice, correct? 5 MR. SNELL: Form. 6 A. Right. I just said I've not tracked it. 7 Q. Okay. So, when you said we have noticed 8 no clinical difference, it's just that you haven't 9 noticed? 10 A. Over time. 11 Q. Well, you haven't used the TVT 12 retropubic in two years? 13 A. I would notice if all of a sudden our 14 exposure rate is going way up or our pain rate is 15 going up or our cure rate is going down or our 16 retention rate is going up, and I have not noticed 17 a clinical change in our sling patients. 18 Q. In your next sentence you say, "I have 19 reviewed photographs of the mesh being stretched 50 20 percent, and it is my opinion that this is a 21 laboratory scenario as the mesh is not similarly 22 stretched during implantation." 23 Did I read that correctly? 24 A. Yes. 25 Q. Is it your view that the mesh cannot be</p>
Page 131	Page 133
<p>1 checked. 2 Q. Well, you said that your 4.5 percent 3 figure goes back about two years, correct? 4 A. Correct. 5 Q. There is not going to be any TVT 6 patients included in that, correct? 7 MR. SNELL: Same objection. 8 A. So you are talking about mechanical cut? 9 Q. We are talking about -- yeah. 10 A. Oh. You said laser cut. 11 Q. Well, retropubic, which is both 12 mechanical and laser cut. 13 A. Well, I've not pulled and sat and looked 14 at, oh, this is my pile of patients with this data 15 and this is my pile with that data, but I certainly 16 pay a lot of attention to our results; and when 17 products change or we are using a new product, 18 we'll -- we'll know it right away if we are seeing 19 different outcomes and stop and then take a look 20 and say, hey, what's going on, what's different. 21 But we have not had to do that when retropubic went 22 to laser cut or now we went to Exact because we are 23 not seeing different outcomes. 24 Q. Are you aware that the TVT retropubic is 25 still available in mechanical cut?</p>	<p>1 stretched in other ways besides implantation? 2 A. Once it's implanted, it's very hard to 3 stretch. 4 Q. There is no stresses that may occur 5 through movement of the body? 6 A. Once the plastic sheaths are off, it's 7 hard to move it, it's hard to adjust it, so that it 8 would even dramatically change our post-op 9 counseling to patients on what restrictions they 10 have after surgery. Because it's so hard to move, 11 we think it would be very difficult for them to 12 distort it in any significant way once the plastic 13 is removed. 14 And we were always instructed to take 15 care to not stretch or distort it before 16 implanting, and in the original TVT, the plastic 17 sheath which was overlapped in the middle, it could 18 separate prematurely; and if it separated and got 19 pulled, like if an assistant took it out carelessly 20 out of the package, I would put that away and start 21 fresh with a new product because it was stretched 22 abnormally before it was implanted, and that's not 23 what we want. So, when we place it with the 24 plastic sheath intact, it does not distort or 25 stretch.</p>

34 (Pages 130 to 133)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 134</p> <p>1 Q. So, your statement that in your opinion 2 it's a laboratory scenario and the mesh is not 3 similarly stretched during implantation, do you 4 have any data or testing to support that? 5 A. No. This is my experience from having 6 looked at the mesh in the lab, looking at videos of 7 it stretching when placed on machines and looking 8 at people taking it out of the package and 9 stretching it too far before it's implanted. 10 Q. When have you looked at mesh in the lab? 11 A. It would be in cadaver courses. We 12 would take it and do whatever we could to try and 13 break or stretch it. 14 Q. When was the last time you had a cadaver 15 course in mesh or you taught a cadaver course in 16 mesh? 17 A. Maybe three years ago. 18 Q. You taught a cadaver course with a TVT 19 retropubic three years ago? 20 A. Yes. 21 Q. The Svenningsen study you cite -- 22 MR. SNELL: Is that the one we had 23 earlier? 24 MR. GRAND: Yeah. 25 MR. SNELL: Did you mark that one 12</p>	<p style="text-align: right;">Page 136</p> <p>1 Q. And you see Sigurd Kulseng-Hanssen also 2 received travel grants from Pfizer and Gynecare? 3 A. Yes. 4 Q. For -- on Page 12 of your supplemental 5 report you state, "The risk of dyspareunia, pain 6 and sexual dysfunction with TVT is very small and 7 less than the pubovaginal sling and Burch 8 colposuspension." 9 Do I read that correctly? 10 A. Yes. 11 Q. Okay. Other than the two sources you 12 cited there, what studies are you pointing to as 13 authority for that? 14 A. I better look at the other 10-year 15 studies to look at the dyspareunia rate. 16 Q. And what do you characterize as very 17 small in terms of risk? 18 A. Well, for Schimpf's report it was less 19 than -- it was like 2 percent or less in the 20 studies. 21 We have a Angioli study, which is a 22 five-year followup looking at TVT versus obturator 23 with 3 percent dyspareunia after five years. 24 I was looking for the Nilsson's 17-year 25 study. I know it's in here.</p>
<p style="text-align: right;">Page 135</p> <p>1 or 13? 2 THE WITNESS: 12. 3 MR. GRAND: 12. 4 BY MR. GRAND: 5 Q. All the authors are Gynecare or Ethicon 6 consultants, correct? 7 MR. SNELL: Foundation. 8 A. I don't know. 9 Q. Did you read the study? 10 A. I did. I don't remember that part. 11 Q. On Page 1277 there is a section called 12 "Conflict of Interest." It says Rune Svenningsen 13 once received travel grants from Johnson & Johnson 14 among other companies. Do you see that? 15 A. I see that, yes. I know that's very 16 common in Europe to attend conferences and be 17 treated by a company. 18 Q. You see Anne C. Staff -- 19 A. Yes. 20 Q. -- has the received speaker fees, travel 21 grants, advisory board fees and remuneration for 22 clinical drug studies from multiple companies, 23 including Johnson & Johnson/Gynecare. Do you see 24 that? 25 A. Yes.</p>	<p style="text-align: right;">Page 137</p> <p>1 Q. Would that and the other study you just 2 mentioned be your sources other than the one you 3 referred to in your report? 4 A. It's the main one looking at long-term, 5 that gave us long-term data to talk about the 6 ongoing rates of dyspareunia and pain. 7 Okay. When I find that, I will tell 8 you. 9 MR. GRAND: I do not have further 10 questions right now. 11 EXAMINATION 12 BY MR. SNELL: 13 Q. Dr. Elser, my name is Burt Snell. I 14 represent Ethicon and Johnson & Johnson. I just 15 want to ask you some followup questions, and let's 16 start on the topic we were just discussing. 17 Mr. Grand asked you about data upon which you were 18 relying concerning the low rates of pain or 19 dyspareunia with the TVT retropubic device. 20 Turn, if you would, to Page 5 of your 21 report. 22 MR. GRAND: Talking about the 23 supplemental? 24 MR. SNELL: Yes. 25 THE WITNESS: Got it.</p>

35 (Pages 134 to 137)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 138</p> <p>1 BY MR. SNELL:</p> <p>2 Q. In the bottom paragraph you cite to a</p> <p>3 paper by Unger this year, 2015?</p> <p>4 A. Yes. Thank you.</p> <p>5 MR. GRAND: Sorry. I just don't see</p> <p>6 it. Oh, got it.</p> <p>7 THE WITNESS: Bottom of Page 5.</p> <p>8 BY MR. SNELL:</p> <p>9 Q. And what was the rate of reoperation for</p> <p>10 pain or dyspareunia in that study?</p> <p>11 A. There was far less. It was 2.7 percent</p> <p>12 overall, but pain or dyspareunia specifically was</p> <p>13 .2 percent.</p> <p>14 Q. Is that a study you are relying on for</p> <p>15 your opinions regarding a low risk of pain or</p> <p>16 dyspareunia?</p> <p>17 A. Yes.</p> <p>18 Q. There is another study, Nguyen 2012.</p> <p>19 I'm not sure if I'm pronouncing that correctly.</p> <p>20 A. Nguyen.</p> <p>21 Q. Nguyen, okay. So I was totally off.</p> <p>22 A. It's N-g-u-y-e-n.</p> <p>23 Q. And that was a study regarding</p> <p>24 reoperation or the need for reoperation due to</p> <p>25 complications?</p>	<p style="text-align: right;">Page 140</p> <p>1 A. Yes.</p> <p>2 Q. Okay. And is that something you cited</p> <p>3 for the opinion that you believe that the rate of</p> <p>4 pain or dyspareunia with TVT is lower than that</p> <p>5 with the Burch or the fascial sling?</p> <p>6 A. Yes.</p> <p>7 MR. GRAND: Just to be clear, are we</p> <p>8 talking now about TVT retropubic or all TVT</p> <p>9 products?</p> <p>10 MR. SNELL: TVT, TVT retropubic.</p> <p>11 BY THE WITNESS:</p> <p>12 A. It says synthetic midurethral sling, but</p> <p>13 again, most of their data would come from TVT data.</p> <p>14 BY MR. SNELL:</p> <p>15 Q. And let's take a look at the Tommaselli</p> <p>16 paper that Mr. Grand marked as Elser No. 11, and I</p> <p>17 would like to just follow up on that point you just</p> <p>18 made, Doctor.</p> <p>19 If you would turn to page -- well, the</p> <p>20 page with Table 3 that Mr. Grand and you were</p> <p>21 discussing. Do you see that?</p> <p>22 A. Yeah, Page 1258.</p> <p>23 Q. If you look at Table 3, now, you had</p> <p>24 made the point that the vast majority of data on</p> <p>25 retropubic comes from the TVT retropubic studies,</p>
<p style="text-align: right;">Page 139</p> <p>1 A. Yes, and their reoperation for pain was</p> <p>2 .04 percent.</p> <p>3 Q. Is that a study upon which you are</p> <p>4 relying?</p> <p>5 A. Yes.</p> <p>6 Q. Do you find those studies reliable?</p> <p>7 A. Yes, those are reliable.</p> <p>8 Q. You already discussed the Schimpf SGS,</p> <p>9 systematic review and meta-analysis, correct?</p> <p>10 A. Yes.</p> <p>11 Q. And the American Urologic Association</p> <p>12 stress incontinence guidelines and meta-analysis?</p> <p>13 A. Yes.</p> <p>14 Q. I think you identified, those are some</p> <p>15 of the items that you are relying upon for the low</p> <p>16 risk of pain or dyspareunia; is that right?</p> <p>17 A. Yes.</p> <p>18 Q. I'm just going to hand you, and I will</p> <p>19 give it to Mr. Grand. Why don't we just mark it.</p> <p>20 Is this the AUA updated table you were talking</p> <p>21 about with regard to rates of pain and sexual</p> <p>22 dysfunction amongst the various stress</p> <p>23 incontinence --</p> <p>24 A. Yes.</p> <p>25 Q. -- surgeries? Okay.</p>	<p style="text-align: right;">Page 141</p> <p>1 correct?</p> <p>2 A. Yes.</p> <p>3 Q. Is this table and does this systematic</p> <p>4 review and meta-analysis support your opinion that</p> <p>5 the vast majority of retropubic data flows from the</p> <p>6 original TVT retropubic device?</p> <p>7 A. Yes. On a total of retropubic slings,</p> <p>8 there were 3974 retropubic slings and 3801 of those</p> <p>9 are retropubic TVT.</p> <p>10 Q. So just so we are clear, 3,801 were</p> <p>11 patients treated with the TVT retropubic device?</p> <p>12 A. Yes.</p> <p>13 Q. And adding up all the retropubic</p> <p>14 devices, it was 3,974?</p> <p>15 A. Yes.</p> <p>16 Q. Fair to say that in the long-term data</p> <p>17 the TVT device makes up well over 95 percent of the</p> <p>18 data available?</p> <p>19 A. Yes. It's been around the longest and</p> <p>20 the most studied.</p> <p>21 Q. And so when these studies are reporting</p> <p>22 rates of complications, whether they use the word</p> <p>23 "TVT, tension-free vaginal tape" or "retropubic</p> <p>24 tape," is it fair to say that that data speaks to</p> <p>25 the TVT retropubic device?</p>

36 (Pages 138 to 141)

Denise M. Elser, M.D.

Page 142	Page 144
<p>1 MR. GRAND: Objection.</p> <p>2 A. Yes. Unless it specifically states</p> <p>3 otherwise, we assume the data is retropublic TVT.</p> <p>4 Q. And is that because over 95 percent of</p> <p>5 the retropublic data flows from the TVT retropublic</p> <p>6 device?</p> <p>7 A. Yes.</p> <p>8 Q. You discussed Table 1 with Mr. Grand. I</p> <p>9 just think just pointing out for the record, there</p> <p>10 was a study in there. I didn't see that you two</p> <p>11 discussed it, but reference number 17, the longest</p> <p>12 study with followup, 100 months. Did that involve</p> <p>13 the TVT device?</p> <p>14 A. Yes, it did.</p> <p>15 Q. And you didn't really discuss Table 2,</p> <p>16 but Table 2 has various other studies and it runs</p> <p>17 two pages; and fair to say the vast majority of</p> <p>18 those studies also include the TVT device?</p> <p>19 A. Yes, most of those are TVT.</p> <p>20 Q. Is there any retropublic device that has</p> <p>21 ever been available to surgeons like yourself that</p> <p>22 has more data than the Ethicon TVT retropublic</p> <p>23 device?</p> <p>24 A. No.</p> <p>25 Q. Is there any retropublic device that has</p>	<p>1 guidelines by the various professional societies?</p> <p>2 A. Yes.</p> <p>3 Q. You and Mr. Grand discussed the</p> <p>4 Ford/Cochrane review from this year. Do you recall</p> <p>5 that?</p> <p>6 A. Yes.</p> <p>7 Q. I just had a quick question. I think it</p> <p>8 was on Page 45. And so is it fair to say the vast</p> <p>9 majority of retropublic data is also from the TVT</p> <p>10 retropublic device?</p> <p>11 A. Yes.</p> <p>12 Q. And at Page 45 where you reference the</p> <p>13 registries -- I will let you get to it.</p> <p>14 A. Yeah, yes.</p> <p>15 Q. You reference and said that those</p> <p>16 registries would include and pertain to the TVT</p> <p>17 retropublic device?</p> <p>18 A. Yes.</p> <p>19 Q. For instance, Kuuva 2002, is that a</p> <p>20 registry that you are familiar with?</p> <p>21 A. Yes.</p> <p>22 Q. You recognize that as one of the</p> <p>23 earliest Scandinavian registries on the original</p> <p>24 TVT retropublic device?</p> <p>25 MR. GRAND: Objection.</p>
Page 143	Page 145
<p>1 nearly the amount of long-term data as you define</p> <p>2 long-term as the TVT retropublic device?</p> <p>3 A. No.</p> <p>4 MR. GRAND: Objection, foundation.</p> <p>5 BY MR. SNELL:</p> <p>6 Q. Doctor, you have been regularly, you</p> <p>7 told us, reading the medical literature for</p> <p>8 decades?</p> <p>9 A. Yes.</p> <p>10 Q. Do you stay abreast in your field with</p> <p>11 regard to stress incontinence devices?</p> <p>12 A. I do.</p> <p>13 Q. You have looked at various meta-analyses</p> <p>14 and systematic reviews?</p> <p>15 A. Yes.</p> <p>16 Q. And in all of those, have you ever seen</p> <p>17 any retropublic device that has nearly the amount of</p> <p>18 data that the TVT retropublic device has?</p> <p>19 A. No.</p> <p>20 Q. Are meta-analyses and systematic reviews</p> <p>21 a recognized approach to evaluating clinical data</p> <p>22 in your field of urogynecology?</p> <p>23 A. Yes.</p> <p>24 Q. Do you rely upon Cochrane reviews,</p> <p>25 systematic reviews and meta-analyses and the</p>	<p>1 A. Yes, I do.</p> <p>2 Q. Well, I mean, you've presented on the</p> <p>3 TVT retropublic device, including clinical data on</p> <p>4 it, to other doctors?</p> <p>5 A. Yes.</p> <p>6 Q. You have presented with slides that</p> <p>7 actually referenced and discuss the Kuuva registry</p> <p>8 for TVT?</p> <p>9 A. Yes.</p> <p>10 Q. You were familiar with that long before</p> <p>11 I ever contacted you?</p> <p>12 A. Yes.</p> <p>13 Q. All right. And a question was posed</p> <p>14 about the retropublic data in the Cochrane review,</p> <p>15 not the website but the actual document. I'm going</p> <p>16 to read it to you. It says, "From the above list</p> <p>17 of registries, the tension-free vaginal tape."</p> <p>18 Would that be the TVT device we have been</p> <p>19 discussing today?</p> <p>20 A. Yes.</p> <p>21 Q. The number of procedures reported range</p> <p>22 from 809 to 4,281 and are found below, and you</p> <p>23 included that information in your report?</p> <p>24 A. Yes.</p> <p>25 Q. I believe Mr. Grand asked you a question</p>

37 (Pages 142 to 145)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 146</p> <p>1 about whether the Cochrane group was wary -- or I</p> <p>2 don't mean to use the wrong term.</p> <p>3 A. Leery.</p> <p>4 Q. -- leery about registry data as opposed</p> <p>5 to randomized controlled data.</p> <p>6 My question to you is this: Did you</p> <p>7 cite in your report where the Cochrane group states</p> <p>8 that the rates in these registries are largely of</p> <p>9 the same order as those reported in the trials</p> <p>10 included in this review?</p> <p>11 A. Yes.</p> <p>12 Q. What's the significance of that, if any,</p> <p>13 with regard to how reliable those registries are?</p> <p>14 A. They seem to be keeping track of the</p> <p>15 data to the same caliber as the long-term RCTs</p> <p>16 because we are getting similar rates of success and</p> <p>17 complications.</p> <p>18 Q. And is that something you look for in</p> <p>19 your analyses, consistency in various types of</p> <p>20 data?</p> <p>21 A. Yes.</p> <p>22 Q. Mr. Grand asked you a couple questions</p> <p>23 about the Svenningsen 2013 study that involved --</p> <p>24 that involved the TVT retropubic device?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 148</p> <p>1 Q. And I believe you testified it's your</p> <p>2 opinion that the old label was just as adequate as</p> <p>3 the new label?</p> <p>4 A. Yes.</p> <p>5 Q. I believe a question was asked about the</p> <p>6 implanting surgeon's training. Let me ask you</p> <p>7 this: Did you have an understanding as to whether</p> <p>8 the implanting surgeon was a medical doctor?</p> <p>9 A. He has "M.D." after his name.</p> <p>10 Q. Do you know whether he was -- had</p> <p>11 undergone further training like a residency in</p> <p>12 urogynecology or gynecology?</p> <p>13 A. His deposition CV had stated he had done</p> <p>14 an OB/GYN residency.</p> <p>15 Q. And when you talked about the basic or</p> <p>16 the risks that flow across incontinence surgeries</p> <p>17 that a surgeon who is going to do incontinence</p> <p>18 surgery would be expected to know of, would those</p> <p>19 risks be taught during gynecologic residency?</p> <p>20 A. Yes.</p> <p>21 MR. GRAND: Objection, foundation.</p> <p>22 Q. Did you undergo a gynecologic residency?</p> <p>23 A. I did.</p> <p>24 Q. Did you learn about all of those basic</p> <p>25 risks that you identified here today?</p>
<p style="text-align: right;">Page 147</p> <p>1 Q. I just have two quick questions about</p> <p>2 that one. The duration of followup is 129 months,</p> <p>3 as it states in the abstract, correct?</p> <p>4 A. Yes.</p> <p>5 Q. Did you find this study reliable?</p> <p>6 A. I did.</p> <p>7 Q. And on the third page they state that</p> <p>8 the methods, definitions and units in this study</p> <p>9 conform to the standards recommended by IUGA and</p> <p>10 the ICS Joint Report on Terminology For Female</p> <p>11 Pelvic Floor Dysfunction.</p> <p>12 Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. Is that a way of discussing whether or</p> <p>15 not this study was conducted within the norms of</p> <p>16 your field of expertise?</p> <p>17 A. It helps us compare apples to apples, so</p> <p>18 instead of that reporting to us, oh, these patients</p> <p>19 were all dry, they are using the definitions and</p> <p>20 the scales created by these societies to help us</p> <p>21 communicate our data.</p> <p>22 Q. You were asked some questions about the</p> <p>23 2015 IFU versus the IFU that was in effect at the</p> <p>24 time of Ms. Corbet's surgery, correct?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 149</p> <p>1 A. Yes.</p> <p>2 Q. Would those include wound complications,</p> <p>3 like the suture erosions and --</p> <p>4 A. Yes.</p> <p>5 Q. Okay. And not to date you, but did you</p> <p>6 undergo your residency before -- before TVT was</p> <p>7 available?</p> <p>8 A. Yes.</p> <p>9 Q. Has the risk of wound complications,</p> <p>10 dyspareunia, pain, voiding dysfunction, de novo</p> <p>11 detrusor overactivity, are those -- have those long</p> <p>12 been known in your field based on basic, elemental</p> <p>13 gynecologic training and knowledge?</p> <p>14 A. Yes.</p> <p>15 Q. You were asked questions about the</p> <p>16 hematoma that Ms. Corbet had, and I think some of</p> <p>17 the questions by Mr. Grand seemed to indicate or</p> <p>18 were prefaced with the terms "after the device was</p> <p>19 placed."</p> <p>20 At the time -- strike that.</p> <p>21 At the time the TVT retropubic device</p> <p>22 was placed in Ms. Corbet, she underwent a prolapse</p> <p>23 procedure as well?</p> <p>24 A. Yes.</p> <p>25 Q. Wouldn't you say that was a posterior</p>

Denise M. Elser, M.D.

Page 150	Page 152
<p>1 colporrhaphy?</p> <p>2 A. Yes.</p> <p>3 Q. A perineoplasty?</p> <p>4 A. Yes.</p> <p>5 Q. And are the risks -- is there a risk of</p> <p>6 hematoma with those procedures?</p> <p>7 A. Absolutely.</p> <p>8 Q. And have you looked at the medical</p> <p>9 literature regarding the risk of hematoma with</p> <p>10 those prolapse surgeries?</p> <p>11 A. I have, and there is several reports</p> <p>12 like an posterior colporrhaphy with risk up to 30</p> <p>13 percent (inaudible) --</p> <p>14 THE REPORTER: Would you please</p> <p>15 repeat.</p> <p>16 THE WITNESS: With posterior</p> <p>17 colporrhaphy, the risk is up to 30 percent in</p> <p>18 the literature of a hematoma.</p> <p>19 BY MR. SNELL:</p> <p>20 Q. And have you looked -- obviously a lot</p> <p>21 of TVT studies and the registries and things like</p> <p>22 that address the rates of hematomas, correct?</p> <p>23 A. Yes.</p> <p>24 Q. The Ford/Cochrane review we just looked</p> <p>25 at said pelvic hematoma occurred in .7 to 1.9</p>	<p>1 A. No.</p> <p>2 Q. Fair to say in your mind they are the</p> <p>3 same product?</p> <p>4 A. Yes.</p> <p>5 Q. They utilize the same Prolene</p> <p>6 polypropylene macroporous mesh?</p> <p>7 A. Yes.</p> <p>8 Q. Have you done any literature searches --</p> <p>9 Mr. Grand asked you about mechanical-cut and</p> <p>10 laser-cut mesh. Have you done any literature</p> <p>11 searches that identify in any clinical studies in</p> <p>12 women that there is a clinically significant</p> <p>13 difference depending upon how the edges of the TVT</p> <p>14 mesh were cut?</p> <p>15 A. No.</p> <p>16 Q. And for TVT, I'm talking about TVT</p> <p>17 retropubic device.</p> <p>18 A. Right. I could not find any clinical</p> <p>19 difference in the literature.</p> <p>20 Q. And therefore, let me ask you, the 4.5</p> <p>21 percent reoperation rate that you went back and</p> <p>22 analyzed in your practice and found, is that</p> <p>23 consistent or inconsistent with the data you have</p> <p>24 seen on TVT retropubic?</p> <p>25 MR. GRAND: Objection.</p>
Page 151	Page 153
<p>1 percent of women. My question to you is, have you</p> <p>2 formulated an opinion about the overall risk of</p> <p>3 pelvic hematoma after the TVT retropubic device,</p> <p>4 and if so, what is that percentage based on your</p> <p>5 synthesis of all of the materials you have read and</p> <p>6 brought here and are relying on?</p> <p>7 A. It seems to be less than 5 percent and</p> <p>8 certainly much lower risk of hematoma with the</p> <p>9 sling than with a prolapse repair.</p> <p>10 Q. Mr. Grand asked you about the</p> <p>11 supplemental report. I just want to make sure.</p> <p>12 I'm not sure maybe I heard things correctly or not.</p> <p>13 I think in response to Mr. Grand's</p> <p>14 questions you said you spent 25 to 30 hours</p> <p>15 drafting your supplemental report. Now, maybe I've</p> <p>16 got that right or wrong. I don't know. I just</p> <p>17 want clarification. How much time did you spend on</p> <p>18 your supplemental report?</p> <p>19 A. So, I spent reading this literature and</p> <p>20 the records and getting ready for the deposition</p> <p>21 about 25 to 30 hours, but preparing the</p> <p>22 supplemental report itself, five or six hours.</p> <p>23 Q. The TVT retropubic device and the TVT</p> <p>24 Exact device, do you view those as significantly</p> <p>25 different?</p>	<p>1 A. It is really consistent with the -- with</p> <p>2 the other data.</p> <p>3 Q. You were asked some questions about</p> <p>4 whether you were an expert or not, and with regard</p> <p>5 to material science you testified you didn't work</p> <p>6 in a lab.</p> <p>7 My question to you is this: Do you</p> <p>8 believe you have specialized or scientific</p> <p>9 knowledge on the use of materials in the pelvic</p> <p>10 floor -- in the treatment of pelvic floor</p> <p>11 disorders?</p> <p>12 A. Yes.</p> <p>13 Q. Have you reviewed the medical literature</p> <p>14 with regard to the use of various materials in the</p> <p>15 treatment of stress urinary incontinence?</p> <p>16 A. Yes, I have.</p> <p>17 Q. How long have you been knowledgeable</p> <p>18 about the different types of materials that a</p> <p>19 surgeon like yourself can potentially use to treat</p> <p>20 stress urinary incontinence?</p> <p>21 A. Well, it's been almost 20 years since I</p> <p>22 first saw Gortex used as a sling, so I have been</p> <p>23 looking at different mesh materials implanted in</p> <p>24 the pelvis for a long time.</p> <p>25 Q. Is it fair to say you have also</p>

39 (Pages 150 to 153)

Denise M. Elser, M.D.

<p style="text-align: right;">Page 154</p> <p>1 evaluated thousands of patients and done thousands 2 of surgeries using various materials? And I'm 3 talking about pelvic floor surgery. 4 A. Yes. 5 Q. Do you believe you are an expert in the 6 clinical application, the efficacy and safety of 7 materials used to treat stress urinary 8 incontinence? 9 A. Yes. 10 Q. You were asked a question about 11 epidemiology, and you testified that you didn't 12 think you were an expert in epidemiology. My 13 question to you is this: What did you mean by 14 that, first of all, when you answered that you 15 weren't an expert in epidemiology? 16 A. It's not my chosen career. I don't go 17 out looking for jobs in epidemiology, but certainly 18 as part of our literature it's something we 19 evaluate when we are looking at studies and how to 20 apply treatments or evaluations in women. 21 Q. And have you analyzed the medical 22 literature, including epidemiologic studies, with 23 regard to the TVT device and other stress urinary 24 incontinence procedures? 25 A. Yes.</p>	<p style="text-align: right;">Page 156</p> <p>1 Q. You were asked about clinical trial work 2 that you had done, and I believe you identified 3 different clinical trials that you were involved in 4 the design of? 5 A. Yes. 6 Q. Do you know how to interpret clinical 7 trial designs? 8 A. Yes. 9 Q. Do you -- is that -- strike that. 10 Is understanding the levels of evidence 11 and the different types of clinical trials one can 12 employ or review, is that a basic competency in 13 your field? I'm talking about to the treatment of 14 stress urinary incontinence. 15 A. Yes. 16 Q. So, do you feel you are an expert in 17 epidemiology in clinical trials as it applies to 18 studies evaluating female pelvic medicine and 19 reconstructive surgery? 20 A. Yes. 21 MR. SNELL: Let's stop and just change 22 the tape. 23 THE VIDEOGRAPHER: The time is 24 2:20 p.m. This is the end of Tape 2 and we 25 are going off the video record.</p>
<p style="text-align: right;">Page 155</p> <p>1 Q. Were you trained on how to evaluate 2 epidemiologic data in your medical school or 3 residency? 4 A. Yes. 5 Q. Is that actually part of the core 6 competencies of urogynecology in the field? 7 A. It is. I would like to clarify it, 8 because I was asked when was the last time I took a 9 statistic course, which was a long time ago during 10 my fellowship, but when we just took our boards for 11 our female pelvic medicine and reconstructive 12 surgery in 2013, there was a very substantial 13 amount of statistical questions, and our review 14 course was substantially based -- I mean, focused 15 on statistics and epidemiology. 16 Q. Do you know how to interpret 17 epidemiologic and statistical data? 18 A. Yes. 19 Q. And as a reviewer of articles for 20 various journals as well as your regular reading of 21 the medical literature, do you analyze the 22 statistics and the statistical significance and 23 things such as cure rates with regard to those 24 treatment modalities? 25 A. Yes.</p>	<p style="text-align: right;">Page 157</p> <p>1 (Recess taken, 2:20 - 2:29 p.m.) 2 (Elser Exhibit 14 was marked for 3 identification as of 11/5/15.) 4 THE VIDEOGRAPHER: The time is 5 2:29 p.m. This is the beginning of Tape 3, 6 and we are back on the video record. 7 BY MR. SNELL: 8 Q. Dr. Elser, we were earlier talking about 9 various studies that you are relying on that 10 support your opinion that Ms. Corbet is at a low 11 risk of future surgery or corrective surgery and 12 that there is a low rate of long-term pain. 13 Turn, if you would, to Page 3 of your 14 supplemental report. 15 A. Okay. 16 Q. And if you want to look at Exhibit 11 as 17 well, my question pertains to the Tommaselli paper 18 from this year regarding medium- and long-term 19 outcomes. This is the study we were discussing 20 where you testified more than 95 percent of the 21 retropubic data comes from the TVT retropubic 22 device. 23 A. Right. 24 Q. And in your report you say that 25 persistent or pain lasting beyond the immediate</p>

40 (Pages 154 to 157)

Denise M. Elser, M.D.

Page 158	Page 160
<p>1 postoperative period was present in only 13 women</p> <p>2 with retropubic midurethral sling out of 3,974,</p> <p>3 Table 3. Do you see that?</p> <p>4 A. Yep.</p> <p>5 Q. Is that consistent or are you relying</p> <p>6 upon that data for your opinion that the risk of</p> <p>7 long-term pain and reoperation is very low?</p> <p>8 A. Yes.</p> <p>9 Q. I just calculated that, and I will</p> <p>10 represent it's 0.3 percent for that rate, whether</p> <p>11 you attribute all 13 women to TVT or not.</p> <p>12 My question to you is, is that 0.3</p> <p>13 percent consistent with other data you have seen</p> <p>14 with that similar risk?</p> <p>15 A. Yes, it is, very low risk.</p> <p>16 Q. Were the American Urologic -- strike</p> <p>17 that.</p> <p>18 The American Urological Association</p> <p>19 stress incontinence, female stress incontinence</p> <p>20 guidelines, the update, I just want to mark for the</p> <p>21 record that that was marked as Elser 14 --</p> <p>22 A. Yes.</p> <p>23 Q. -- that you were referring to earlier,</p> <p>24 and I believe Mr. Grand has something that he is</p> <p>25 updating.</p>	<p>1 A. Right.</p> <p>2 Q. Do you recall that?</p> <p>3 A. I do recall that.</p> <p>4 MR. SNELL: The tables -- I will go</p> <p>5 ahead and mark this as Exhibit No. 15 just so</p> <p>6 you can reference it and we can save time.</p> <p>7 MR. GRAND: Do you have a copy of it?</p> <p>8 MR. SNELL: I will give it to you.</p> <p>9 (Elser Exhibit 15 was marked for</p> <p>10 identification as of 11/5/15.)</p> <p>11 BY MR. GRAND:</p> <p>12 Q. Doctor, do you have that paper handy</p> <p>13 by --</p> <p>14 A. I don't.</p> <p>15 MR. SNELL: We can go off the record.</p> <p>16 THE VIDEOGRAPHER: The time is</p> <p>17 2:36 p.m., and we are going off the video</p> <p>18 record.</p> <p>19 (Discussion was had off the</p> <p>20 record.)</p> <p>21 THE VIDEOGRAPHER: The time is</p> <p>22 2:38 p.m., and we are back on the video</p> <p>23 record.</p> <p>24 BY MR. SNELL:</p> <p>25 Q. Dr. Elser, we have marked the Karram and</p>
Page 159	Page 161
<p>1 MR. GRAND: Are you done?</p> <p>2 MR. SNELL: No, no. I just want to</p> <p>3 make sure the record is clear that why I am</p> <p>4 doing 14 as opposed --</p> <p>5 MR. GRAND: The Cochrane summary which</p> <p>6 I had previously marked as Elser 10, we are</p> <p>7 changing that to Elser 13 to correct my</p> <p>8 mistake in marking exhibits.</p> <p>9 MR. SNELL: And that's why I've now</p> <p>10 marked the AUA Guideline as Exhibit 14. So</p> <p>11 thank you, Mr. Grand.</p> <p>12 (The document marked at Page 110 as</p> <p>13 Exhibit 10 was re-marked as Exhibit</p> <p>14 13.)</p> <p>15 BY MR. SNELL:</p> <p>16 Q. You were asked a question about the risk</p> <p>17 of dyspareunia with the posterior prolapse surgery</p> <p>18 that Ms. Corbet underwent, and I believe you</p> <p>19 testified that it was much higher than the rate</p> <p>20 seen with the TVT retropubic; is that correct?</p> <p>21 A. Yes.</p> <p>22 Q. And I think you cite to probably in both</p> <p>23 of your reports, I thought it was a meta-analysis</p> <p>24 by Micky Karram and Christopher Maher, Surgery For</p> <p>25 Posterior Vaginal Wall Prolapse.</p>	<p>1 Maher paper on posterior repair, correct?</p> <p>2 A. Yes.</p> <p>3 Q. What exhibit is that?</p> <p>4 A. 15.</p> <p>5 Q. If you look at Tables 1 and 2, which</p> <p>6 pertain to normal posterior colporrhaphy and a</p> <p>7 site-specific repair, you wrote in your report that</p> <p>8 the overall rates of dyspareunia is 18 percent for</p> <p>9 either way. Do you recall that?</p> <p>10 A. Yes.</p> <p>11 Q. Is that a meta-analysis that you are</p> <p>12 relying on?</p> <p>13 A. Yes. The Table 1 refers to traditional</p> <p>14 posterior colporrhaphy. When they added up all the</p> <p>15 studies, the dyspareunia rate was 18 percent and</p> <p>16 the site-specific repair, the dyspareunia rate for</p> <p>17 all the studies average was also 18 percent.</p> <p>18 Q. You mentioned earlier the Kahn paper.</p> <p>19 That's another paper, the Kahn paper, you are</p> <p>20 relying on with regard to the dyspareunia rates for</p> <p>21 posterior repair?</p> <p>22 A. Yes. The Kahn paper is cited in this</p> <p>23 table.</p> <p>24 MR. SNELL: I would like to mark as --</p> <p>25 what exhibit are we on?</p>

41 (Pages 158 to 161)

Denise M. Elser, M.D.

Page 162	Page 164
<p>1 THE REPORTER: 16. 2 (Elser Exhibit 16 was marked for 3 identification as of 11/5/15.) 4 BY MR. SNELL: 5 Q. Exhibit 16 is the registry by Kuuva and 6 Nilsson. My question to you is very simple. Is 7 that the registry we earlier discussed that 8 specifically pertains to the TVT retropubic device? 9 A. Yes. 10 (Elser Exhibit 17 was marked for 11 identification as of 11/5/15.) 12 BY MR. SNELL: 13 Q. I would like to mark as Exhibit 17 14 another document, and before I do, so Mr. Grand 15 marked various DVDs, thumb drives and some 16 materials you brought here today in response to 17 their request that you produce your file? 18 A. Yes. 19 Q. And as I look to the left, there are 20 multiple binders that have not been marked but that 21 you bought those as well? 22 A. Yes. 23 Q. And are those materials that you are 24 relying on for your opinions in this case? 25 A. Yes.</p>	<p>1 professional practice that you present to other 2 doctors with regard to stress and urge 3 incontinence? 4 A. Yes. This was at a -- at an ACOG 5 course. 6 Q. Questions were asked of you about the 7 pathology report after -- 8 THE VIDEOGRAPHER: Excuse me, 9 counselor. Your microphone. 10 BY MR. SNELL: 11 Q. Some questions were asked about the 12 pathology report following the mesh excision in 13 Mrs. Corbet's case. Do you recall that? 14 A. Yes. 15 Q. And that there was chronic inflammation 16 reported in the pathology report? 17 A. Yes. 18 MR. SNELL: Can I have another exhibit 19 sticker. 20 BY MR. SNELL: 21 Q. So, Dr. Elser, when the original surgery 22 was done, that was a transvaginal surgery where the 23 placement of TVT and the posterior colporrhaphy was 24 accomplished? 25 A. Yes.</p>
Page 163	Page 165
<p>1 Q. You've also brought what's been marked 2 as Elser Exhibit 17. Can you just tell us what 3 that is? 4 A. The subpoena request asked me to bring 5 any lectures that I've given on topics of 6 incontinence, so this was a update I gave on 7 urogynecology in September of this year. 8 Q. Is that a lecture you would have given, 9 is that to patients or doctors or who? 10 A. It was to OB/GYNs. 11 Q. Okay. Does that pertain -- does that 12 lecture pertain to stress incontinence? 13 A. It talks about incontinence, both urge 14 and stress, but does specifically discuss stress 15 incontinence. 16 Q. And did you present to gynecologic 17 surgeons on the TVT retropubic device and other 18 midurethral slings? 19 A. Yes, I did discuss slings, midurethral 20 slings in this talk. 21 Q. Did you present and discuss with other 22 surgeons clinical study data regarding both stress 23 incontinence and urge incontinence treatments? 24 A. I did. 25 Q. And that's just part of your normal</p>	<p>1 Q. And that was in July 2011 -- 2 A. Yes. 3 Q. -- as you wrote in your reports? 4 A. It was also a cystocele repair, because 5 we keep saying a sling and posterior repair, but it 6 was a cystocele repair as well as the posterior 7 repair. 8 Q. And does the cystocele repair -- is that 9 a prolapse surgery? 10 A. Yes. 11 Q. Okay. Does it have all those same risks 12 you identified for posterior repair; namely, wound 13 complications, pain, effect on urination and 14 bladder function? 15 A. Yes. 16 Q. And did you see that at the time of the 17 original surgery some of Mrs. Corbet's vaginal 18 tissue was excised and sent to pathology as well? 19 A. Yes. 20 (Elser Exhibit 18 was marked for 21 identification as of 11/5/15.) 22 BY MR. SNELL: 23 Q. I would like to give you Exhibit 18. Do 24 you recognize that as the pathology report from the 25 initial date of surgery when Mrs. Corbet had her</p>

42 (Pages 162 to 165)

Denise M. Elser, M.D.

Page 166	Page 168
<p>1 prolapse surgeries and the placement of the 2 retropubic sling and the perineoplasty? 3 A. Yes. 4 Q. And does that pathology report document 5 that she had mild chronic inflammation in her 6 vaginal tissues before the TVT retropubic sling had 7 even been placed and grown in? 8 A. Yes. 9 Q. You opined that Mrs. Corbet's prognosis 10 is good and she is at a very low risk of surgery in 11 the future; is that correct? 12 A. Yes. 13 Q. And is that based upon all of the -- are 14 you relying on the TVT studies we have been 15 discussing today and that are cited in your reports 16 and are contained in the thumb drive and materials 17 produced? 18 A. Yes. 19 MR. SNELL: I will turn over the 20 witness. I will just note for the record 21 there are literally seven or eight binders 22 that we haven't marked, but you are free to, 23 if you would like. 24 MR. GRAND: I will say on the record 25 that I have reviewed those binders and that</p>	<p>1 about some of these larger review studies you have 2 cited in your report, they all rely on studies 3 whose primary endpoint was efficacy, correct? 4 A. They primarily do. I won't say that 5 they all do. 6 Q. Okay. The majority of the studies had 7 efficacy endpoints as the primary outcome, correct? 8 A. Yes. 9 Q. Can you point to a single TVT retropubic 10 study where its primary endpoint was a safety 11 endpoint? 12 A. Not right now. I would have to look 13 through them. 14 Q. And in fact, most of the studies that 15 have been included in these reviews that we have 16 been talking about today as noted by the Cochrane 17 report are short- to medium-term studies, correct? 18 MR. SNELL: Object to form, misstates. 19 A. Most of the studies are short- to 20 medium- term as defined by Cochrane, and most of 21 the studies use efficacy as the endpoint which is 22 easier to measure; and because we are seeing such a 23 low complication rate, the ability to do an RCT 24 with your primary endpoint being a complication 25 that's running at 2 percent would be very difficult</p>
Page 167	Page 169
<p>1 they contain literature that is already cited 2 in the reliance materials that I have, so I 3 didn't feel a need to mark them and burden our 4 court reporter with having to transport tons 5 of binders. 6 MR. SNELL: That's fine. 7 MR. GRAND: Just a couple of quick 8 question. 9 FURTHER EXAMINATION 10 BY MR. GRAND: 11 Q. The pathology report that Mr. Snell just 12 showed you, the difference between that one and the 13 pathology report that was done at the time of 14 revision was a foreign body response, correct, 15 reaction? 16 A. Yes. 17 Q. So, one may have -- while they both may 18 have inflamed tissue, one has inflamed tissue 19 because of a foreign body reaction, correct? 20 MR. SNELL: Objection, foundation, 21 form. 22 A. One has foreign body response associated 23 with a foreign body being there. 24 Q. Thank you. Now, we have talked about a 25 lot of studies today, and I want to -- when we talk</p>	<p>1 to carry out. 2 Q. Have you looked at the underlying 3 studies in the Cochrane review? 4 A. Many of them; not every single one. 5 Q. You are aware that they collected 6 different safety endpoints in those studies, 7 correct? 8 A. Meaning that it was not the same in each 9 study? 10 Q. Yes. 11 A. Yes. 12 Q. So therefore, it would be very hard to 13 combine those studies for any safety analysis, 14 correct? 15 MR. SNELL: Objection, form. 16 A. They combine the data, but it's not all 17 the exact same data points. 18 MR. GRAND: No further questions. 19 FURTHER EXAMINATION 20 BY MR. SNELL: 21 Q. Mr. Grand asked you just a couple of 22 questions there, and I want to follow up. 23 You reviewed a lot of studies about the 24 TVT retropubic device, correct? 25 A. Yes.</p>

43 (Pages 166 to 169)

Denise M. Elser, M.D.

Page 170	Page 172
<p>1 Q. Whether or not their primary endpoint</p> <p>2 was safety or complications, did those studies</p> <p>3 report on safety and complications?</p> <p>4 A. Yes.</p> <p>5 Q. Did they report rates of complications?</p> <p>6 A. Yes.</p> <p>7 Q. Did they discuss perioperative and</p> <p>8 operative data, how long it took to do the surgery,</p> <p>9 the discharge times, things of that nature?</p> <p>10 A. Many of them did.</p> <p>11 Q. Are those important data in your field</p> <p>12 as a urogynecologist?</p> <p>13 A. Yes.</p> <p>14 Q. Is that information you considered in</p> <p>15 forming your opinions about TVT retropubic?</p> <p>16 A. Yes.</p> <p>17 Q. And the question was asked about</p> <p>18 specifically a study regarding the primary endpoint</p> <p>19 of safety. Do the registries like the Kuuva</p> <p>20 Nilsson registry we discussed, is one of their</p> <p>21 primary functions to report safety in very large</p> <p>22 patient groups?</p> <p>23 A. Yes.</p> <p>24 Q. And do they do that, in fact?</p> <p>25 A. Yes.</p>	<p>1 that study and find out whether there are errors in</p> <p>2 their analysis or whether they properly accounted</p> <p>3 for certain factors which might affect their</p> <p>4 statistical analysis of the study?</p> <p>5 A. Up to a certain level.</p> <p>6 Q. Up to a certain level, but you wouldn't</p> <p>7 hold yourself out as an expert to perform those</p> <p>8 tasks, correct?</p> <p>9 MR. SNELL: Form.</p> <p>10 A. I would consult with the statistician.</p> <p>11 Q. You would consult with a statistician.</p> <p>12 With respect to safety endpoints, there</p> <p>13 is a difference in a study that has a primary</p> <p>14 endpoint of safety and a study that just collects</p> <p>15 data about safety as a secondary endpoint, correct,</p> <p>16 or even a post hoc analysis, correct?</p> <p>17 A. Right, because it may not be powered to</p> <p>18 measure differences in that secondary outcome.</p> <p>19 Q. Okay. So -- exactly. So, some of the</p> <p>20 studies that we have been talking about today may</p> <p>21 not have even been powered to capture safety</p> <p>22 endpoints, correct?</p> <p>23 MR. SNELL: Form.</p> <p>24 A. They might have been powered to tell a</p> <p>25 difference between two in between, safety between</p>
Page 171	Page 173
<p>1 Q. And are those data reliable specifically</p> <p>2 to the TVT retropubic device?</p> <p>3 A. They appear to be.</p> <p>4 MR. SNELL: No further questions.</p> <p>5 FURTHER EXAMINATION</p> <p>6 BY MR. GRAND:</p> <p>7 Q. The registry data, registry data can</p> <p>8 only collect followup safety endpoints if the</p> <p>9 patient returns to that physician participating in</p> <p>10 the registry, correct?</p> <p>11 A. Yes, and that's why the registries are</p> <p>12 so beautiful in Norway where as far as a captive</p> <p>13 audience and it's not so easy for a patient to go</p> <p>14 somewhere else.</p> <p>15 Q. With respect to -- there is a difference</p> <p>16 between being competent in an area and being an</p> <p>17 expert in an area, correct?</p> <p>18 A. I guess it depends on your definition.</p> <p>19 Q. Okay. Well, the NIH isn't running to</p> <p>20 you asking you to design clinical trials, asking</p> <p>21 you to design clinical trials for them, are they?</p> <p>22 A. No.</p> <p>23 Q. And while you feel competent to review a</p> <p>24 clinical study in a published article, would you</p> <p>25 also feel competent to do an in-depth analysis of</p>	<p>1 two procedures. It doesn't mean they are not</p> <p>2 effectively collecting safety data.</p> <p>3 Q. Right. And in fact, many of the studies</p> <p>4 involved a small number of patients and only were a</p> <p>5 year-long, if not less, correct?</p> <p>6 A. Many of them.</p> <p>7 Q. And those studies may not be adequately</p> <p>8 powered to find certain complications that may</p> <p>9 arise with mesh, correct?</p> <p>10 MR. SNELL: Form.</p> <p>11 A. It's possible.</p> <p>12 Q. In fact, some of the studies we were</p> <p>13 looking at were only three-month studies, correct?</p> <p>14 A. Some were.</p> <p>15 MR. SNELL: Foundation, I think, on</p> <p>16 three month.</p> <p>17 Q. In a three-month study would you expect</p> <p>18 the rate of -- strike that.</p> <p>19 MR. GRAND: I have no further</p> <p>20 questions.</p> <p>21 FURTHER EXAMINATION</p> <p>22 BY MR. SNELL:</p> <p>23 Q. Doctor, with regard to your ability to</p> <p>24 interpret and understand clinical trials, is it</p> <p>25 correct that you present to other surgeons on</p>

44 (Pages 170 to 173)

Denise M. Elser, M.D.

Page 174	Page 176
<p>1 clinical trial data and how to analyze those</p> <p>2 studies?</p> <p>3 A. How to interpret the data, yes.</p> <p>4 Q. Yes. I'm sorry. And in your role as</p> <p>5 being on the FDA advisory -- strike that.</p> <p>6 In your role in consulting with the FDA,</p> <p>7 are you expected to and do you analyze clinical</p> <p>8 trial data regarding gynecologic devices?</p> <p>9 A. Yes. Let me be clear. I'm not here as</p> <p>10 an FDA representative.</p> <p>11 Q. No, that's fine. I don't know the scope</p> <p>12 of it.</p> <p>13 And with regard to the primary analyses,</p> <p>14 in your report you were referencing several of the</p> <p>15 studies like Jonsson Funk that interrogated these</p> <p>16 captive audience databases. Do you recall that?</p> <p>17 A. Yes.</p> <p>18 Q. And do you recall that those studies,</p> <p>19 their primary goal, primary power, what they did is</p> <p>20 they integrated huge databases with thousands of</p> <p>21 patients, and they specifically looked for safety</p> <p>22 endpoints like what was the rate of sling revision,</p> <p>23 removal due to exposure, voiding dysfunction?</p> <p>24 A. Yes.</p> <p>25 Q. On Page 5 there is a study from Welk</p>	<p>1 M. Elser, and we are off the video record.</p> <p>2 (At 2:58 p.m. the deposition was</p> <p>3 concluded.)</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>
Page 175	Page 177
<p>1 2015, and you state that it has a 3.3 percent</p> <p>2 10-year cumulative reoperation rate?</p> <p>3 A. Yes.</p> <p>4 Q. Did you find that similar to the 9-year</p> <p>5 3.7 percent rate by Jonsson Funk?</p> <p>6 A. Very similar.</p> <p>7 Q. And just so we are clear, you and</p> <p>8 Mr. Grand were discussing how many patients were in</p> <p>9 various studies, but do you recall that that study</p> <p>10 by Welk was a Canadian database that analyzed over</p> <p>11 50,000 women who had received sling placements?</p> <p>12 A. Yes.</p> <p>13 Q. And so they evaluated safety endpoints,</p> <p>14 and that was what they primarily reported on,</p> <p>15 safety endpoints in over 50,000 women getting</p> <p>16 slings with a 10-year followup?</p> <p>17 A. Yes.</p> <p>18 Q. Are you aware of any data like that for</p> <p>19 the Burch or autologous slings?</p> <p>20 A. No.</p> <p>21 MR. SNELL: That's all I have.</p> <p>22 MR. GRAND: No further questions.</p> <p>23 THE VIDEOGRAPHER: The time is</p> <p>24 2:58 p.m. This is the end of Tape 3. It's</p> <p>25 also the end of the deposition of Dr. Denise</p>	<p>1 CERTIFICATE OF CERTIFIED SHORTHAND REPORTER</p> <p>2 I, PAULINE M. VARGO, a Certified</p> <p>3 Shorthand Reporter of the State of Illinois,</p> <p>4 C.S.R. No. 84-1573, do hereby certify:</p> <p>5 That previous to the commencement of the</p> <p>6 examination of the witness, the witness was duly</p> <p>7 sworn to testify the whole truth concerning the</p> <p>8 matters herein;</p> <p>9 That the foregoing deposition transcript</p> <p>10 was reported stenographically by me, was thereafter</p> <p>11 reduced to typewriting under my personal direction</p> <p>12 and constitutes a true record of the testimony</p> <p>13 given and the proceedings had;</p> <p>14 That I am not a relative, employee,</p> <p>15 attorney or counsel, nor a relative or employee of</p> <p>16 such attorney or counsel for any of the parties</p> <p>17 hereto, nor interested directly or indirectly in</p> <p>18 the outcome of this action.</p> <p>19 CERTIFIED TO THIS 10th DAY OF NOVEMBER,</p> <p>20 A.D., 2015.</p> <p>21</p> <p>22</p> <p>23 Pauline M. Vargo, RPR, CRR</p> <p>24 Illinois CSR No. 84-1573</p> <p>25</p>

45 (Pages 174 to 177)

Denise M. Elser, M.D.

Page 178

A	48:15 51:19	agreements	answered 35:7	57:9 171:24
abbreviate	52:20 53:6	29:20	106:2 118:23	articles 14:17
59:12	additionally	ahead 24:16	154:14	29:1,3 36:5,12
abbrevo 18:22	78:3	33:8 47:4	anybody 74:5	36:24 38:11,25
20:13 21:14	address 28:7	56:10 57:23	apareunia 81:8	39:18,22 40:18
64:2	64:9 102:23	64:7 65:18	apart 16:10	41:5,8,16,24
abdefattah 40:4	150:22	71:7 93:17	apologize 75:4	42:15,22,25
abdominal	addressed 95:22	101:24 160:5	appear 130:5,5	43:3,22 44:12
33:11 60:5,7	addressing	al 5:10,11 6:8,9	171:3	44:18 48:10,12
77:18	106:14	alive 124:23	appeared 69:13	51:1 52:13
ability 168:23	adequate 74:16	allowable	appears 51:20	55:8 56:1,13
173:23	84:13 87:18	105:22	55:12 67:16	56:14,21 57:3
able 43:6 108:19	148:2	allowed 71:20	apples 147:17	57:6,13 100:1
abnormally	adequately	alternative 97:9	147:17	155:19
133:22	73:10,16 86:13	american 34:7	application	aside 57:18
abreast 143:10	173:7	139:11 158:16	154:6	84:10 123:24
absolutely 29:24	adhesion 79:5	158:18	applied 68:23	asked 14:21,21
85:7 150:7	adjust 133:7	amid 128:3,7	applies 17:22	15:3 28:21
abstract 147:3	administration	amount 143:1	118:5 156:17	32:25 34:17
accepts 96:21	34:12	143:17 155:13	apply 68:21	35:7 99:9
access 58:8	advancing 127:1	ams 20:24 60:11	118:15,20	103:12 105:6
accommodate	advantage 21:2	64:5	154:20	106:2 118:22
7:15	21:7,24 22:3	analyses 146:19	appreciate 48:9	125:14 128:16
accompany	86:25	174:13	approach 21:18	137:17 145:25
98:13	adverse 76:9,16	analysis 5:19	22:25 60:5	146:22 147:22
accomplished	78:1,22 80:22	26:10,14 28:7	114:22,22	148:5 149:15
164:24	86:22 94:13	100:24 102:7	115:11,11,13	151:10 152:9
account 29:22	106:10	169:13 171:25	120:11,12	153:3 154:10
accounted 172:2	advisement	172:2,4,16	123:6,7 143:21	155:8 156:1
accurate 49:22	28:17	analyze 36:4,13	approximately	159:16 163:4
122:18,21	advisory 135:21	83:21 155:21	38:25	164:6,11
acog 164:4	174:5	174:1,7	april 64:23	169:21 170:17
action 1:5	affect 172:3	analyzed 40:24	area 77:18 83:25	asking 16:1
177:18	age 125:22	152:22 154:21	171:16,17	21:18 27:14
actual 38:19	127:1	175:10	arent 16:19	28:21 59:20
145:15	agents 58:20	analyzing 35:22	106:20	80:2,4 92:20
acute 77:9,17	59:10	35:22	arm 97:17,18,20	96:17 171:20
81:7	aging 107:16	anesthesia 78:20	97:25 98:9,12	171:20
added 38:25	126:19	78:21	arms 98:13	asserting 64:17
40:21 42:15	ago 10:25 24:18	angioli 136:21	arrive 23:15	assessed 64:20
76:25 77:7	36:8 95:22	anne 135:18	111:22	111:11
78:23 120:24	100:19 103:5	answer 7:17	arrived 27:15	assistant 133:19
161:14	134:17,19	17:11 26:16	article 5:10,11	associated 5:20
adding 141:13	155:9	29:23 85:8	5:17,19 36:14	79:20 80:4
addition 62:19	agree 117:4,13	96:5 112:11	40:6,10,13	167:22
additional 4:11	127:7,9	124:17	41:1 44:14,16	association 93:6

Denise M. Elser, M.D.

Page 179

139:11 158:18 assume 142:3 atrophy 98:22 98:25 99:5,6 107:18 attached 18:4 attachment 32:20 attempted 124:10 attempts 102:8 attend 135:16 attendant 85:19 attended 125:8 attention 76:8 89:13 131:16 attorney 177:15 177:16 attorneys 38:11 38:17 39:25 42:14 43:1 56:23 57:14 attribute 127:8 158:11 atypical 79:5 aua 5:14 139:20 159:10 audience 171:13 174:16 august 52:22,25 55:22,25 56:18 authority 136:13 authors 126:9 135:5 autologous 175:19 availability 19:13,14 available 11:14 19:15 39:21 40:14,22 47:10 58:11 61:3 96:11 123:1 131:25 141:18 142:21 149:7	average 20:16 161:17 averaged 123:17 aware 38:24 46:12 55:7 56:21 85:2,9 88:13 93:5 114:9 131:24 169:5 175:18 <hr/> B b 2:10 4:1 5:1 53:18 back 17:24 23:19 24:13 26:14,17 49:3 53:11 54:20 57:19 75:9 80:14 82:3 86:11 87:13 89:12 91:15 108:16 112:21 119:7 124:16 125:5 131:3 152:21 157:6 160:22 background 34:16 backup 28:15,19 balloon 30:3 ballpark 120:25 band 107:13 base 99:4 based 37:22 46:10 63:11 65:14 90:21 96:14 99:13,21 99:22 101:20 106:13 116:11 149:12 151:4 155:14 166:13 basic 148:15,24 149:12 156:12 basically 31:9 60:21 118:3 124:14	basing 68:1 90:20 92:21,22 99:3 101:19 basis 35:4 68:5 bathroom 65:12 beautiful 171:12 beginning 87:12 93:18 157:5 behalf 2:2,7 7:8 believe 8:7 14:23 18:9 20:15 21:12 22:13 23:1,23 25:18 27:12 50:24,24 57:8 64:8 69:16 71:2,3 73:25 74:3,12,16 99:8 124:19 125:21 140:3 145:25 148:1,5 153:8 154:5 156:2 158:24 159:18 believes 85:19 benefit 71:25 bergen 1:1 6:10 berl1157514 1:3 berl1458914mcl 1:2 best 25:24 better 59:8,18 69:8 79:11 83:12 106:3 136:14 beyond 24:3,13 44:17 50:22 116:22 157:25 big 76:12,13 bigger 75:21 120:6 billing 8:11 22:9 22:10 binders 51:2 162:20 166:21 166:25 167:5	biocompatibil... 127:20 bit 36:9 69:5 75:10 103:4 108:21 bladder 58:5 63:7 65:25 66:19,25 67:2 71:10,11,19 76:19 98:16 107:5,13,14 165:14 bleeding 74:5 77:2,23 79:22 81:9 82:5 blood 69:15 74:7 board 135:21 boardroom 1:15 boards 155:10 body 70:19,24 80:25 81:1,21 82:1,13,14,19 82:25 83:2,21 85:11 133:5 167:14,19,22 167:23 book 110:10 boston 21:1 64:4 bottom 40:3 60:18,19 69:6 96:7 138:2,7 bought 162:21 bound 55:12 bowel 76:19 107:6 box 13:10 break 7:14,18 17:6 44:5 47:22,25 55:4 108:8,20 111:25 134:13 bring 26:22 50:15 83:20 163:4 brochure 90:25 91:2	brook 1:16 6:7 brought 8:8,13 8:14 26:20 41:2 49:7,9,17 49:19 50:3 112:9 151:6 162:16 163:1 bulking 58:19 59:10 bullet 76:16 77:3 87:1 burch 58:18 59:17 136:7 140:5 175:19 burden 110:17 167:3 burned 53:25 burt 2:10,11 4:5 6:16 13:23 15:19 28:13 31:25 50:25 75:18 119:17 120:3 124:5 137:13 busy 15:6 butler 2:8 5:5 6:16 13:23 52:17,18 55:17 55:21 butlersnow 2:11 butrick 92:25 <hr/> C c 1:14 2:1 53:18 135:18 177:4 cadaver 134:11 134:14,15,18 calculated 158:9 calculation 26:23 calculations 25:9 caliber 146:15 call 76:8 81:24 117:8,9 called 7:2 28:10
---	--	--	---	---

Denise M. Elser, M.D.

Page 180

29:16 55:12 98:9 135:11 camera 75:10 canadian 175:10 canal 107:7 cant 25:5 30:2 64:19 118:4,14 capacity 71:10 71:19,21 captive 171:12 174:16 capture 172:21 care 11:11 27:6 80:16 90:21 133:15 career 36:3 56:7 154:16 carelessly 133:19 carry 20:3,7,10 81:21 92:23 169:1 case 1:8 4:9 8:16 8:19 9:8,13,14 9:14,17,22,23 9:24 12:16 14:19 16:10,25 17:21,21 24:7 39:17 42:3,4 47:9 49:15 52:3,6,15,22 56:8,16 90:10 90:17 96:6 162:24 164:13 cases 9:19 10:3 15:15 17:5 22:23 78:5 120:18,19 catchall 62:8 catheters 33:21 caught 26:2 72:17 causal 90:6 93:6 causally 91:12 cause 79:6 81:11 90:19 91:25	92:9,18 caused 73:1,3 93:2,2 126:25 causes 91:13 92:15 causing 92:14 caution 29:19 cdroms 49:10,11 52:16 54:24 cds 50:22 51:15 53:25 cell 70:19 center 1:15 2:9 certain 21:3 23:19 54:16 59:7 88:14 101:2 172:3,5 172:6 173:8 certainly 40:13 45:14 46:21 47:3 56:11 74:6 81:13 82:2 83:5 88:19 103:11 131:15 151:8 154:17 certificate 177:1 certified 1:13 177:1,2,19 certify 177:4 change 130:15 131:17 132:17 133:8 156:21 changed 22:9,11 94:19 changes 18:2 88:23 130:13 changing 159:7 characterize 136:16 checked 131:1 checks 34:16 chef 67:2 chicago 1:14 chief 66:18,24 chosen 154:16	christ 19:22 christopher 159:24 chronic 70:19 70:25 71:2,3,4 77:9,17 81:8 82:3 83:3,7,14 83:19 85:10 89:15 94:10 100:6 164:15 166:5 circle 57:19 cite 91:16,17 92:12 93:18 109:3 123:12 134:21 138:2 146:7 159:22 cited 41:14 48:7 48:10 93:8 123:2 136:12 140:2 161:22 166:15 167:1 168:2 cites 43:21 citing 118:20 civil 1:5 clarification 151:17 clarify 34:11 69:14 155:7 clark 31:5 classes 29:8,9 classification 128:7 classifications 128:3,7 clear 10:9 24:2,8 26:4 38:13 48:9,11,14 49:18 51:9 53:22 54:23 58:22 70:14 87:15 91:1 99:9 140:7 141:10 159:3 174:9 175:7	clearly 116:15 clients 18:16,18 22:19 23:6 clinical 31:19,21 33:5,6 35:1,2,3 35:9,10,22,23 36:1 109:12 113:7 114:5 122:9 125:8 129:14 130:1 132:8,17 135:22 143:21 145:3 152:11 152:18 154:6 156:1,3,6,11 156:17 163:22 171:20,21,24 173:24 174:1,7 clinically 82:2 82:18 152:12 close 37:5 closing 47:15,17 clot 69:15 club 36:4,10,16 cochrane 5:12 109:6,7 110:23 111:10 114:3 116:3 118:19 120:10 143:24 144:4 145:14 146:1,7 150:24 159:5 168:16 168:20 169:3 colace 90:1 collect 171:8 collected 169:5 collecting 173:2 collection 57:2 collects 74:8 172:14 colporrhaphy 91:20,24 92:6 93:3 150:1,12 150:17 161:6 161:14 164:23 colposuspension	115:8 136:8 com 1:25 2:5,11 combination 38:8,9 109:24 combine 122:8,9 169:13,16 combining 122:17 come 43:13 57:16 82:2 140:13 comes 140:25 157:21 comfortable 94:22 coming 57:24 commencement 177:5 comments 96:6 common 135:16 commonly 60:10 103:9 communicate 147:21 companies 135:14,22 company 135:17 comparable 22:7 comparative 106:20 compare 39:6 147:17 compared 100:3 128:4 compares 120:11 comparing 100:11 114:21 114:23 115:1 115:10 120:18 120:19 comparison 33:20 100:16 competencies 155:6
--	--	---	--	---

Denise M. Elser, M.D.

Page 181

competency 156:12	30:15	172:10,11	120:3 124:4,7	78:16 79:2,3,8
competent 171:16,23,25	conferences 135:16	consultant 9:8 10:22 11:16,20	160:7	79:21 80:16,16
compiled 56:22	confidentiality 29:20	15:16 16:24	corbet 1:1,1 4:9	82:9,15 83:3,8
complained 66:19	conflict 135:12	consultants 135:6	4:12,13 5:24	83:15,25 85:3
complaint 46:25	conform 147:9	consultation 12:5 34:11	6:8,15 7:8,9	88:20 89:3,10
66:24 70:1	confusing 7:20 25:19 97:21	125:8	12:16 16:10,19	89:11 91:3,6
complaints 47:6	connected 93:4	consultations 13:15	17:21 39:16	91:21,25 93:11
66:18 67:2,5	connection 8:12 56:8	consulting 12:6 15:12 22:10	46:14 51:20,22	93:14,25 94:3
70:4,9	consent 61:16 61:18,19,25	174:6	52:21 56:8	94:4,6 97:14
complete 110:7	62:3,5,7,11	contacted 145:11	64:9,10 67:17	97:15,18 98:16
completed 108:24	68:9,13,20,23	contained 55:5 166:16	67:22 68:8	98:19,23 99:11
completely 43:13 101:4	consenting 61:10,11	contain 167:1	70:8 84:16	99:12 100:17
complication 91:2 117:19	consents 61:7,12	contingence 33:23	85:20 86:5	101:9 102:25
168:23,24	consequences 126:23	continued 70:4 70:8	89:15 94:24	103:12 105:10
complications 5:20 28:3	conservative 58:1 59:1	contribute 90:7	96:8,11,14	105:20 106:15
111:15 126:4,5	consider 35:1,13 35:15,18 94:5	contributed 90:9,14,17	106:24 149:16	106:22 111:4
138:25 141:22	94:14 106:1,4	99:1	149:22 157:10	113:4,7,18
146:17 149:2,9	106:24	contributes 99:5	159:18 165:25	114:6 115:3,10
165:13 170:2,3	considered 50:5 170:14	control 33:14 58:4 114:5,5	corbets 72:25 75:8 87:17	115:11,15
170:5 173:8	consistency 146:19	controlled 33:21 113:7 116:20	97:12 99:10	116:12 118:16
compound 23:8	consistent 127:4 127:9 152:23	122:1,8,9	147:24 164:13	118:21 120:12
comprehensive 50:25	153:1 158:5,13	146:5	165:17 166:9	120:16,20,23
concept 102:11	constipation 58:4 89:14,15	copied 53:16	core 155:5	121:2,7,11,12
concerning 137:18 177:7	89:20,23,24	copies 50:11 53:25 75:18	12:22,23 15:6	121:14,16
conclude 125:24 126:10	90:5,13,22,25	copy 8:3,14 13:19 17:25	16:18 17:1,19	123:3,14,15,18
concluded 176:3	91:5,8,13,16	32:8 37:11,18	17:22 19:2,17	124:12 125:9
conclusion 101:25 102:1	92:13,17 93:2	37:19 41:1	20:18 21:13	125:20 126:6
126:14	93:7	43:8 46:18	22:15,16 23:14	126:12 127:5
conclusions 123:11	constitute 49:13	50:15 53:10	25:4 26:13	127:24 128:24
conditions 80:5 80:6	constitutes 177:12	54:25 61:21,25	28:5 34:19,23	129:3,6 130:23
conducted 46:9 46:13 147:15	consult 128:23	112:3 119:9,13	34:24 36:25	131:3,4,6
conducting		119:15,18	37:25 38:1,4,5	132:4 135:6
			40:15 43:2	139:9 141:1
			45:14,15 46:22	147:3,24
			47:1,10 49:7	150:22 159:7
			49:11 57:6,7	159:20 161:1
			57:10 61:3	166:11 167:14
			63:8,9,12,23	167:19 168:3,7
			64:2,5,6,24,25	168:17 169:7
			65:20 66:6,7,9	169:14,24
			66:14 67:15,18	171:10,17
			68:10,16,24	172:8,15,16,22
			69:3 70:1,5,9	173:5,9,13,25
			70:16,20 78:10	corrective 157:11
				correctly 111:16

Denise M. Elser, M.D.

Page 182

114:19 115:21 116:17 117:2 132:23 136:9 138:19 151:12 couldnt 17:11 counsel 6:12 14:22 57:25 108:25 177:15 177:16 counseled 96:21 counseling 133:9 counselor 87:4 164:9 counted 72:20 121:15 counter 58:11 county 1:1 6:10 couple 72:21 82:4 94:20 95:22 102:20 146:22 167:7 169:21 course 36:7 57:21 71:15 134:15,15,18 155:9,14 164:5 courses 35:25 36:2 134:11 court 1:1 6:9,19 53:9 54:23 167:4 courtesy 124:7 cover 23:22 53:17 54:1,1 covered 11:4 84:23 cream 107:23 108:3,4 create 74:5 created 147:20 criteria 71:20 criticism 72:3 crochrane 109:20 crr 2:16 177:23	csr 2:17 177:24 ct 1:8 cumulation 53:20 cumulative 175:2 cure 130:15 132:15 155:23 cured 114:16 115:14,16 curious 95:17 current 47:5 73:22 87:18 currently 11:20 11:24 12:9 18:22,25 20:2 27:23 29:7,8 29:12 34:1 57:21 58:14 60:8,13,23 107:23 cut 107:11,13 130:6,9,22,22 131:8,10,12,22 131:25 152:14 cv 18:1,2 19:18 19:25 28:25 29:3 31:22,23 32:6,17 148:13 cycle 93:1 cystoccele 66:12 165:4,6,8 D d 1:12 3:1,4 7:1 53:19 148:9 177:20 data 5:4 22:21 23:17 27:20 28:19 30:3 55:13 56:5 57:10 63:20 94:17,18,21,21 100:4 103:9 114:4,6 116:5 116:22 117:10	118:10,18 122:9 123:9 131:14,15 134:4 137:5,17 140:13,13,24 141:5,16,18,24 142:3,5,22 143:1,18,21 144:9 145:3,14 146:4,5,15,20 147:21 152:23 153:2 155:2,17 157:21 158:6 158:13 163:22 169:16,17 170:8,11 171:1 171:7,7 172:15 173:2 174:1,3 174:8 175:18 database 175:10 databases 22:19 174:16,20 date 6:4 8:24,25 10:24 11:6,13 18:5 19:9 46:11 53:3 149:5 165:25 dated 13:24 40:8 51:21 52:1,10 52:12,14,22 55:22 dates 23:16 25:8 day 43:17 128:2 177:19 daytime 65:23 de 125:17 127:3 149:10 death 68:10 69:2 decades 94:20 102:3 143:8 december 13:24 69:7,11 decision 21:4 96:15 defendants 1:8 2:7 6:17	deficiency 59:11 define 143:1 defined 168:20 definition 171:18 definitions 147:8,19 degree 116:15 demonstrate 93:6 demonstrated 109:8 denise 1:12 3:4 4:3,5,7,10 5:5 5:22 6:11 7:1 175:25 depending 152:13 depends 171:18 deponent 6:11 deposed 7:10 8:18 9:2 22:11 deposition 1:11 4:3 6:6 8:3,21 9:16 11:4,6,13 15:2 16:3 55:7 64:10,18,21 68:3,4 148:13 151:20 175:25 176:2 177:9 deps 1:25 describe 116:14 described 67:24 68:15,19 design 30:12 31:16 33:13,23 35:1,2,4,9,10 35:16 36:1 156:4 171:20 171:21 designed 31:10 31:21 33:1,5 129:2 designing 31:19 designs 156:7 desire 65:11	despite 71:8 details 27:4,19 deterioration 126:25 determine 27:15 27:21 72:2 108:20 detrusor 86:15 149:11 develop 107:11 developing 12:3 development 5:4 11:25 55:13 56:5,13 57:9 device 31:6,8 58:9 105:25 121:23 137:19 141:6,11,17,25 142:6,13,18,20 142:23,25 143:2,17,18 144:10,17,24 145:3,18 146:24 149:18 149:21 151:3 151:23,24 152:17 154:23 157:22 162:8 163:17 169:24 171:2 devices 12:1 35:16 130:14 141:14 143:11 174:8 devote 15:9,12 diagnose 66:8 diagnosed 67:9 67:11 70:14 diagnosis 66:17 67:13 didnt 16:4 24:13 41:10 45:13,14 67:13 85:3 88:3 93:10 95:3 117:22,25 126:14 127:14
--	---	--	--	--

Denise M. Elser, M.D.

Page 183

142:10,15 153:5 154:11 167:3 difference 76:24 100:23 101:9 107:3 129:14 129:17 130:2,3 132:8 152:13 152:19 167:12 171:15 172:13 172:25 differences 129:23 172:18 different 18:15 22:8 33:20 53:19 61:15,15 62:4 66:15 67:6 72:11 101:1,5,5,6 102:9 121:14 122:17 130:14 131:19,20,23 151:25 153:18 153:23 156:3 156:11 169:6 difficult 43:11 133:11 168:25 difficulties 126:18 direct 100:16 direction 177:11 directly 23:1 48:7 102:5 112:11 177:17 disagree 88:22 88:23 discharge 79:5 170:9 disclose 29:25 discomfort 79:6 81:12 discovery 1:15 discuss 36:12,23 58:15 119:5 142:15 145:7 163:14,19,21	170:7 discussed 20:6 44:10 61:1 63:7 139:8 142:8,11 144:3 162:7 170:20 discusses 43:22 discussing 52:3 80:23 137:16 140:21 145:19 147:14 157:19 166:15 175:8 discussion 48:25 112:18 160:19 disk 4:11,13,15 4:17,18,20,21 53:4 disks 54:13 disorders 153:11 dispute 67:24 dissection 78:6 78:11 distort 133:12 133:15,24 division 1:1,5 6:10 docket 1:2,3 doctor 50:3,19 72:3 87:24 88:3 140:18 143:6 148:8 160:12 173:23 doctors 63:2 78:10 82:22 83:6,12 87:21 89:2 145:4 163:9 164:2 document 13:11 55:12 115:5 145:15 159:12 162:14 166:4 documents 8:10 44:19 49:14 54:16 129:16 129:23	doesnt 7:19 27:6 36:17 39:9 42:10 43:25 71:25 92:13,13 113:13 173:1 doing 29:12 48:3 74:3 79:15 85:22 87:25 89:6 90:3 122:25 159:4 dont 8:23,25 9:1 9:15,18 10:24 11:5,11 12:18 13:4,21 16:5 19:9 20:7 21:12,15,15 22:12 23:16,23 24:5 25:7 26:17 27:3,7 27:12,18 28:20 29:7,20 32:1,5 32:16 40:12,24 41:3 43:16 47:16,19 50:6 50:12,12 51:4 51:5,12 53:21 56:17 57:8 58:1 59:13,21 59:24 60:23 61:23 63:15,25 71:6 72:9 73:3 73:5 80:7,9,16 81:25 83:1,10 83:19,19,22,24 84:2,11,18 85:7,13,15,17 85:18,21 86:24 88:21,22 89:7 90:4 93:8,24 95:10,13,15 96:4 104:22,24 105:9,10 107:24 110:6 112:9,12 114:8 114:11,23 125:16 128:23	130:2,15 132:1 135:8,10 138:5 139:19 146:2 151:16 154:16 160:14 174:11 doubting 11:8 downers 19:23 dr 6:11 7:6 10:21 13:24 15:22 46:5,13 49:6 53:11 64:23 65:2 66:5,8 67:8,10 67:14,22 84:14 84:15 85:2,15 85:19 86:4 88:11 89:22 92:25 96:24,25 97:7 98:9,22 108:19 137:13 157:8 160:25 164:21 175:25 drafted 39:16 drafting 151:15 dramatically 133:8 draw 89:13 drive 2:9 5:3 49:10 50:10,22 50:24 51:2,11 51:13 54:6,15 55:2 166:16 drives 21:3 162:15 dropped 22:2 66:19,24 67:2 drug 34:12 135:22 dry 147:19 due 126:10 138:24 174:23 duly 6:24 7:2 177:6 duration 147:2 dvds 49:10 53:19 162:15	dysfunction 77:11 81:7 92:11,14,15,19 136:6 139:22 147:11 149:10 174:23 dyspareunia 46:25 67:23 70:1 81:8 90:14,17,19 91:1,13 93:7 93:18,25 94:25 98:19 99:1,5 102:15,23 103:15 104:11 104:21,25 106:14 125:15 136:5,15,23 137:6,19 138:10,12,16 139:16 140:4 149:10 159:17 161:8,15,16,20 <hr/> E <hr/> e 1:1 2:1,1 3:1 4:1 5:1 6:8 108:14,14 earlier 52:3 63:8 134:23 157:8 158:23 161:18 162:7 earliest 144:23 early 5:4 52:25 55:13 56:5 57:9 easier 37:9 75:22 168:22 easy 171:13 edges 130:5 152:13 education 89:8 90:25 edward 19:23 edwards 4:15,22 51:25 52:15
--	---	--	---	---

Denise M. Elser, M.D.

Page 184

effect 147:23 165:13	157:2,8 158:21 159:6,7 160:9	erosions 123:13 149:3	exact 10:19,20 18:22 20:13	159:13,13 160:5,9 161:3
effective 116:23 117:18	160:25 162:2 162:10 163:2	errors 172:1	21:8,10,24	161:25 162:2,5
effectively 173:2	164:21 165:20	especially 79:19 125:22	22:2 63:18,21 64:2 131:22	162:10,13 163:2 164:18
effectiveness 115:19	176:1	esq 2:5,10	151:24 169:17	165:20,23
effects 94:13,23 106:10 126:24 129:10	emotional 102:1	estimate 18:12	exactly 85:21 172:19	exhibits 54:14 54:17 75:15 159:8
efficacy 117:13 117:18 118:1 154:6 168:3,7 168:21	employ 59:19 60:7 156:12	estimated 16:16	exam 47:6,13	existed 39:20
eight 166:21	employee 177:14,15	estimates 15:14	examination 3:3 7:4 46:13,19 137:11 167:9 169:19 171:5 173:21 177:6	expected 148:18 174:7
either 27:19 42:9 63:6 65:23 73:5,7 79:2 95:3 107:9 114:17 115:13 118:1 161:9	empty 65:25	estrogen 107:18 107:23 108:2	examined 7:3 66:5 67:14,17 93:21	expecting 43:16
elderly 59:16	emptying 63:7	et 5:10,11 6:8,9	example 15:22 24:10 98:14	experience 31:19 92:22 93:12,13,14 94:8 99:4,22 100:5 101:14 101:22 102:2 122:7 130:2 134:5
electronic 53:21	emr 22:21	eth 5:7,8	examples 92:23	experienced 64:11
elemental 149:12	encountered 126:18	ethicon 1:4,4,6 4:11,13,15,17 4:20,21 6:8,17 9:11 11:17 12:6,10,13 17:14 20:20 30:6,24 51:18 51:22,24 52:8 88:13 129:17 135:5 137:14 142:22	exams 46:10	experiencing 69:18
elevate 60:10	endpoints 117:23 118:1 168:7 169:6 171:8 172:12 172:22 174:22 175:13,15	ethicons 129:22	exception 20:14 80:21	expert 4:7,9 9:3 9:7,10,19 10:2 10:23 11:16 17:4,4 34:25 35:2,8,11,13 35:15,18 43:6 45:18 83:25 127:24 128:23 153:4 154:5,12 154:15 156:16 171:17 172:7
elevated 71:9	english 76:2	europe 135:16	excised 165:18	expertise 147:16
elicited 128:19	enlightening 79:19	evaluate 22:22 154:19 155:1	excision 164:12	experts 15:20 28:18 37:24 50:9
elliot 15:22	envelope 53:4	evaluated 121:22 126:3 154:1 175:13	excited 94:17	explants 129:5
elmhurst 19:24 19:25	epidemiologic 154:22 155:2 155:17	evaluating 35:23 126:19 143:21 156:18	excluded 125:2	exposed 79:6 81:11
elser 1:12 3:4 4:2,3,5,7,10 5:2,5,22 6:11 7:1,6,24 10:21 13:24,25 32:12 32:13 37:14,15 49:6 51:15 53:11,14 54:7 54:13 55:2,11 55:20 75:6,15 108:19 110:18 110:23 119:25 120:1 124:2 137:13 140:16	epidemiology 35:19,25 154:11,12,15 154:17 155:15 156:17	evaluations 154:20	excuse 71:16 87:3 99:2 118:25 164:8	exposure 63:6 70:15 79:15
	event 86:22	evidence 98:22 103:4 109:8,9 109:11,13 110:14 116:12 116:23,25 117:5,10,11 122:12 123:22 156:10	exercise 31:11 58:6	
	epithelium 107:7,17		exhibit 4:2,3,5,7 4:9,11,13,15 4:17,18,20,21 5:2,3,4,5,7,9 5:10,11,12,13 5:13,14,17,19 5:22,24 7:24 8:2,6 13:22,25 17:24 32:13 37:15 54:14,16 54:24 110:18 110:20 120:1 124:1,2 157:2 157:16 159:10	
	eric 1:1			
	eroded 107:5			
	erosion 23:3 79:16 106:25 107:1,4,11			

Denise M. Elser, M.D.

Page 185

80:21 84:23 97:13 99:20 101:16 107:1,2 107:6,15,20 130:16 132:14 174:23 extend 85:15 extremely 107:10 eyeballing 121:16	feel 7:14 37:10 59:3 65:11 94:21 119:12 156:16 167:3 171:23,25 feeling 53:23 69:15 101:20 102:1 fees 8:11 135:20 135:21 fellow 60:21 94:16 fellows 60:22 fellowship 155:10 felt 69:8 female 5:15 34:8 147:10 155:11 156:18 158:19 field 57:17 143:10,22 147:16 149:12 155:6 156:13 170:11 fifth 40:2 figure 131:3 file 41:2,2,6,8,9 41:11 49:7 53:20 55:5,6 61:22 162:17 files 53:21 56:15 filling 71:11 find 11:9 40:18 56:4 63:1 93:9 103:10 111:23 111:25 114:25 117:18 137:7 139:6 147:5 152:18 172:1 173:8 175:4 finding 21:22 47:7 65:7 findings 46:8 71:9 116:16 fine 42:11 67:7 90:3 95:8,16	167:6 174:11 finish 7:17 88:6 first 7:2 8:2 10:22 12:15,18 12:21 32:4,5 34:16,18,20 37:20 39:16 45:8 55:25 56:12 60:16 66:10 72:11,12 76:16 77:8 92:7 102:21 107:3 109:5 114:25 125:18 153:22 154:14 firstline 58:25 96:13 five 26:15 69:7 105:23 106:6,7 106:9 114:10 114:17 115:19 116:6,22 117:1 117:5,9,9 120:15 121:2,4 136:23 151:22 fiveyear 94:21 106:11 136:22 fix 92:7 fixed 59:14 fixes 92:6 fleischmann 46:5,13 flipping 119:7 floor 1:15 80:24 91:11 92:25 102:24 106:21 126:25 147:11 153:10,10 154:3 flow 148:16 flows 141:5 142:5 focus 21:17 focused 155:14 follow 124:10 140:17 169:22	followed 69:23 following 62:23 69:11 70:5 84:6 88:15 102:15,23 125:19 164:12 follows 7:3 followup 22:23 24:20 25:1 26:12 105:17 106:1,5 121:2 125:20 136:22 137:15 142:12 147:2 171:8 175:16 font 5:9 120:6 food 34:11 ford 110:3 144:4 150:24 foregoing 177:9 foreign 70:19,24 80:25 81:1,21 81:25 82:13,14 82:19,25 83:2 83:21 85:10,11 167:14,19,22 167:23 forgot 32:25 form 18:18 24:14,16 28:4 33:8 35:6 41:19 47:2,11 49:17 53:2 56:10 57:23 61:16,17,18,19 62:3,5,7,10,11 63:13,24 65:18 65:24 68:13,14 68:18,23 70:2 70:21 73:6 74:15 78:12,18 79:12 80:1,7,8 80:15 81:23 82:10,16 83:9 83:16 84:1 85:4,16 89:4	92:16 97:3,19 98:2 101:10,23 103:1 104:16 105:1,21 106:2 109:13,14 111:2,24 112:3 112:6,11 113:12 114:7 115:4 117:15 117:24 118:8 122:22 126:13 127:25 128:12 128:25 129:7 130:24 132:5 167:21 168:18 169:15 172:9 172:23 173:10 formation 79:5 forming 170:15 forms 61:8,25 115:2 formulated 151:2 fort 2:9 forth 119:8 forward 37:10 40:6 108:24 found 57:13 111:14 145:22 152:22 foundation 39:3 47:4 68:18 82:16 83:9,17 85:4 88:16 97:19 98:2 101:10 103:2 104:17 116:1 129:20 135:7 143:4 148:21 167:20 173:15 four 19:20 114:9 115:24 116:4 fourth 69:6 fouryear 124:20 frail 59:15 free 37:10 50:1
--	---	---	---	---

Denise M. Elser, M.D.

Page 186

119:12 166:22 freefloating 13:10 frequency 79:4 frequent 65:19 65:22 frequently 25:15 66:1 91:13 fresh 133:21 front 17:25 112:5 function 58:5 165:14 functions 170:21 funk 174:15 175:5 further 29:18 69:5 77:1 99:18 115:17 137:9 148:11 167:9 169:18 169:19 171:4,5 173:19,21 175:22 future 106:25 107:8,15 157:11 166:11	give 29:23 32:8 118:15 119:9 122:18 127:19 139:19 160:8 165:23 given 21:5 163:5 163:8 177:13 gives 79:10,13 79:17 106:7 122:20 giving 87:21 glass 75:3 go 8:6 24:13,16 26:14 29:18 33:8 39:4 44:3 44:4,17 47:4 48:19 54:7 56:10 57:23 59:4 61:13 62:8 65:18 69:5 71:7 77:3 80:14 84:19 91:10,14,15 96:4 98:15 101:4,23 103:17 116:8 154:16 160:4 160:15 171:13 goal 174:19 goes 83:22 131:3 going 7:12,13 10:11,19 17:2 25:11 28:14 37:13 38:14 39:2 43:10,17 44:9 45:20 47:21 48:23 49:16 51:3,5 51:10,14,16 53:6,9,13 54:10,23,25 60:15 66:13 74:1,25 75:6 75:12 76:4 78:19 82:13 87:9 88:8	95:18 97:22 102:5 106:12 108:10 110:13 110:22 115:25 117:5 118:11 119:11 120:7 128:14 131:5 131:20 132:14 132:15,15,16 139:18 145:15 148:17 156:25 160:17 golkow 1:24,25 2:14 6:3 good 7:6 10:11 19:22 59:14 91:22 96:8 106:7 108:7 120:5,25 122:7 166:10 gortex 153:22 grand 2:5 3:6,8 3:13 6:14,14 7:5,7 8:1 11:8 11:15 13:18,21 14:2 15:18,25 16:8 17:6,8 18:19,24 25:11 25:18,24 26:3 26:21 27:8,9 28:14,20,24 29:23 30:5,23 32:2,11,15,19 32:23 33:3 37:13,17 38:19 38:23 42:8,16 43:24 44:3,7 44:11,22 45:2 45:4 48:2,8,14 48:21 49:5,20 49:23 50:8,18 51:3,10,14 53:8,13,17,23 54:4,22 55:3 61:24 62:2 74:9,11,25	75:4,12,18,22 75:25 76:3 80:9,13,17,19 86:9,10 87:5 87:14 88:6,9 97:5,6,22,25 98:3 104:2 108:4,18 110:21 112:23 118:25 119:24 120:3,8,9 124:4,9 127:16 127:18 128:20 128:22 129:21 134:24 135:3,4 137:9,17,22 138:5 139:19 140:7,16,20 142:1,8 143:4 144:3,25 145:25 146:22 148:21 149:17 151:10 152:9 152:25 158:24 159:1,5,11 160:7,11 162:14 166:24 167:7,10 169:18,21 171:6 173:19 175:8,22 grands 151:13 granted 101:12 grants 135:13 135:21 136:2 granulation 82:3,5 great 32:10 greater 82:14 114:10 117:5 121:2 greek 75:24 76:1 groin 77:17 104:5 groundbreaki... 92:3	group 57:5 101:1 146:1,7 groups 170:22 grove 19:23 grown 166:7 guess 18:2 22:25 27:10 51:4 68:22 72:21 105:5 108:23 120:14 122:4 171:18 guideline 5:14 159:10 guidelines 139:12 144:1 158:20 guys 15:18 gyn 148:14 gynecare 1:6,6 4:11,13,15,17 4:20,21 5:7,9 51:18,23,25 52:8 60:12 135:5,23 136:2 gynecologic 148:19,22 149:13 163:16 174:8 gynecology 34:6 34:7 148:12 gyns 163:10
G gather 122:12 gathering 103:3 general 17:3,4,9 17:13,13,18,20 31:18 78:20 102:22 generally 26:11 62:13 63:1 78:19 generic 62:12 79:17 getting 45:22 72:22 86:11 89:12 146:16 151:20 175:15 giant 70:19				H h 4:1 5:1 66:22 half 127:19 hand 6:22 130:8 139:18 handy 160:12 happen 37:1 81:2 84:24 86:8 107:16 126:11 happened 28:6 happy 7:15 20:12 43:8 hard 50:11,15

Denise M. Elser, M.D.

Page 187

91:23 133:2,7 133:7,10 169:12 harm 88:19,21 harrell 66:5,8 67:8,10,14,22 84:14,15 85:2 85:15,19 86:4 88:11 96:24,25 97:7 harrells 64:23 65:2 havent 15:23 63:16 72:20 74:23 84:3 100:10 120:24 129:5 130:20 130:25 132:8 132:11 166:22 heal 128:4 health 1:5 hear 46:16 127:14 heard 46:15 132:1 151:12 held 6:6 help 43:20 53:4 58:3 147:20 helped 33:23 helps 147:17 hematoma 69:22,24 72:25 73:1,11,17 74:2,6,8,13 77:3,24 97:12 149:16 150:6,9 150:18,25 151:3,8 hematomas 150:22 hemorrhage 77:2,24 81:8 hereto 177:17 heterogeneity 102:12 hey 131:20	high 71:21 84:7 107:21 higher 101:13 123:16 159:19 highest 109:7,13 highlight 103:25 highlighted 104:4 119:14 119:18 highlights 86:24 highly 7:20 hoc 172:16 hold 17:2 31:24 34:25 35:8 48:2 83:24 112:2 118:22 172:7 holding 85:25 honest 50:7 hope 79:22 hospital 19:15 19:19,22,23,24 19:24 20:7 61:3,9 68:9,13 68:20,23,24 hospitals 19:20 20:2 61:6,8 62:4,4,7,11,14 hours 13:2,15 14:6 15:8,11 16:9,14,23 17:10 65:23 151:14,21,22 huge 174:20 hundred 24:11 24:11,12 hypermobility 59:13 hypertonicity 91:11 93:1 <hr/> I <hr/> ics 147:10 id 4:2 5:2 ideal 106:7 identification	7:25 14:1 32:14 37:16 54:18 75:16 110:19 120:2 124:3 157:3 160:10 162:3 162:11 165:21 identified 124:20 128:18 139:14 148:25 156:2 165:12 identify 6:12 39:18 43:6 50:19 152:11 ifu 73:10,16,20 73:22 74:18 84:17,17 86:13 88:2,20 89:7,9 147:23,23 ill 65:8 119:24 illinois 1:13,16 2:17 6:7 177:3 177:24 illustrates 126:18 im 6:2 7:7,12 10:1,9,11,13 11:8,9,11 12:2 13:22 14:8,16 16:1 17:2 19:18 20:1 21:17,18,22 23:1 25:18 26:1 27:1,6,14 27:15 28:21,22 29:25 33:9 35:3,10 37:13 38:13,14 39:2 39:11,13 43:11 43:11,16 45:22 48:2,8 49:16 50:19 51:3,5 51:10,14,16 53:13,22 54:4 54:6 57:4 60:15 61:9,10	63:18 65:7 66:2,15 71:24 73:12,13 74:25 75:6,12 76:4 80:4,13 86:11 86:22 92:17,20 92:22 93:12,16 94:7 95:3,12 95:14,17 96:17 97:5,22 103:22 103:22 104:3 105:5,7 110:13 110:22 112:13 112:24 115:25 118:9 119:11 119:19 120:5,7 121:19 126:17 127:14,17 128:1,16 130:1 138:19,19 139:18 145:15 151:12 152:16 154:2 156:13 174:4,9 ime 46:5 immediate 157:25 implant 24:24 65:16 67:11 75:8 78:4 87:25 89:16,18 89:20 94:25 implantation 71:13 84:7 87:17 94:13 132:22 133:1 134:3 implanted 27:22 27:25 70:25 84:14,15 85:11 85:20 86:5 97:4 103:16 133:2,22 134:9 153:23 implanting 61:14 84:22	97:1,8 133:16 148:6,8 implicated 120:23 important 170:11 importantly 47:6 imprensa 30:20 30:21 31:1 58:10 impressions 66:11 improvement 114:16 inaudible 150:13 incidence 100:11,12 101:3 102:4,23 103:6 107:19 125:23 incident 24:7 101:7 include 26:7 55:9 58:19 64:4 142:18 144:16 149:2 included 26:10 27:4,17 51:2 77:2 113:11 118:7 124:25 125:21 131:6 145:23 146:10 168:15 includes 26:23 including 10:4 13:13 76:18 77:2,17,23 90:23 111:11 135:23 145:3 154:22 incomplete 63:6 inconsistent 152:23 incontinence
--	--	--	---	--

Denise M. Elser, M.D.

Page 188

5:15 20:21,23 29:13 33:2,12 57:25 58:12 61:19 62:18,23 64:12,16 65:1 65:16 66:9,14 66:25 67:12 71:9,18 73:14 74:4 77:21 79:1 81:7,9 84:6 85:22 86:14 90:6 94:11 95:25 96:19,21 100:22 104:7 114:15 115:3 125:24 126:10 126:11,20,22 127:4 139:12 139:23 143:11 148:16,17 153:15,20 154:8,24 156:14 158:19 158:19 163:6 163:12,13,15 163:23,23 164:3 incorrect 71:15 increase 84:6 increased 125:18 126:10 126:11 increasing 106:10 125:23 indepth 171:25 indicate 83:6 99:10 113:23 149:17 indicated 58:20 59:10 68:8 69:7 indicates 113:9 indicating 67:8 indications 20:22	indicator 93:24 indirectly 177:17 inflamed 167:18 167:18 inflammation 70:19 82:3 164:15 166:5 information 37:22 43:4 47:10 56:4 83:6,13 84:2 87:22,24 88:20 89:2,10 106:8 113:3,6 115:18 122:13,19,20 122:24 145:23 170:14 informed 61:7 initial 14:9,10 165:25 initially 5:12 124:20 injections 58:19 59:7 injury 68:9 69:2 74:7 instability 86:15 instance 46:24 144:19 instances 58:17 instructed 133:14 intact 98:6 133:24 intake 64:23 65:2 integrated 174:20 integrates 78:4 intend 28:11 intention 24:6 intentionally 25:19 intercourse 77:13 79:7,25	81:13 82:6 interest 135:12 interested 46:8 177:17 internal 22:18 129:16,23 international 34:5 interpret 155:16 156:6 173:24 174:3 interrogated 174:15 interstim 71:13 71:25 72:9,10 intravaginal 31:9 intravesical 30:3 intrinsic 59:11 invasive 71:12 72:14 78:16 investigate 56:4 investigator 30:9 31:13 33:6 invited 124:16 invoice 4:5 8:14 13:1,3,23 14:3 22:14 invoices 15:15 15:21,24 16:3 involve 113:15 120:16 142:12 involved 11:24 30:17 60:20 71:17 113:17 113:24 118:12 121:10,13 146:23,24 156:3 173:4 involving 8:20 9:11,20 18:11 60:1 62:18 105:25 106:18 irrelevant 43:14 irritation 82:23	82:24 isd 59:12 isnt 42:17 44:9,9 132:3 171:19 issue 22:14 84:3 93:15 issued 17:4,13 issues 85:3 item 45:8 items 139:15 iuga 147:9 ive 32:19 41:13 82:1,18 93:16 109:19 131:13 132:1,6 151:15 159:9 163:5 J january 70:16 75:13 89:23 jeff 6:14 jeffrey 2:5 7:7 jersey 1:1 6:10 jgrand 2:5 jobs 154:17 john 1:7 johnson 1:6,7 6:17,18 11:21 11:22,25,25 12:6,7,9,10,12 12:13 135:13 135:13,23,23 137:14,14 joint 147:10 jonsson 174:15 175:5 journal 34:6,6,7 36:4,10,15 journals 34:2 57:16 155:20 judgments 50:11 july 12:18,22 32:11 37:20 52:1,10 60:16 64:12 99:11	165:1 june 52:14 justice 48:5 K k 33:15,16 kahn 91:17 161:18,19,22 karram 5:17 159:24 160:25 kathleen 7:8 64:9 kathryn 1:1 5:24 6:8,15 7:9 46:14 keep 22:18 45:20 53:5 56:25 65:8 66:13 95:5 165:5 keeping 146:14 kimberly 31:5 kind 15:12 knew 39:20 53:6 103:5 132:2 know 7:10,15,21 11:5 12:17 15:21 16:9 19:9 20:1 21:23 24:6 27:3 28:6,20 28:22 29:20 31:3 32:1 33:1 33:4 40:24 41:3,24 42:10 43:3,22,25 47:5 48:17 50:5,6,13 51:4 51:5 53:18,19 53:22 63:10 66:3 68:5,20 70:18 71:6 72:21 73:3,8 74:6 79:14 80:7,9 81:25 83:19,22 84:18
---	---	---	---	---

Denise M. Elser, M.D.

Page 189

84:19,22,23,24 84:24 85:3,15 85:17,18,21,24 88:10,17 89:7 89:24 94:15,22 96:3 100:1 101:3 102:14 103:21 104:20 104:24 105:6,9 105:10,14 107:18,24 110:6 112:9 113:20 114:3,8 114:23 123:20 125:2,4,14,16 129:17 130:3 130:13 131:18 135:8,15 136:25 148:10 148:18 151:16 155:16 156:6 174:11 knowing 28:2 102:1 knowledge 88:1 149:13 153:9 knowledgeable 153:17 known 85:10 86:4 149:12 knows 42:9 74:4 85:17,23 kulsenghanssen 136:1 kuuva 5:19 144:19 145:7 162:5 170:19	86:20 87:16,16 87:18,19 88:24 148:2,3 labeled 44:25 52:17 55:1 laboratory 132:21 134:2 laceration 74:1 lacerations 73:18 74:14 76:17 lack 59:18 lacks 39:3 lags 116:24 large 5:9 53:20 81:22,24 170:21 largely 76:21 146:8 larger 168:1 laser 130:6,9,22 131:10,12,22 lasercut 129:15 129:18,24 130:4,18 152:10 lasting 157:25 launch 88:15 law 1:1 6:10 lawn 19:22 le 1:14 lead 92:18 leading 64:12 67:21 116:15 leak 31:12 lean 75:9 learn 123:9 148:24 lecture 5:22 163:8,12 lectures 163:5 leery 114:4,8 146:3,4 left 40:4 97:13 97:16 98:5,5,6 98:9,10,15	162:19 leg 77:18 letter 5:5 45:6 55:19,20 level 60:21 109:7 172:5,6 levels 109:8 156:10 limitations 116:9 122:23 limited 12:5 59:7,8 116:19 line 3:14,15,16 3:17 60:19 72:11,12 link 93:5 linked 91:19 list 38:3,7,15,16 38:19 39:1,6 40:3,11 41:7 41:17,21,22 42:13,18,19,24 43:17 44:13,18 45:9,10,16,25 47:17,20 48:16 67:13 100:2 108:20,25 145:16 listed 55:6 77:8 80:21 listen 25:25 listening 95:12 lists 121:21 literally 166:21 literature 13:14 14:16 39:22 40:17 49:14 57:15 90:23 92:24 99:23,24 102:3 111:11 143:7 150:9,18 151:19 152:8 152:10,19 153:13 154:18 154:22 155:21 167:1	litigation 1:7 4:11,14,15,17 4:20,22 8:13 9:11 10:23 12:6 16:11 22:10 51:19,23 51:25 52:9 little 21:22 36:9 48:1 69:5 75:10 84:21 108:21 115:17 llp 2:3,8 long 12:24 30:14 48:1 83:23 103:4 111:2,24 145:10 149:11 153:17,24 155:9 170:8 longer 25:2 98:13 107:12 110:13 116:24 longest 123:22 141:19 142:11 longterm 52:13 93:25 94:5,8 94:14,15,16,22 100:4 102:16 105:15,20,23 106:1,4 107:19 113:25 117:5,9 121:23 122:24 126:19 137:4,5 141:16 143:1,2 146:15 157:12 157:18 158:7 look 13:1 17:12 17:24 24:2,3,6 25:6 26:16,18 26:19 27:5,11 31:22,23 34:10 39:9,14,22 40:2 47:12,21 64:18 65:4 66:10 68:3 76:15,16 85:5 89:19 90:4	95:2,10,15,17 95:21 98:7 101:4 102:18 106:8 108:20 110:11,24 112:2,10 114:24 118:2,9 118:17 120:7 120:14 121:17 122:14,16,24 125:5,5 131:19 136:14,15 140:15,23 146:18 157:16 161:5 162:19 168:12 looked 14:18 23:16 24:12,17 27:4 41:23 50:14 53:5 56:1 63:20 82:1 94:2 96:3 100:19 102:15 109:19 111:24 120:11 128:6,9 131:13 134:6 134:10 143:13 150:8,20,24 169:2 174:21 looking 32:3 39:11 62:16 64:20 65:8 66:2,22 94:12 95:5,11 105:7 112:13,24 118:4 134:6,7 136:22,24 137:4 153:23 154:17,19 173:13 looks 27:7 67:1 120:17,22,24 121:9,13 lose 58:3 65:12 loss 74:7 lost 126:2
--	---	--	---	--

Denise M. Elser, M.D.

Page 190

lot 22:21 32:21 48:15,15 75:20 79:20 82:8 106:14 131:16 150:20 167:25 169:23	140:24 141:5 142:17 144:9 168:6	materials 26:20 26:22 38:4 44:24 45:3,9 45:17 48:16 49:19 50:20 52:5 82:21 127:24 128:2 128:23 151:5 153:9,14,18,23 154:2,7 162:16 162:23 166:16 167:2	35:16 38:25 44:18 45:16,25 46:11,13 49:13 51:1,19 52:21 105:25 143:7 148:8 150:8 153:13 154:21 155:2,21	127:20,21 128:4,5,10,15 129:2,6,15,18 129:24 130:4,8 130:18,18 132:19,21,25 134:2,6,10,15 134:16 152:6 152:10,14 153:23 164:12 173:9
lots 59:23 88:4 122:25	managed 89:25 management 5:15 manufacturer 11:21 manufacturers 29:21 120:20 mark 8:2 13:20 13:21 32:11 37:3,13 43:8 50:1,12,12 51:3,8,10,12 51:15 53:13 55:9 74:25 75:6,12 110:14 110:22 119:11 119:24 124:1 134:25 139:19 158:20 160:5 161:24 162:13 167:3	matter 6:7 100:21 102:22 matters 177:8 maximum 71:21 md 4:3,5,7,10 5:5,22 mean 10:16 11:5 11:12 19:14 22:19 25:6,16 26:11,19 35:24 37:5 38:18 44:25 50:11 56:7 63:18 80:8 84:14 89:1 116:1 145:2 146:2 154:13 155:14 173:1 meaning 85:17 85:18 105:2 169:8 means 25:20 107:4 116:23 meant 54:3 measure 168:22 172:18 mechanical 129:14,18,24 130:4,8,22 131:8,12,25 mechanicalcut 130:18 152:9 medical 4:12 11:25 34:2	medicine 34:8 94:18 155:11 156:18 medium 117:1 157:18 168:20 mediumterm 117:7,8 121:22 168:17 meetings 36:11 member 34:23 mentioned 137:2 161:18 meridien 1:14 mesh 1:6 4:11 4:14,15,17,20 4:22 5:7,8 8:12 9:10,11 10:23 11:17,21 15:16 16:11,24 17:14 18:11,15,17 20:19 22:17 24:11,11 25:14 26:7 27:22,25 29:2,2 51:18 51:23,25 52:9 59:4 60:1,6,7,9 61:2,16 62:18 70:12,15,24 73:2,2 78:3,5 79:6,14,15 81:4,5,11,22 81:25 82:9,11 82:17 84:6,7 84:23 85:19 94:13 97:12,13 102:24 103:16 106:11 107:4,6 107:11 111:20	meshes 60:12 mess 47:16 metaanalyses 143:13,20,25 metaanalysis 102:9 104:5,10 109:21,25 119:6 123:8 139:9,12 141:4 159:23 161:11 methods 116:15 147:8 micky 159:24 microphone 164:9 microscopically 83:22 middle 7:16 133:17 midurethral 58:17 86:19 115:1,6 140:12 158:2 163:18 163:19 mild 98:22 99:6 166:5 millimeters 71:11 milo 2:13 6:2 mind 14:10 27:7 152:2 mine 67:1 68:19 miniarc 18:23 20:24 minimize 86:17
low 111:14 137:18 138:15 139:15 157:10 157:12 158:7 158:15 166:10 168:23				
lower 100:12 123:17 127:19 140:4 151:8				
lunch 44:5 47:25 108:8,12,22				
M				
m 1:12,12,12,17 2:16 3:4,4 4:3 4:5,7,10 5:5,22 6:5,11 7:1,1 48:23 49:3 54:10,12,20 87:8,10,12 108:7,10,13,16 112:17,21 148:9 156:24 157:1,5 160:17 160:22 175:24 176:1,2 177:2 177:23	marked 4:2 5:2 5:13 7:24 13:25 32:13 37:15 51:22,24 52:8 54:13,15 54:17 55:11,20 75:15 110:18 120:1 124:2 140:16 157:2 158:21 159:6 159:10,12 160:9,25 162:2 162:10,15,20 163:1 165:20 166:22 marking 13:23 54:6 159:8 master 1:3 material 35:12 35:13 43:4 44:25 48:6 82:17 153:5			
machines 134:7 macroporous 127:21 128:18 152:6 magnifying 75:3 maher 5:17 159:24 161:1 main 137:4 major 111:14 majority 40:20 40:21 60:6				

Denise M. Elser, M.D.

Page 191

minimum 105:17,22,24 107:21	muscles 100:9 <hr/> N <hr/>	37:22 38:25 40:18 43:4 46:1 52:10 58:10 66:19 67:2 74:17,18 74:18,23 76:12 76:13 77:4,7 79:10 80:22 84:12 87:16 103:14 131:17 133:21 148:3	127:3 149:10 number 8:10 23:17 27:16,16 41:24 58:16 65:11 111:12 116:20 121:3,4 121:21 123:12 127:9 142:11 145:21 173:4	66:5 150:20 occasional 67:5 occasionally 21:1 occur 76:19 77:19 86:15 133:4 occurred 150:25 occurrence 126:21 occurring 107:9 offer 59:24 offering 88:18 128:14 office 2:9 25:9 27:21 30:4 42:14 60:22,24 61:13 67:1 78:10,14 oh 36:8 57:11 63:18 65:9 67:5 75:11 94:7 95:23 109:24 131:10 131:14 138:6 147:18 okay 7:23 8:17 10:6,20,21 13:6 17:6 19:7 19:21 22:1,6 23:12,21 24:8 24:22 25:2,17 29:4 31:3 32:25 33:10 34:18,22 36:22 37:8 38:6,13 38:24 39:9,13 40:2 42:8 43:10,15 44:7 45:23 46:4,12 46:16,18 47:18 48:13,20 49:20 50:8 51:3 52:20 53:8 54:22 55:15 56:20,25 58:13
misrepresenta... 50:13	naperville 19:24	newer 74:21	numbered 44:22	
misstates 23:9 101:23 106:16 113:12 115:4 117:15 118:8 118:23 168:18	narrow 11:1	nextnext 121:20	numbers 101:13 104:13,23,25 111:22	
mistake 159:8	nationwide 5:19	nguyen 138:18 138:20,21,22	numerous 62:17 <hr/> O <hr/>	
modalities 155:24	natural 125:23 126:11	night 65:20	o 108:14,14,14	
moderate 116:12	nature 170:9	nih 171:19	oab 71:12,18 99:10	
moment 114:12	nearby 107:5	nils 2:10	oak 1:16 6:7 19:22	
monday 14:13 14:15,24	nearly 143:1,17	nilsson 5:19 162:6 170:20	oakbrook 1:15	
monofilament 127:22	necessarily 21:18 78:9 122:21	nilssons 136:24	ob 148:14 163:10	
month 46:12 57:17 72:22 173:16	necessary 78:1	nine 121:15	object 26:1 35:6 39:2 49:16 115:25 117:15 119:17 168:18	
months 37:2,3 69:8 70:7 93:21 94:3 105:17 121:4 125:19 142:12 147:2	need 7:14 15:25 27:11 29:22 37:18 48:17,17 49:24 55:9 58:2 68:3 75:2 75:18 81:5 82:4 84:25 85:5 87:5 95:10,15 102:18 110:12 138:24 167:3	nonresponsive 74:10	objecting 15:18 objection 17:3 23:5,8 24:16 47:11 68:14,17 83:16 88:7,16 103:1 104:16 106:16 118:22 126:16 129:19 131:7 142:1 143:4 144:25 148:21 152:25 167:20 169:15	
morning 7:6 46:17	needed 59:4	nonspecific 81:10	observed 111:12	
motion 128:21	needs 78:5	nonvoting 34:22	obstetrics 34:6,7	
move 74:9 133:7 133:10	nerves 76:18	normal 126:24 161:6 163:25	obturator 21:11 21:14 104:11 120:11 136:22	
movement 133:5	neuromodulat... 72:14	norms 147:15	obviously 48:6	
moving 37:10	neuromuscular 77:16	norway 171:12		
multiple 77:6 135:22 162:20	never 14:10 15:20 31:3 67:17 82:18 103:5 129:2	note 11:3 28:17 64:10 66:10,22 67:1 127:2 166:20		
multitasker 95:14	new 1:1 2:4,4 4:18 6:9 12:3	noted 70:18 168:16		
		notes 25:9 90:2		
		notice 4:3 8:3 50:4 132:13		
		noticed 15:2 129:13 132:7,9 132:16		
		november 1:17 3:2 6:4 177:19		
		novo 125:17		

Denise M. Elser, M.D.

Page 192

59:22 60:15,17 61:1,12 63:22 65:6,14 66:21 67:4 68:7,12 69:17 71:23 72:1 75:10 76:6,7,10 80:25 86:16,24 86:25 88:10,13 89:22 91:1,4,9 91:19 92:2,12 92:20 95:5,9 95:13,23 96:5 97:24 99:24 100:15 101:17 103:20 104:20 105:5 108:1,4 108:23 110:1,5 110:15 111:1,6 111:18 112:9 113:13,16,23 119:7,14,16,23 121:15 127:17 128:6 129:12 130:7 132:3,7 136:11 137:7 138:21 139:25 140:2 149:5 157:15 163:11 165:11 168:6 171:19 172:19 old 148:2 older 103:11 once 70:24 108:23 133:2,6 133:12 135:13 ones 24:19 34:4 40:21 41:13 80:22 116:5 oneyear 94:21 ongoing 71:1 82:23 83:3,7 83:13 99:19 100:3 101:18 107:20 137:6 online 111:24	open 34:10 107:6 opened 22:3 53:4 opening 107:7 operate 19:20 operating 60:24 74:5 102:2 operation 114:17 operative 98:8 170:8 opined 166:9 opinion 46:22 47:1,8 65:15 69:10 72:25 73:5 80:20 84:11 85:25 86:3 89:14 90:5,9,13,16 94:24 95:8 96:7,12,18,25 98:25 132:20 134:1 140:3 141:4 148:2 151:2 157:10 158:6 opinions 8:12 39:19 41:18 42:2 46:7,10 47:23 52:6 85:14 127:19 128:14,18 138:15 162:24 170:15 opposed 21:4 33:6 43:13 73:2,2 82:23 97:9 114:4 118:6 146:4 159:4 option 59:3,14 72:7 96:8,13 options 58:1,9 58:14 59:19 96:10	order 51:8 146:9 organ 12:1 30:18 59:25 60:2,9,13 107:5 organs 76:18 original 8:15 10:17 11:4 12:17 39:7,17 40:10,14 46:3 76:22 79:2,8 79:11 87:18 89:12 133:16 141:6 144:23 164:21 165:17 originals 53:11 outcome 100:23 123:10 168:7 172:18 177:18 outcomes 114:10 131:19 131:23 157:19 overactivity 149:11 overall 138:12 151:2 161:8 overbroad 26:1 overlapped 133:17 overthecounter 31:8 overweight 58:3 oxford 109:8 <hr/> P <hr/> p 2:1,1 66:22 108:7,10,13,16 112:17,21 156:24 157:1,5 160:17,22 175:24 176:2 package 130:4 133:20 134:8 page 3:5,6,7,8,9 3:14,15,16,17 4:6 5:6,13 8:7	33:9,11,17,17 33:24 34:10 37:6,8 39:10 44:20 45:21 60:18 62:16 64:7,9 66:16 67:20,21 69:6 71:7 73:9,12 73:13 76:5 86:13,21 89:13 91:10,14,17 93:18 96:6 99:8 110:20 111:6 112:24 114:1,13,25 118:4 119:4,5 119:19,21 120:15 121:17 121:20,20 126:17 127:2 127:12,15,16 127:20 129:12 135:11 136:4 137:20 138:7 140:19,20,22 144:8,12 147:7 157:13 159:12 174:25 pages 4:4,8 5:12 5:23 44:17 67:6 110:9 142:17 paid 15:22 pain 77:9,13,17 79:6,24 81:8 81:11 84:24 92:10,10,18 94:10 96:2 99:19 100:2,4 100:6,11,13,20 100:23 101:15 101:19 102:4 104:5 132:14 136:5 137:6,18 138:10,12,15 139:1,16,21	140:4 149:10 157:12,25 158:7 165:13 panel 34:12,19 paper 13:10 38:18 112:7 138:3 140:16 157:17 160:12 161:1,18,19,19 161:22 papers 47:16 paragraph 99:17 111:9 138:2 paralegal 55:21 part 33:23 34:17 49:9 78:6 90:11,18 135:10 154:18 155:5 163:25 partially 84:25 participate 125:5 participated 125:9 participating 171:9 particular 21:19 105:16 118:15 parties 177:16 partner 72:10 79:7 81:12 pathology 5:24 70:11,13,18 82:1 164:7,12 164:16 165:18 165:24 166:4 167:11,13 patient 21:5,20 28:1 58:24,24 61:10,11,13 66:19 67:3 69:8 71:11,20 82:12,19 90:24 96:16 101:6,12 101:16 170:22
---	---	---	---	--

Denise M. Elser, M.D.

Page 193

171:9,13 patients 9:15 18:19 22:20 23:7 24:13,18 25:6 26:10 27:16,22 28:5 57:22,24 58:7 58:15,21 59:8 59:8,11 63:1,2 71:18 72:10 77:14 79:7 81:12 82:2 83:20 84:8,24 90:21 93:14 94:8 100:6,19 101:1,14 102:2 103:15,16 120:23 121:1 121:21 122:2,5 130:17,21 131:6,14 132:17 133:9 141:11 147:18 154:1 163:9 173:4 174:21 175:8 pauline 1:12 2:16 6:20 177:2,23 pauls 93:19 100:18 pay 131:16 pdf 53:20 54:1 pelvic 1:6 4:11 4:14,15,17,20 4:21 8:12 12:1 30:18 34:8 51:18,23,25 52:9 58:5 59:25 60:2,9 60:13 77:18 80:24 84:19 85:24 91:11 92:18,25 100:9 102:24 106:21 126:25 147:11	150:25 151:3 153:9,10 154:3 155:11 156:18 pelvis 128:4 153:24 pennsylvania 2:9 people 94:2 134:8 percent 23:3,11 23:15 24:23 26:5 27:2,13 27:16 63:7,10 63:22 84:7 100:5 101:3,7 101:9,9 104:6 104:13 114:15 115:13,14,16 123:13 125:18 125:19 127:3 131:2 132:20 136:19,23 138:11,13 139:2 141:17 142:4 150:13 150:17 151:1,7 152:21 157:20 158:10,13 161:8,15,17 168:25 175:1,5 percentage 151:4 percentages 118:15 perform 18:11 22:18 58:18 59:21 62:17,25 72:9,18 172:7 performed 62:22 72:15 perineoplasty 150:3 166:2 period 23:19,21 24:3,4,6,23 26:12 88:15 101:2 106:11	124:21 126:6 158:1 perioperative 170:7 periurethral 58:19 permanent 68:9 69:2 78:4 80:6 81:1,15,17 82:6 87:25 persistent 157:25 person 128:1 personal 177:11 personally 72:9 pertain 52:2 144:16 161:6 163:11,12 pertaining 52:15 pertains 157:17 162:8 pertinent 44:10 pessary 58:10 pfizer 136:2 ph 1:24 pharma 31:3 pharmaceutical 31:7 phone 13:15 125:9 photographs 132:19 phrase 82:20 physical 58:7 72:13 physician 96:16 171:9 physicians 36:13,23 89:8 piece 81:22,24 pieces 130:8 pile 32:1 131:14 131:15 place 70:24 73:21,23 75:7 84:13 87:16	89:7 97:18 126:2 133:23 placed 86:19 134:7 149:19 149:22 166:7 placement 164:23 166:1 placements 175:11 plaintiffs 1:2 2:2 7:8 37:24 43:5 plastic 133:6,12 133:16,24 please 6:12,23 37:10 75:19 119:1 150:14 point 10:11 16:20 27:5 28:23 55:9 68:22 76:16 125:20 140:17 140:24 168:9 pointing 136:12 142:9 points 77:3 87:1 169:17 polypropylene 152:6 polyps 82:5 pop 4:18 52:11 population 101:6,12 126:20 pore 128:10,15 portion 97:17 98:5,6,10 posed 145:13 position 86:19 107:22 possible 173:11 post 89:18 90:22 172:16 posterior 5:17 90:22 91:3 92:5,6 93:3 99:18 100:3,13	100:20 101:17 102:16 149:25 150:12,16 159:17,25 161:1,6,14,21 164:23 165:5,6 165:12 postmarketing 30:19 postop 103:7 105:7 133:8 postoperative 158:1 postoperatively 70:8 93:22 94:3 potential 69:1 93:25 94:12 117:19 potentially 123:19 153:19 power 174:19 powered 172:17 172:21,24 173:8 practice 15:6,9 18:9 23:18 28:12 36:11,18 36:20,23 57:20 94:18 101:21 122:7 128:21 130:12 132:4 152:22 164:1 practices 63:5 practicing 56:11 pre 103:7 105:6 preexisted 99:11 prefaced 149:18 preferable 105:23 preference 58:6 preferred 22:5 prematurely 133:18 preop 103:6 preparation
--	--	--	---	---

Denise M. Elser, M.D.

Page 194

14:4 38:15 prepare 12:25 38:6,16 prepared 14:3 15:14 38:17,21 42:6,13 48:17 preparing 14:7 39:15 50:20 151:21 presence 99:20 100:21 present 2:2,7 58:24 116:19 158:1 163:16 163:21 164:1 173:25 presentation 5:22 96:14 presented 98:19 145:2,6 presently 15:5 pressure 31:10 69:15 presumably 115:14 123:2 pretty 50:6,25 62:11 81:10 86:6 previous 177:5 previously 28:1 40:19 126:24 159:6 primarily 168:4 175:14 primary 168:3,7 168:10,24 170:1,18,21 172:13 174:13 174:19,19 print 54:5 printed 39:21 40:16,19 42:13 prior 11:13 16:3 16:20,23 24:15 39:20 65:16 67:8,10 69:25	89:16 92:14 94:25 private 36:19 probable 7:21 probably 15:22 16:16 25:21 45:21 47:24 93:9 108:7 117:25 123:22 159:22 problem 50:2 90:12 96:22 problems 77:16 procedure 5:21 59:17 62:9 68:24 69:3 71:12 73:4 78:16 94:11 96:22 124:12 126:23 149:23 procedures 18:10 20:16 22:18 24:11,12 60:1 61:5 82:4 86:15 101:2 106:22 111:13 115:2 116:24 145:21 150:6 154:24 173:1 proceed 6:21 93:17 proceedings 177:13 produce 16:2 162:17 produced 15:21 16:3 28:19 116:21 166:17 producing 15:19 product 8:19,20 10:12 20:4,24 21:4,20 22:24 29:16 30:6,24 31:5,7 41:25 56:5,6 60:11 63:23 84:20,21	89:3,10 118:6 118:16,21 123:14,17 131:17 133:21 152:3 production 3:12 25:12 28:15 44:24 45:3 products 9:12 9:21 10:14 11:17,18 12:3 17:14 18:15 19:4,5,8,12,15 20:7,11,19,20 26:6,7 31:4 60:8,9 64:2,5 82:22 101:6 113:11,16 118:6 120:20 131:17 140:9 professional 144:1 164:1 prognosis 166:9 program 33:24 programs 88:18 prolapse 5:18 12:1 25:15 30:18 60:1,2,9 60:13 61:20 62:18,23 73:1 73:4 74:4 81:2 85:23 96:20 100:7 101:14 102:5 126:21 149:22 150:10 151:9 159:17 159:25 165:9 166:1 prolene 78:3,5 152:5 proliferate 4:18 9:13 9:14 17:15 41:25 44:9 52:11 97:1,4 97:21 98:14 pronouncing	138:19 proper 100:25 properly 172:2 provide 83:5,12 provided 38:10 38:12 39:23,25 41:13 46:11 52:18 55:17 56:17 57:14 82:21 115:18 publications 127:5 published 29:1 33:25 116:22 171:24 pubovaginal 104:12 115:8 136:7 pubovesical 59:21 pull 14:17 36:12 44:1 68:4 102:8 pulled 23:17 38:12 39:21 56:16 106:17 113:3,6 124:15 131:13 133:19 punctures 73:17 74:14 76:17 puncturing 74:1 purposes 10:10 94:12 110:12 110:13 put 17:2 27:18 30:4 31:10 38:22 39:5 51:5 53:3 84:10 90:24 122:13 133:20 putting 28:22 87:25 pyramid 109:9 pyramids 109:12	Q quality 116:12 question 7:17,22 10:8 57:12 65:15 66:2 80:18 86:9 88:5 96:4 99:15 105:6 122:15,16 144:7 145:13 145:25 146:6 148:5 151:1 153:7 154:10 154:13 157:17 158:12 159:16 162:6 167:8 170:17 questioning 48:8 questionnaire 64:23 65:2,9 65:10 95:22 99:14,16 105:11,14 126:7,8 questionnaires 103:8 121:10 125:11 questions 7:7 27:14 47:20 57:20 60:16 65:10 72:24 96:1 109:3 110:6 124:17 137:10,15 146:22 147:1 147:22 149:15 149:17 151:14 153:3 155:13 164:6,11 169:18,22 171:4 173:20 175:22 quick 144:7 147:1 167:7 quite 103:4
---	--	--	--	---

Denise M. Elser, M.D.

Page 195

R	167:15,19	recess 54:12	92:7	113:22 114:2
r 1:1,14 2:1	reactions 76:17	87:10 108:12	recurrence	118:10,12
108:14 177:4	77:6 78:1,22	157:1	77:21 81:9	144:13,16,23
raise 6:22	79:21 80:22	recognize	126:20,21	145:17 146:8
randomized	read 11:5 36:12	144:22 165:24	reduced 177:11	146:13 150:21
33:14,21 71:12	41:13 44:12	recognized	refer 10:11 37:9	170:19 171:11
109:12 113:7	51:16 53:17	143:21	72:10 110:12	registry 114:4
114:5,5 116:20	56:15,18 57:16	recollection 13:5	reference 11:12	124:1,14,16,18
122:1,8,9	75:23,24 76:1	16:6	142:11 144:12	144:20 145:7
146:5	85:6 93:16	recommend	144:15 160:6	146:4 162:5,7
range 75:10	111:16 114:19	18:16 57:21	referenced	170:20 171:7,7
106:6 145:21	115:21 116:17	58:15	36:10 116:1	171:10
ranged 111:13	117:2 129:25	recommendati...	145:7	regular 35:4
rare 103:10	132:23 135:9	58:16,25	referencing	155:20
rate 23:2,3,10	136:9 145:16	recommended	174:14	regularly 143:6
23:12 26:5	151:5	147:9	referred 26:5	relate 63:12,23
27:13 28:11	reading 14:16	recommending	63:2 137:3	64:1
63:6 109:12	39:20 56:13	18:17 21:21	referring 10:13	related 8:11,15
117:19 132:14	66:17 93:15	reconstructive	10:14 44:21	57:17 91:2,12
132:14,15,16	102:3 143:7	34:8 155:11	69:16,21 73:20	92:10 102:5
136:15 138:9	151:19 155:20	156:19	108:2 111:3,19	106:10
140:3 152:21	ready 151:20	record 6:2,5,13	111:20 114:21	relating 8:19
157:12 158:10	really 25:22	11:3,12 13:14	119:21 130:1	29:2,13 30:18
159:19 161:15	42:17 71:6	13:22 17:3	158:23	41:25 57:9
161:16 168:23	79:14 92:3,7	28:17,23 37:12	refers 26:6	91:5 102:15
173:18 174:22	94:17,19,20	38:22 48:19,24	161:13	129:23
175:2,5	101:19 123:23	49:1,4,18 54:7	reflected 53:17	relative 42:2
rates 22:9,10	130:1 142:15	54:11,21,22	reframe 7:22	82:8 177:14,15
102:3 106:10	153:1	87:9,13 97:23	refresh 13:5	relatively 22:7,8
111:14 118:18	reason 21:19	108:11,17	regard 33:2	relevant 39:18
118:20 127:4	23:13 88:3	112:15,17,19	139:21 143:11	39:23 46:7,21
130:15,16	recall 12:15,24	112:22 119:12	146:13 153:4	47:1,23 52:6
137:6,18	37:25 83:1	142:9 156:25	153:14 154:23	reliable 116:21
139:21 141:22	90:4 114:11	157:6 158:21	155:23 161:20	139:6,7 146:13
146:8,16	144:4 160:2,3	159:3 160:15	164:2 173:23	147:5 171:1
150:22 155:23	161:9 164:13	160:18,20,23	174:13	reliance 38:6,16
161:8,20 170:5	174:16,18	166:20,24	regarding 71:17	39:6 40:11
rect 33:22 168:23	175:9	176:1 177:12	96:2 127:20	41:7,17 42:18
rects 111:11	receive 88:4	records 4:12	138:15,23	47:17,20 48:16
122:23 123:1	received 15:23	14:18 17:12	150:9 157:18	108:20,25
146:15	35:21 88:11	45:17,25 46:1	163:22 170:18	167:2
reach 126:14	130:18,21	46:11 49:14	174:8	relied 38:4 41:5
react 82:17	135:13,20	51:1,19 52:21	regardless	50:20 109:16
reaction 70:20	136:2 175:11	67:7,10 89:19	123:14 127:8	relook 113:21
70:24 71:1	receiving 103:16	151:20	registries 111:12	114:2
76:9 85:11	106:15	rectocele 66:12	113:4,8,14,15	rely 41:10 45:14

Denise M. Elser, M.D.

Page 196

61:7 84:18	100:20 101:18	136:5,18 137:3	requests 3:12	retropublic
93:10 103:15	102:6,16 115:8	137:21 145:23	require 76:20	10:15,18 17:22
109:17 143:24	151:9 161:1,7	146:7 147:10	required 78:7	20:3 63:14,17
168:2	161:16,21	151:11,15,18	105:17	63:23 86:5
relying 48:12	165:4,5,6,7,8	151:22 157:14	rereview 56:16	97:8 104:11,15
93:12 137:18	165:12	157:24 161:7	research 29:12	104:18 106:19
138:14 139:4	repairs 62:19	164:7,12,16	29:15 30:17	111:19,21,23
139:15 151:6	repeat 150:15	165:24 166:4	129:9	112:1 113:1,10
157:9 158:5	report 4:7,9	167:11,13	reserved 37:21	113:11,15,17
161:12,20	5:12,24 8:15	168:2,17 170:3	59:15	114:22 115:11
162:24 166:14	12:17,20,21,25	170:5,21	residency	118:5,13,21,24
remained 97:18	13:15 14:4,7,9	174:14	148:11,14,19	119:2 120:12
remarked 5:13	14:10,12,15,20	reported 2:15	148:22 149:6	120:16 121:25
110:19 159:13	14:22 15:3	64:22 103:5	155:3	123:13,14,21
remember 8:23	16:17,20 17:9	105:3 111:13	resident 60:20	124:11 130:22
8:25 9:15,23	17:14,20 18:5	118:24 119:2	residents 60:23	131:11,21,24
10:24 12:18	22:14 23:2	145:21 146:9	resolve 77:14	132:12 134:19
16:5 23:16,23	24:10 26:6,17	164:16 175:14	resolved 69:11	137:19 140:8
24:5 25:7	26:18,25 27:3	177:10	respect 8:10	140:10,25,25
26:17 56:17	27:7,11,12,19	reporter 1:13	22:17 35:22	141:5,6,7,8,9
85:8,13 135:10	32:4,4,5,8,12	6:19,22 13:16	58:13 59:25	141:11,13,23
remembered	37:10,11,14,20	53:9,12 54:23	87:15 89:14	141:25 142:3,5
126:5	37:22 38:3	119:1 150:14	123:11 171:15	142:5,20,22,25
removal 174:23	39:7,8,11,12	162:1 167:4	172:12	143:2,17,18
removed 70:15	39:15,16,17	177:1,3	response 37:24	144:9,10,17,24
78:6,13 81:5	40:15,23 41:15	reporting 127:3	43:5 65:14	145:3,14
84:25 97:17	42:5,9,18,20	141:21 147:18	80:25 81:2,22	146:24 149:21
98:5,10 133:13	42:23 43:14,21	reports 14:18	82:1,13,14,19	151:3,23
remuneration	46:1,3,5 48:11	17:5,18 39:5	82:25 83:3,21	152:17,24
135:21	50:21 52:25	43:6 45:18	121:8 151:13	157:21,21
render 47:8	53:7 60:16,16	48:7 50:21	162:16 167:14	158:2 159:20
renewed 14:18	62:16 64:8	89:23 103:7	167:22	162:8 163:17
reoperation	67:20 70:13	113:8 150:11	restrictions	166:2,6 168:9
23:10,12,20	71:8 86:11,12	159:23 165:3	133:9	169:24 170:15
26:5 27:13	89:12 90:24	166:15	result 99:19	171:2
28:11 138:9,24	91:16 93:11,19	represent	101:18	retrospective
138:24 139:1	93:21 95:18	137:14 158:10	results 30:2	33:15,16
152:21 158:7	98:8 106:9	representative	105:16 112:1	returns 171:9
175:2	108:5 109:4	174:10	116:11,21	review 13:14
reoperations	110:7,11,13,17	reprinted 118:3	122:17 123:23	41:21 45:13
28:8	110:22,25	request 25:11	126:19 131:16	55:22 70:11
repair 73:1,4	111:3,3,7,24	28:14 43:10	resume 34:9	104:10 106:13
76:20 81:21	117:16,22,25	46:18 53:16,24	retained 9:7	109:6,20,21
90:23 91:3	118:3 119:5,19	56:22,24 61:24	10:22 12:16	110:1,3 111:10
92:5 99:18	119:22 123:12	162:17 163:4	retention 79:4	114:3,24 115:6
100:3,7,8,13	125:21 127:13	requested 20:10	132:16	116:3,9 117:14

Denise M. Elser, M.D.

Page 197

117:14,17 120:10 125:11 139:9 141:4 144:4 145:14 146:10 150:24 155:13 156:12 168:1 169:3 171:23 reviewed 42:25 43:5 45:9,11 45:25 46:1,2,4 49:15 50:5,20 67:9 74:17,20 101:21 102:8 116:5 117:21 129:16,22 132:19 153:13 166:25 169:23 reviewer 34:1 155:19 reviews 109:7 143:14,20,24 143:25 168:15 revised 38:2 40:3 41:22 75:13 108:24 revision 23:2 62:22,25 63:3 63:6 70:12 77:25 97:22 98:18 167:14 174:22 revisions 72:16 72:18,19 rid 82:4 right 6:22 11:2 17:11 20:25 26:4 37:21 39:4 47:8,15 51:14 64:19 65:7 68:22 69:20,23 73:14 76:2,12,14,23 78:14,17 81:14 84:4 89:5 91:7 92:17 93:15	95:19 97:11,15 97:18,25 98:6 98:16 103:13 104:3 105:7,9 105:12,19 107:24 112:5 115:12,16,16 117:20 118:14 119:10 121:19 123:4 124:19 127:6 128:20 131:18 132:6 137:10 139:16 145:13 151:16 152:18 157:23 160:1 168:12 172:17 173:3 risk 67:23 73:10 73:17,25 74:2 74:12,13 80:23 81:16,18,21 86:13,17 100:2 100:4 106:25 107:8,15 136:5 136:17 138:15 139:16 149:9 150:5,9,12,17 151:2,8 157:11 158:6,14,15 159:16 166:10 risks 79:20 80:4 80:21 85:18,22 85:23,24 86:3 86:7 148:16,19 148:25 150:5 165:11 road 1:16 robust 117:11 role 174:4,6 room 32:22 60:25 roughly 30:16 rounds 60:21 rpr 2:16 177:23 rules 7:13 run 8:7	rune 135:12 running 103:23 168:25 171:19 runs 100:4 104:6 142:16 <hr/> S <hr/> s 1:14 2:1,5 4:1 5:1 56:12 108:14,14,14 177:4 sacrocolpopexy 33:12 safe 116:24 safety 117:14,16 117:22,22 154:6 168:10 169:6,13 170:2 170:3,19,21 171:8 172:12 172:14,15,21 172:25 173:2 174:21 175:13 175:15 samaritan 19:23 sat 34:18,20 131:13 satisfied 55:5 satisfy 57:1 save 160:6 savich 2:13 6:2 saw 69:25 153:22 saying 11:12 20:21 24:9,22 25:3,14,22 42:19 71:24 92:17 94:7 100:12 165:5 says 52:12 66:18 67:2 76:17 80:3 86:17 90:3 114:14 115:18 116:8 135:12 140:12 145:16	scales 147:20 scandinavian 144:23 scenario 132:21 134:2 schimpf 104:6,9 139:8 schimpfs 136:18 school 155:2 science 35:12,13 153:5 scientific 21:1 64:4 153:8 scope 174:11 scratch 129:10 search 13:14 39:22 40:17 searches 57:15 152:8,11 seat 65:13 second 8:17 39:11 48:20 54:8 111:9 114:13 126:2 secondary 172:15,18 secondtothelast 60:19 section 73:14 76:9 78:23 86:23 91:16 93:17 98:15 109:6 113:1 116:8 135:11 secur 9:21 see 8:8 13:1 32:6 40:4,6,10,12 44:18 45:5,18 55:23 64:14 66:24 69:6 76:11 77:1,8 77:11,13,16,21 78:22,24 86:20 88:21 97:23 101:15 105:24 108:6 115:17	118:3 121:25 124:6 125:6 127:22 130:2 130:15 135:14 135:15,18,23 136:1 138:5 140:21 142:10 147:12 158:3 165:16 seeger 2:3 6:14 seegerweiss 2:5 seeing 28:1 72:23 131:18 131:23 168:22 seek 39:17 seeking 96:20 seen 8:4 20:4 46:4 67:7 70:13 74:23 82:21 84:5 90:2 109:18 128:13 143:16 152:24 158:13 159:20 sees 89:22 select 57:5 selfreported 105:13 sense 7:20 24:21 sensory 71:24 sent 42:25 165:18 sentence 67:21 69:6 73:13 111:19 132:18 separate 51:13 133:18 separated 53:18 133:18 separately 92:9 september 163:7 series 33:15,16 serve 9:7 11:20 served 9:3,6,10 9:19 11:16 session 108:22
---	--	---	---	---

Denise M. Elser, M.D.

Page 198

set 47:15 57:18 123:24	similarly 132:21 134:3	61:2,2,16 72:16 83:20	81:23 82:10,16 83:9,16 84:1	softener 90:3
seven 49:10,11 51:15 54:24 166:21	simple 101:16 162:6	84:22 103:16 104:12,19	85:4,16 88:5,8 88:16 89:4	sole 89:9
sexual 92:10,14 92:15,18 136:6 139:21	single 168:9 169:4	111:20 115:7 117:11 118:24	92:16 97:3,19 97:24 98:2	solid 130:6
sgs 139:8	sit 9:16 17:12 34:1	119:2 121:14 141:7,8 163:18	101:10,23 103:1 104:16	somebody 22:2 28:1 84:22
sheath 133:17 133:24	sitespecific 161:7,16	163:19,20 175:16,19	105:1,21 106:2 106:16 109:14	somewhat 114:4
sheaths 133:6	six 93:21 94:2,16 106:3 151:22	small 55:12 71:19 136:6,17	112:14 113:12 114:7 115:4,25	soon 106:13
sheet 54:1	sixmonth 94:18	173:4	117:15,24 118:8,22 120:4	sorry 7:9 10:7,9 12:2 18:19
shelf 22:2,4	size 128:10	smith 89:22 98:9 98:22	122:22 124:6 126:13,16	26:2 27:1 34:10,20 63:18
shes 80:14	sizes 128:15	smooth 130:5	127:14,25 128:12,17,25	66:15 73:12,13 84:15 86:12,22
short 110:11 112:3,6,11 116:25 117:6,8 168:17,19	skews 123:22	smoother 130:6	129:7,19 130:24 131:7	97:5 103:22 118:9 119:7,19
shorter 110:14 112:7	skipping 64:7	snell 2:10,11 3:5 3:7,9 4:5 6:16	132:5 134:22 134:25 135:7	126:1 127:14 138:5 174:4
shorthand 1:13 177:1,3	slides 145:6	6:16 11:3,11 13:7,20,23	137:12,13,24 138:1,8 140:10	sort 8:7 58:23 62:8 68:12
shortterm 102:17 105:15 113:24	sling 18:17 21:1 21:14,21 25:16	15:20 16:2,6 17:2 18:18	140:14 143:5 150:19 156:21	96:13 101:19
show 40:18 50:10 114:14 128:10	25:17 26:6 27:22,25 52:13	23:5,8 24:14 24:16 25:25	157:7 159:2,9 159:15 160:4,8	sound 123:5
showed 167:12	58:16,17 59:4 63:5 65:16	26:18,25 27:5 28:4,16,22	160:15,24 161:24 162:4	sounds 11:2
showing 49:19 84:5	72:19 73:2,4 81:4,24 82:9	29:18 30:22 32:16 33:8	162:12 164:10 164:18,20	source 87:24 89:9
shows 92:8	82:11,14 84:7 84:15,25 85:12	35:6 38:18,21 39:2 41:19	165:22 166:19 167:6,11,20	sources 136:11 137:2
side 97:13 98:10	86:8 87:25 97:17,20 98:5	42:6,11 43:19 44:1,4,8,20,23	168:18 169:15 169:20 171:4	space 103:23
signed 68:8	98:10,15 99:19 99:20 100:4,8	47:2,4,11,24 48:6,13,19	172:9,23 173:10,15,22	spare 110:16
significance 146:12 155:22	100:11,21,22 101:5,16,19	49:16,21 50:1 50:9 51:7,12	175:21 snip 78:10	speaker 12:9 135:20
significant 78:6 78:11 114:16 133:12 152:12	102:6,24 106:15 107:20	53:2,15 54:2 56:10 57:23	snow 2:8 5:5 6:17 13:24	speaks 141:24
significantly 90:8,10 151:24	113:11,11 115:2,9 132:17	61:17 62:10 63:13,24 65:18	52:17,18 55:17 55:21	special 35:21,24 specialized 153:8
sigurd 136:1	136:7 140:5,12 151:9 153:22	70:2,21 73:6 74:15 75:19	societies 144:1 147:20	specific 10:11,12 21:6 42:20,22 64:19 79:18 84:21 85:8 110:1
similar 28:18 118:18 146:16 158:14 175:4,6	158:2 165:5 166:2,6 174:22 175:11	78:12,18 79:12 80:1,7,11,15		specifically 14:20 31:10 33:2 38:15 41:14 58:6 59:12 64:9 88:2 106:19 111:25 113:14
	slings 18:21 23:18 26:8,9 29:2 59:21			

Denise M. Elser, M.D.

Page 199

124:16 138:12	36:7 155:15,22	76:25	100:16,18,25	suggest 82:22
142:2 162:8	status 90:22	studied 84:3	101:4,5,7,8	suggesting 54:4
163:14 170:18	stay 143:10	129:5 141:20	104:8,9 105:4	69:17 71:14
171:1 174:21	stenographica...	studies 4:18	114:6 115:1	96:24 97:7
specifics 27:12	177:10	33:1,19 35:23	118:19 120:15	sui 12:1 18:10
84:20	sticker 51:5	52:11 71:17	121:3,4 123:3	18:16 30:18
speeches 15:25	164:19	84:5 93:5,10	124:10,14,17	57:22 67:5
spell 30:21	stool 90:3	100:11,24	124:18 125:12	suite 2:9
spend 43:17	stop 8:17 19:3,7	101:20 102:8,9	125:17 126:17	summary 5:12
151:17	19:11 131:19	102:14,16,17	134:21 135:9	110:22 111:2
spent 8:11 14:6	156:21	102:19,22	136:21,25	112:4,6 114:12
16:11,24 17:10	straight 80:12	103:11,14	137:1 138:10	114:14 159:5
151:14,19	street 2:3	104:14,18,20	138:14,18,23	superior 1:1 6:9
sphincteric	stress 5:15 20:21	105:7,15 106:8	139:3 142:10	supplement 15:3
59:11	20:23 29:13	106:12,14,17	142:12 146:23	37:21 95:18
spring 1:16	33:2 57:24	106:18,20,21	147:5,8,15	supplemental
staff 135:18	58:12 61:18	107:19 109:3	157:19 163:22	4:9 14:4,7,12
standards 147:9	64:11 66:13,25	117:21 118:17	168:10 169:9	14:15,22 16:17
start 21:25 39:9	71:9 96:19	120:15 122:1,5	170:18 171:24	16:20 18:5
58:1,5 133:20	114:15 115:3	122:8,10,11,18	172:1,4,13,14	22:14 32:4
137:16	126:20 128:11	122:25 123:20	173:17 174:25	37:14 38:3
started 12:19	139:12,22	127:10 128:9	175:9	39:8,12 48:16
14:19 108:21	143:11 153:15	135:22 136:12	studying 29:16	52:25 108:5
starts 45:6	153:20 154:7	136:15,20	128:2	109:4 111:6
state 60:19	154:23 156:14	139:6 140:25	stuff 32:18 44:2	119:4 127:12
67:21 73:9	158:19,19	141:21 142:16	44:9 49:17	136:4 137:23
92:13 95:1	163:12,14,14	142:18 150:21	50:4,15	151:11,15,18
111:9 113:13	163:22 164:2	152:11 154:19	submit 14:22	151:22 157:14
129:12 136:5	stresses 133:4	154:22 156:18	submitted 12:21	support 134:4
147:7 175:1	stretch 133:3,15	157:9 161:15	17:21 38:20	141:4 157:10
177:3	133:25 134:13	161:17 166:14	41:22	supports 28:15
stated 148:13	stretched 132:19	167:25 168:1,2	subpoena 163:4	92:24 99:24
statement 99:25	132:22 133:1	168:6,14,17,19	subsequent 28:3	supposed 29:25
134:1	133:21 134:3	168:21 169:3,6	104:8	sure 19:18 21:25
statements	stretching 134:7	169:13,23	subset 58:20	24:9,25 25:18
28:18	134:9	170:2 172:20	59:7	26:11 27:6
states 142:2	strictly 124:18	173:3,7,12,13	substantial	31:24 43:18
146:7 147:3	strike 14:10	174:2,15,18	23:17 155:12	48:21 57:4,13
statistic 36:2	19:4 74:9	175:9	substantially	65:5 72:1 73:8
155:9	80:14,17 86:9	study 30:3,10,12	155:14	86:18 89:21
statistical	96:11 97:5	30:15,19,19	success 146:16	93:16 95:4
155:13,17,22	114:25 129:11	31:14,16 33:5	sudden 132:13	104:3 106:3
172:4	149:20 156:9	33:7,22 71:20	suffered 89:15	110:24 120:8
statistician	158:16 173:18	71:22 91:17,19	94:25	138:19 151:11
172:10,11	174:5	92:3,8 94:2,6	suffering 46:25	151:12 159:3
statistics 35:25	structures 76:18	94:14,15	57:22 82:12,19	surgeon 74:3

79:16 84:18 148:8,17 153:19 surgeons 85:15 86:1,14 122:25 142:21 148:6 163:17,22 173:25 surgeries 62:18 62:20,23,24,25 63:3 77:25 81:16 104:7 139:25 148:16 150:10 154:2 166:1 surgery 5:17,24 24:18 25:16 34:8 58:11,13 61:10,11,14,19 61:20 64:13 66:23 67:8,10 67:11 68:21 69:8,11 73:21 73:24 74:4,8 79:15,17,21 80:5,8,10,24 81:3,4,6,14 84:19 85:23,23 85:24 86:7 89:6,7 91:20 92:12,15 94:9 99:11 100:7,22 101:14 102:24 102:24 114:18 115:20 116:22 117:12 125:19 133:10 147:24 148:18 154:3 155:12 156:19 157:11,11 159:17,24 164:21,22 165:9,17,25 166:10 170:8 surgical 5:14 58:14 59:3,19	68:24 69:3 76:20 96:20 103:9 126:23 surprise 40:20 116:4 surprised 71:19 115:23 suspended 88:14,17 suture 82:9,15 149:3 sutures 81:1,15 81:17,19 82:6 82:8 svenningsen 5:11 123:25 134:21 135:12 146:23 swear 6:20 switch 87:5 sworn 6:24 7:3 177:7 symptoms 64:11 64:16,22 65:1 69:10,18 99:10 114:17 synthesis 151:5 synthetic 140:12 systematic 104:10 109:21 139:9 141:3 143:14,20,25 T t 4:1 5:1 108:14 table 118:3,5 120:14 121:18 121:19,20 139:20 140:20 140:23 141:3 142:8,15,16 158:3 161:13 161:23 tables 112:10 160:4 161:5 tabulated 112:1	take 28:16 29:22 32:16 47:25 53:10 54:23 83:19 90:21 95:1 100:25 104:1 110:24 124:7 128:20 131:19 133:14 134:12 140:15 taken 1:12 54:12 87:10 108:12 157:1 takes 70:24 talk 36:4 86:7 91:11 103:7 104:10 106:12 117:16 119:22 137:5 163:20 167:25 talked 95:24 148:15 167:24 talking 21:7 43:12 44:24 61:14 78:11 80:10,11,12,13 90:25 92:25 98:12,14 100:2 100:15 102:19 110:2,25 115:7 131:8,9 137:22 139:20 140:8 152:16 154:3 156:13 157:8 168:16 172:20 talks 163:13 tampon 31:9 tape 5:20 86:18 86:18 87:4,5,8 87:12 141:23 141:24 145:17 156:22,24 157:5 175:24 tapes 40:5 113:1 115:19 tasks 172:8 taught 134:15	134:18 148:19 teaching 29:8 60:20 technologies 1:24 2:14 6:3 tell 13:7 14:6 25:5 30:2 36:9 47:22 95:7 130:7 137:7 163:2 172:24 tells 83:13 template 62:1 temporary 67:25 79:21,23 80:2,3,5 83:15 ten 48:3 70:7 106:9 107:20 121:14 125:22 126:23 tend 80:5 tendered 13:11 tends 59:14 62:7 tension 86:18 107:12 tensionfree 5:20 40:5 86:19 141:23 145:17 term 116:24 117:1 146:2 168:20 terminology 147:10 terms 87:21 100:24 126:1 136:17 149:18 testified 7:3 18:10 64:10,17 67:22 85:2,9 148:1 153:5 154:11 157:20 159:19 testify 28:11 177:7 testimony 81:19 85:5,6 177:12 testing 134:4	text 48:10 thank 18:21 31:25 72:17 75:17 109:2 120:5 124:8 138:4 159:11 167:24 thats 13:18 14:19 17:20 19:25 27:13 30:4,6,24 33:24 42:11 44:23 49:22 50:3,14,16 51:7 52:1 54:2 58:10 60:17 62:13 63:15 67:7 68:12,22 69:13,16 72:14 78:9,15,15 80:8,15 81:13 82:7 86:6 92:8 93:13,24 95:7 95:8,8,16 96:15 99:13,22 104:3,15 110:10 112:5,8 114:21 120:17 121:4 123:13 125:24 133:22 135:15 159:9 161:19 163:25 167:6 168:25 171:11 174:11 175:21 therapy 58:7 72:14 theyre 118:24 theyve 100:7 124:15 thigh 77:18 thing 32:3 55:10 74:2 81:3 things 38:2 55:5 55:6 150:21 151:12 155:23
--	---	---	---	---

Denise M. Elser, M.D.

Page 201

170:9	8:11,18 9:7	167:25 168:16	transmitting	true 62:13 63:15
think 9:18 11:6	12:5,19 22:11	172:20	55:21	177:12
16:14 22:12	22:22,22 23:19	todays 6:3	transobturator	truth 177:7
25:15 27:18	23:21 24:5	toilet 65:13	40:5 114:22	try 7:21 22:25
32:17 45:20,22	26:19 29:5	told 42:6 43:24	115:10	44:4 47:22
47:22 50:3	34:18,20 36:6	44:1 63:11	transport 167:4	134:12
53:12 60:17	40:14 48:22	143:7	transvaginal	trying 11:9 20:1
61:23 62:13	49:2 54:9,19	tommaselli 5:10	60:5 164:22	21:15,17 23:1
63:15,19,25	55:25 57:16	119:5,10,22	travel 135:13,20	25:19 27:15
67:1,6 71:4	63:19 64:20	140:15 157:17	136:2	43:11,11 48:2
76:24 79:10	65:21 66:6	tons 167:4	treat 12:1 27:23	50:17,19 72:2
81:3 87:17,24	67:15 69:19	top 13:9 45:1	58:2 60:2,9,12	95:4 110:16
93:24 95:3	73:21,24 74:7	71:8	72:3 78:1 92:8	turn 76:4 108:5
97:20 103:3	75:7 83:23	topic 137:16	153:19 154:7	114:12,13
107:8,10 110:8	84:14 85:20	topics 163:5	treated 72:6,8	137:20 140:19
122:11,14	86:4 87:7,11	total 13:13	121:22 135:17	157:13 166:19
123:5 130:10	87:17 88:15	16:14 25:6	141:11	tvr 10:15
132:1 133:11	89:25 91:23	104:14 141:7	treating 58:12	tv 4:9 5:4,7,9,21
139:14 142:9	92:4 96:22	totally 138:21	72:3 115:3	8:19,20 9:4,5
144:7 149:16	97:2,9 98:18	track 22:19,19	treatment 57:21	9:20,21 10:2,8
151:13 154:12	101:2 103:5	27:20 53:5	71:15 96:20	10:12,14,16,17
159:22 173:15	108:6,7,9,15	103:15 146:14	97:10 153:10	10:22 17:9,22
thinking 83:18	112:16,20	tracked 23:18	153:15 155:24	18:22 20:3
thinning 107:16	125:22 126:12	104:21,22,25	156:13	55:13 56:5,12
third 8:7 147:7	126:22 132:10	105:2,10	treatments 59:1	56:13 57:2,9
thorough 57:2	134:14 147:24	130:11,17,20	154:20 163:23	57:10 63:12,14
thought 26:25	149:20,21	130:25 132:4,6	trees 32:21	63:16,23 64:2
39:23 82:18	151:17 153:24	traditional	trial 28:10 33:14	73:10,16,22
85:21 88:7	155:8,9 156:23	59:19,20 81:20	33:21 35:1,2,3	74:17 75:6
92:4 159:23	157:4 160:6,16	115:2,7 117:12	35:9,10 36:1	80:12 82:22
thousands 154:1	160:21 165:16	161:13	43:13 48:18	86:5 88:14
154:1 174:20	167:13 175:23	trained 155:1	128:15,19	96:7,12 97:8
three 26:14 87:1	times 9:2,3	training 35:21	156:1,7 174:1	104:15 106:15
121:6 134:17	170:9	35:24 36:3	174:8	111:12,18,19
134:19 173:16	tissue 62:19 78:4	88:4,10,14,18	trials 31:19,21	111:23 112:1
threemonth	82:3,5 165:18	148:6,11	109:12 113:7	113:10,15,17
94:17 173:13	167:18,18	149:13	113:24,25	118:5,11,13,16
173:17	tissues 166:6	trainings 12:12	114:10,14	118:18,21
throws 25:22	titles 51:16	transcript 177:9	115:18,24	119:3 120:16
thumb 5:3 49:10	today 6:20 7:8	transcripts 4:12	116:4,14,20	121:25 123:16
50:10,22,24	8:3,9,13 10:10	51:20 52:21	121:9 122:10	123:20,23
51:2,11,13	12:5 24:10	55:8	146:9 156:3,11	124:1,11
54:6,15 55:2	25:5 41:2 49:7	transient 70:25	156:17 171:20	125:25 127:4
162:15 166:16	49:25 50:15	71:5 82:23	171:21 173:24	127:10 129:13
thursday 3:2	145:19 148:25	83:7,14,23	tried 114:25	130:21 131:5
time 6:4 7:12,14	162:16 166:15	transition 20:12	117:18	131:24 132:11

Denise M. Elser, M.D.

Page 202

133:16 134:18 136:6,22 137:19 140:4,8 140:8,10,10,13 140:25 141:6,9 141:11,17,23 141:25 142:3,5 142:13,18,19 142:22 143:2 143:18 144:9 144:16,24 145:3,8,18 146:24 149:6 149:21 150:21 151:3,23,23 152:13,16,16 152:24 154:23 157:21 158:11 159:20 162:8 163:17 164:23 166:6,14 168:9 169:24 170:15 171:2 tvto 4:17 9:21,22 9:23 10:4 17:17 19:1 20:3 21:13 52:2,9 120:19 tvtr 18:25 120:23 121:14 tvts 122:25 twice 9:5,6 two 10:2 19:10 24:18 33:18 100:16 102:2 104:18 130:8 131:3 132:12 136:11 142:10 142:17 147:1 172:25 173:1 twostage 71:13 twoyear 24:23 type 121:23 128:3 typed 66:20 types 33:19	45:17 58:14 59:18 104:7 122:5,10,11,18 128:5 146:19 153:18 156:11 typewriting 177:11 typical 62:17 typically 15:12 60:4 <hr/> U <hr/> u 56:12 ultimately 89:1 uncertainty 116:16 undergo 69:2 148:22 149:6 undergoing 101:2 undergone 124:11 148:11 underlying 104:24 117:21 117:21 169:2 understand 21:15 24:9 35:10 43:12 49:6,23 57:4 74:21 83:10 89:5 95:4 96:17 173:24 understanding 15:5 47:21 58:23 70:23 97:16 98:4 105:5 148:7 156:10 understood 27:18 underwent 71:13 149:22 159:18 unger 138:3 unique 79:14 81:3	units 147:8 unusual 82:20 update 5:16 18:7 45:24 158:20 163:6 updated 17:4 111:10 139:20 updating 158:25 uptodate 18:1 47:10,12 urethra 31:11 59:13,14 76:19 77:1 98:11 urge 64:11,16 65:1,16 66:9 67:11 71:17 73:14 79:1 84:6 86:14 90:6 95:24 125:23 126:22 163:13,23 164:2 urgency 71:25 125:17 126:22 127:3 urinary 5:15 29:13 33:12 64:12 66:13,25 79:4,4 114:15 115:3 153:15 153:20 154:7 154:23 156:14 urinate 65:11 urination 65:19 65:22 165:13 urine 65:12 urogynecologic 34:5 urogynecologist 170:12 urogynecology 94:19 143:22 148:12 155:6 163:7 urologic 139:11 158:16	urological 158:18 urology 1:5 use 18:21,23,25 19:5 20:19 21:4,7,10,12 21:19,23 22:4 58:9 60:6,8,10 60:12 61:16 119:12 141:22 146:2 153:9,14 153:19 168:21 uses 68:13 usually 51:7 71:18 109:15 109:25 utilize 152:5 <hr/> V <hr/> vagina 81:17 vaginal 5:17,20 40:5 60:7 79:5 82:7 91:3 98:22 99:4,6 107:7,17 123:12 141:23 145:17 159:25 165:17 166:6 vague 21:23 62:12 68:12,15 68:19 86:6 validated 103:8 105:14 121:10 valuable 122:12 vargo 1:13 2:16 6:20 177:2,23 various 55:8 104:7 139:22 142:16 143:13 144:1 146:19 153:14 154:2 155:20 157:9 162:15 175:9 vary 58:23 62:3 vast 140:24 141:5 142:17	144:8 verbal 121:8 version 119:11 versus 6:8 21:11 21:20,24 79:15 81:4 87:16 113:24 115:11 130:18,22 136:22 147:23 vesair 29:16,17 vessel 74:7 vessels 73:18 74:14 76:18 vicious 93:1 video 4:3 6:6 48:23 49:3,18 54:10,20 87:9 87:13 108:10 108:16 112:17 112:21 156:25 157:6 160:17 160:22 176:1 videographer 2:12 6:1,3,19 48:22 49:2 54:9,19 75:11 87:3,7,11 108:9,15 112:16,20 156:23 157:4 160:16,21 164:8 175:23 videorecorded 1:11 videos 134:6 view 22:6 83:2 109:20 132:25 151:24 viewed 43:4 visit 90:2 voiding 77:11 81:7 149:10 174:23 voluminous 50:6 vs 1:3
--	---	--	--	---

Denise M. Elser, M.D.

Page 203

W	69:18 72:1	31:25 32:21,24	105:3,20	163:7
walking 49:24	79:1,7 103:5	42:12 48:4	149:25 172:6	yearlong 24:3,4
110:17	103:12 105:3	75:2,9,17,20	wound 149:2,9	26:12 173:5
wall 5:17 82:7	waste 7:12	75:24 76:1	165:12	years 10:24
91:3 159:25	water 2:3	103:22,24	write 99:17	18:13 19:10
want 8:7 13:7	way 7:20 17:7	120:6 127:17	writing 8:15	24:15,18 26:15
14:17 21:23	25:22 28:2	135:2 137:25	13:14 14:20	26:15 36:8
24:2,8 31:23	40:6 50:6	138:7 140:11	written 17:18	40:22 56:14
32:15 33:1	56:22 72:4	150:16 166:20	109:6	101:21 105:23
37:11 39:5	73:5 75:5	177:6,6	wrong 10:1 62:8	106:9 107:20
43:16,21,23	113:20 126:3	women 31:11	84:19 92:8	114:10,17
47:3,5,9,16,19	132:14 133:12	33:24 59:15	97:1,8 146:2	115:20 116:6
48:4 49:21,23	147:14 161:9	93:21 104:13	151:16	116:22 117:1,6
50:12 55:10	ways 133:1	104:19 106:15	wrote 12:20	117:9,9 121:2
57:19 65:3,4	wear 31:11	106:18,21	13:2 40:14,22	121:5,6 125:22
68:4,5 72:1,24	website 5:12	114:15 115:14	66:11 68:2	126:23 129:13
76:2,8 80:16	110:23 145:15	124:11,15,20	70:7 71:8	131:3 132:12
84:19 86:6	week 14:13,15	124:25 125:3,7	86:12 161:7	134:17,19
89:5,20 91:15	14:25 15:8,11	125:15,22	165:3	136:23 153:21
94:20 95:5,13	16:21,23 18:2	126:4 127:3	X	yep 158:4
95:17,21 99:9	62:17	151:1 152:12	x 3:1 4:1 5:1	yesterday 74:20
103:17 105:24	weeks 15:13,13	154:20 158:1	Y	york 2:4,4
106:6 108:4	94:16 106:3	158:11 175:11	yeah 11:8 15:20	young 59:15
109:2,5 110:11	weight 58:3	175:15	30:22 37:9	youve 16:23
120:3 122:24	weiss 2:3 6:15	womens 1:5	38:19 45:22,22	27:22 43:5
123:25 124:4	welk 174:25	wont 28:5 168:4	53:23 54:2	68:8 86:24
133:23 137:15	175:10	word 59:18	66:18 72:17	101:20 102:8
151:11,17	went 23:19	76:25 98:1	79:23 89:21	123:2 145:2
157:16 158:20	26:17 55:4	141:22	91:22 95:12	163:1
159:2 167:25	131:21,22	work 12:16	103:19 108:3	Z
169:22	152:21	14:11,14 15:12	112:10 124:7	0
wanted 24:25	whats 36:15	16:10 19:19	131:9 134:24	0 104:12 158:10
26:11 34:11	48:14 73:12	60:24 61:6	140:22 144:14	158:12
43:3 110:5	79:14 107:3	72:13 153:5	year 16:9,20	000 15:23
warn 91:7	122:25 131:20	156:1	17:10 18:11,14	104:14 175:11
warned 67:22	131:20 146:12	worked 12:17	20:15,17 23:24	175:15
68:9 86:13	163:1	13:13 19:16	23:25,25 24:1	03427878 5:7
warning 73:17	whove 106:21	working 12:2,19	24:7,10,20,20	03427883 5:8
73:25 74:2,12	willing 125:4	14:20 15:16	25:1 30:16	04 139:2
74:13,16 86:14	wise 122:14,15	16:19 36:3	70:5 72:19	05 108:7
warnings 79:11	witness 3:3 6:21	52:24 61:9	75:14 105:18	06 108:10,13,13
79:13,17,18	6:24 7:2 13:9	works 128:1	105:24 106:1,7	108:16
warns 73:10,16	13:11,12,17	worsen 91:24	110:2 138:3	1
wary 146:1	16:5 18:20	wouldnt 81:24	144:4 157:18	1 4:3,6 5:6 7:24
washington 2:9	25:13,21 27:2	94:5 100:25		
wasnt 10:9	29:24 30:1	101:8,25 103:9		

Denise M. Elser, M.D.

Page 204

8:2,10 60:18	129 147:2	121:4 161:8,15	177:20	36 54:12,20
87:8 100:5	13 4:5 5:12,13	161:17 165:20	21 54:10,12	86:13 89:13
101:7,9 108:13	48:23 110:20	165:23	2100 1:16	160:17
108:16 112:17	135:1 158:1,11	1885 2:10	24 3:16,17	37 4:9 91:17
112:21 120:14	159:7,14	19034 2:9	25 4:12 14:8	370 1:24
123:13,18	137 3:5	1997 91:17	51:21 84:7	38 91:14 93:18
142:8 150:25	14 1:17 3:14 4:5		87:8,10 151:14	160:22
161:5,13	5:14,24 6:5	2	151:21	3801 141:8
10 5:9,13 48:23	66:2,3 112:17	2 4:5,16,22	250 110:9	3974 141:8
49:3 54:10,12	127:3 157:2	13:22,25 23:10	250page 110:17	
54:12,20 75:13	158:21 159:4	62:16 87:12	25th 52:22,25	4
75:15 110:18	159:10	111:6 121:19	267 2:10	4 4:9 23:3,15
110:23 159:6	14th 64:12 99:11	123:13,18	27 5:5 55:25	24:23 26:4
159:13	15 4:12,16,19,20	136:19 138:11	27th 55:22	27:2,13,15
100 142:12	4:22 5:5,17	138:13 142:15	28 3:14	28:11 33:9
10005 2:4	7:25 14:1	142:16 156:24	281 145:22	34:10 37:14,15
108 3:17	32:14 36:8	156:24 157:1,1	29 157:1,5	63:7,10,22
10th 177:19	37:16 51:21	157:5 160:17	291 1:8	125:18 131:2
10year 118:18	52:12 54:18	160:22 161:5	2nd 52:1,14	145:22 152:20
125:20 126:5	66:3 75:16	168:25 175:24		40 13:15,16
136:14 175:2	112:21 120:2	176:2	3	400 2:9 120:23
175:16	121:3 124:3	20 115:14	3 4:7 32:12,13	41 23:10 96:6
11 5:10,24 7:25	125:19 157:3	153:21 156:24	104:14 119:5	42 99:8
14:1 32:14	160:5,9,10	157:1	119:21 121:18	4281 111:13
37:16 54:18	161:4 162:3,11	2002 144:19	121:20 122:4	43 3:15
75:16 87:8,10	165:21	2007 40:8 93:19	136:23 140:20	45 112:24 118:4
87:10,12	150 18:13 20:17	2009 5:15	140:23 141:10	144:8,12
119:25 120:1,2	156 125:8	2011 64:13,24	141:14 157:5	482 122:4
124:3 140:16	157 5:14	69:7,12 99:11	157:13 158:2,3	483 124:25
157:3,16	159 5:13	165:1	158:10,12	125:7
160:10 162:3	16 5:19 162:1,2	2012 11:1 70:7	175:1,1,5,24	
162:11 165:21	162:5	138:18	30 14:8 15:13	5
110 5:12 159:12	160 5:17	2013 24:19	16:16 64:7	5 1:17 3:2 4:4
12 4:5 5:11	161 110:20	34:14,17 70:16	150:12,17	5:12 7:25 14:1
65:11 105:17	162 5:19,22	124:1 146:23	151:14,21	23:3,15 24:23
108:7,10,13	165 5:24	155:12	31 4:19,20 52:12	26:4 27:2,13
124:1,2 125:18	167 3:6	2014 12:22	64:9 67:21	27:15 28:11
134:25 135:2,3	169 3:7	13:24 32:12	87:10,12	32:14 33:17
136:4	17 5:22 49:3	34:15,19 37:21	319 122:1	37:16 51:15
120 1:7 5:10	129:13 142:11	74:21 104:9	31st 52:10 89:23	54:18,24 63:7
124 5:11	162:10,13	2015 1:17 3:2	32 4:7 67:20,21	63:10,22 75:16
1256 120:15	163:2	6:4 34:21,22	69:6	76:5 101:3,9
1258 140:22	171 3:8	52:1,10,14,22	327 125:7	118:18 120:2
1275 126:17	173 3:9	53:1 55:23,25	3377 1:24	124:3 131:2
1277 127:2	17year 136:24	111:10 138:3	34 71:7 104:6	137:20 138:7
135:11	18 5:24 65:10	147:23 175:1	35 73:13 121:1,3	151:7 152:20

Denise M. Elser, M.D.

Page 205

157:3 160:10	75 5:7,9			
162:3,11	77 2:3			
165:21 174:25	780 71:10			
50 16:13,14,15	8			
132:19 175:11	8 4:12 5:5,5			
175:15	51:21 54:17			
500 2:9 104:19	55:20 127:12			
106:18	127:16			
513 2:10	80 114:14			
54 4:11,13,15,17	115:13,16			
4:18,20,21 5:3	800 15:23 71:21			
5:4,5	801 141:10			
542 124:23	809 111:13			
5672 1:24	145:22			
575 38:25	82 121:6			
58 175:24 176:2	841573 1:14			
59 4:8	2:17 177:4,24			
591 1:24	877 1:24			
5a 4:11 54:14	888 2:4			
55:1				
5b 4:13 55:1	9			
5c 4:15	9 1:17 4:5 5:7			
5d 4:17	6:5 75:1,6,15			
5e 4:18	127:3 150:25			
5f 4:20	90 18:14 20:16			
5g 4:21 54:14	917 1:24			
5th 6:4	95 141:17 142:4			
6	157:20			
6 3:15 4:16,22	974 141:14			
5:3,23 53:14	158:2			
54:7,16 55:2	99 104:13			
104:6 125:18	9th 1:15 13:24			
60 15:10 121:4	9year 175:4			
603 124:20				
61 3:16				
610 2:4				
62 13:15,17				
6574 2:4				
7				
7 4:3,19,20 5:4				
5:24 52:12				
53:18 54:17				
55:11 138:11				
150:25 175:5				